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            Cytokines are key regulators of the inflammatory response and play an important role in 
facilitating intercellular communication between various immune cell types. Interleukin-1b (IL-1b) 
is a potent pro-inflammatory cytokine that is required for robust initiation of innate immune 
response and subsequent development of adaptive immunity. IL-1b is first synthesized as an 
inactive cytoplasmic, non-glycosylated, precursor molecule (proIL-1b) by monocytes and 
macrophages in response to invading pathogenic microbes. The activation of caspase-1 by 
inflammasomes cleaves proIL-1b into mature biologically active IL-1b that is released from cells 
via a non-classical, endoplasmic reticulum-independent secretory pathway directly from the 
cytoplasm via Gasdermin D membrane pores. IL-1b binds to its heterodimeric receptor 
(IL-1R1•IL1RAP) on various immune cells, resulting in an inflammatory response that in short 
transient bursts can be therapeutic. However, increased and sustained expression of IL-1b is known 
to be associated with many autoinflammatory diseases. Therefore, understanding the molecular 
 v 
mechanisms regulating human IL1B gene transcription is important for discovering potential 
regulatory control points in this immunologically important gene, as well as for designing more 
effective and safer anti-IL-1b therapies than those currently available. Most of our present 
understanding of IL1B gene regulation is from activated monocytes, but not much is known about 
its regulation in lymphoid CD4 T cells. Previous studies from our lab have shown that the Spi-
1/PU.1 (Spi1) transcription factor is absolutely necessary for IL1B gene transcription in monocytes. 
Using mRNA expression and Chromatin Immunoprecipitation (ChIP), we have shown that the 
IL1B gene in TCR-activated CD4 T cells is transcribed from a low-activity bivalent 
H3K4me3+/H3K27me3+ promoter in a Spi1-independent manner. Our lab has previously reported 
that IL1B gene transcription is dependent upon long-range chromatin looping mediated by a mutual 
DNA-binding domain interaction between two transcription factors, Spi1 at the promoter and 
C/EBPb at a distal enhancer. Using in vitro interaction and computational analysis, we have 
generated a predicted molecular structure of the C/EBPb:Spi1 protein-protein interaction and 
demonstrated that C-terminal tail residues beyond the C/EBPb leucine zipper are critical for 
mediating its interaction with the DNA-binding domain of Spi1. We have also reported that a small 
molecule can effectively bind to a pocket on Spi1 disrupting its interaction with C/EBPb, thereby 
significantly reducing IL1B gene transcription in TLR4-activated THP-1 monocytes. Using 
mRNA kinetic expression profiling, relatively-specific transcription factor inhibition and ChIP, 
we have identified a differential involvement of NF-κB and C/EBPβ transcription factors in 
TLR4-dependent IL1B gene transcription in monocytes. We have also demonstrated that serine 
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Chapter 1: Introduction 
1.1. Overview of the Immune System  
            Our human bodies are constantly exposed to a wide range of microorganisms from the 
environment. The majority of these microorganisms are not harmful and peacefully coexist within 
the host. However, some of the microorganisms are pathogenic and can lead to a number of 
life-threatening conditions. The constant interplay between the host and these foreign agents has 
led to the development of a complex immune system to protect the host from these invading 
pathogenic microbes. The immune system is composed of a complex interactive network of cells, 
tissues, organs, humoral factors and cytokines that protects the host against the invading foreign 
pathogens. The primary function of the immune system is to discriminate “self” antigens from 
“non-self” antigens. This ability of the immune system, to avoid the destruction of the host’s own 
cells and tissues is referred to as self-tolerance (Chaplin, 2010). The failure of self-tolerance can 
lead to a broad range of autoimmune diseases where the host’s immune system attacks and destroys 
its own cells and tissues. The immune system is broadly divided into two distinct groups based on 
the speed and specificity of the response: innate immunity and adaptive immunity. 
            The innate immune system serves as the first line of host defense against invading 
pathogens and other foreign agents. The innate immune response occurs rapidly upon exposure to 
pathogens and relies on the recognition of conserved molecular structures among a wide array of 
pathogens (Janeway and Medzhitov, 2002). It provides “non-specific” destruction of pathogens 
and does not lead to the formation of long-lasting immunologic memory. It also plays a crucial 
part in the initiation of an adaptive immune response.  
            In contrast to innate immunity, the adaptive immune response is highly specific to a 
particular pathogen and takes longer to develop. In addition to pathogen specificity, a key feature 
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of adaptive immunity is the generation of long-lasting immunologic memory which ensures a more 
rapid and effective response against a specific pathogen during its second encounter (Bonilla and 
Oettgen, 2010). This feature of adaptive immunity forms the basis of vaccination and provides 
lasting protective immunity. The two main cell types of the adaptive immune system are T 
lymphocytes and B lymphocytes. The receptor on individual lymphocytes is highly specific and 
distinct as a result of random somatic gene rearrangement during their maturation. The clonal 
expansion nature of lymphocytes is a hallmark of the adaptive immune response. When a specific 
antigen binds to a receptor on a naïve lymphocyte, that particular cell gets activated and starts to 
clonally expand. This gives rise to a clone of identical lymphocytes bearing the same antigen 
receptor (Heinzel et al., 2018). 
 
1.2. Innate Immune System: Cells and Pattern Recognition 
            The innate immune system as the first line of defense consists of a series of anatomical, 
physiological and chemical barriers to prevent the foreign pathogens from entering the host. These 
barriers include: epithelial cell layers that express tight cell-cell contacts (intact skin); secreted 
mucus that traps infectious pathogens; epithelial cilia that clears the mucus and other trapped 
particles; and low stomach pH and bacteriolytic enzymes like lysozyme in tears, saliva and other 
secretions (Chaplin, 2010; Turvey and Broide, 2010). Once an infectious pathogen penetrates these 
physical and chemical barriers, the cellular and humoral components of the innate immune 
response are triggered to effectively remove the invading foreign pathogen. 
            Immune cells develop from the pluripotent hematopoietic stem cells in the bone marrow. 
These stem cells can differentiate into either common myeloid or common lymphoid progenitor 
cells.  Myeloid progenitor cells are the precursor to several prominent innate immune cells 
including macrophages, dendritic cells, granulocytes and mast cells (Chaplin, 2010). Macrophages 
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are highly phagocytic cells that engulf microbes and other foreign particles that are marked for 
clearance by immunoglobins (Ig) or the complement system. During inflammation, monocytes 
circulating in the blood differentiate into macrophages and migrate into the tissues to fight 
infection. Both monocytes and macrophages have a broad range of pattern recognition receptors 
which, upon encountering microbes, initiates a cascade of downstream signaling events that result 
in the expression of many pro-inflammatory genes. Macrophages are broadly classified into M1 
macrophages (classically activated) and M2 macrophages (alternatively activated). M1 
macrophages are activated by Toll-like receptor ligands such as Lipopolysaccharides (LPS) or type 
2 interferon (IFN-g) and express pro-inflammatory cytokines. M1 macrophages play an important 
role in host defense against bacteria, protozoa, viruses and also aid in antitumor immunity (Murray 
and Wynn, 2011). M2 macrophages are generally stimulated by interleukin-4 (IL-4) or IL-13. M2 
macrophages have an anti-inflammatory function and play a role in wound healing and tissue 
repair (Italiani and Boraschi, 2014). Dendritic cells (DC) are specialized antigen presenting cells 
(APC) that phagocytize antigen and present it to lymphocytes. When an immature DC encounters 
a pathogen, it rapidly matures and migrates to lymph nodes where lymphocytes reside. DCs act as 
a bridge between innate and adaptive immune systems. Unlike classical DCs, plasmacytoid DCs 
are relatively long-lived and respond to viral infection by secreting large quantities of type 1 IFN 
(Geissmann et al., 2010).   
            Mast cells generally reside in connective tissue and mucous membrane, and when activated, 
release a number of chemical mediators like histamine that causes increased blood flow and cell 
trafficking to the area of infection. These cells play an important role in allergic responses and 
wound healing (Oskeritzian, 2012). Granulocytes include neutrophils, eosinophils, and basophils 
are characterized by the presence of dense secretory granules in the cytoplasm. All three types of 
granulocytes are generally short-lived. Neutrophils are phagocytic cells that play a major role in 
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microbial clearance and tissue repair. They accumulate at sites of bacterial infection and produce 
large quantities of reactive oxygen species that are cytotoxic to microbial pathogens (Winterbourn 
et al., 2016). Basophils are key initiators of immediate hypersensitivity, allergic immune responses 
and immunity against parasitic infections. These cells release substantial amounts of histamine and 
IL-4 in response to infection. Eosinophils are very similar to basophils and provide host response 
against helminths and other multicellular parasites (Stone et al., 2010). Unlike above mentioned 
innate immune cells, Natural Killer (NK) cells are derived from differentiation of common 
lymphoid progenitor cells, which also give rise to T lymphocytes and B lymphocytes of the 
adaptive immune system. NK cells do not have any antigen-specific receptors. Instead, they have 
cell surface receptors for Major Histocompatibility Complex (MHC) class I molecules. The 
cytotoxic activity of NK cells is inhibited when they interact with MHC class I molecules on the 
host cell. Normal host cells are MHC class I positive and escape from the lytic activity of NK cells. 
Tumor cells and virus-infected host cells generally downregulate MHC class I molecule expression 
and are targeted by NK cells for killing. NK cells also express Fc receptors and can mediate 
antibody dependent cell-mediated cytotoxicity (Caligiuri, 2008).  
            The cellular component of the innate immune response is dependent upon a limited-
repertoire of germline-encoded pattern recognition receptors (PRRs), which has the ability to 
detect conserved molecular structures that are shared by a large variety of microorganisms. These 
microbe-derived structures are known as pathogen-associated molecular patterns (PAMPs) 
(Matzinger, 1994; Medzhitov and Janeway, 1997). PAMPs are distinct from host self-antigens and 
are required for microbial survival. Mutations in these structures are generally lethal for microbes 
and are conserved among large groups of pathogens (Medzhitov and Janeway, 1997). PAMPs 
include bacterial components such as LPS, peptidoglycan, lipoteichoic acid, and unmethylated 
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CpG motifs DNA, as well as fungal molecules like b-glycans and viral glycoproteins and nucleic 
acids (Mogensen, 2009).  
            In addition to PAMPs, the innate immune system, via PRRs, can also recognize a wide 
variety of host nuclear and cytosolic products that are released from the stressed cells undergoing 
necrosis or tissue damage. These secondary endogenous signals are known as damage-associated 
molecular patterns (DAMPs) (Venereau et al., 2015). Well-characterized DAMPs include high 
mobility group box 1 protein, heat-shock proteins, uric acid, S100 proteins, defensins, host nucleic 
acid and ATP, which under normal physiological conditions are not exposed to PRRs on the 
immune cells. Additionally, DAMPs also include a number of extracellular matrix components 
such as biglycan, fibronectin, heparan sulfate, hyaluronan and fibrinogen (Roh and Sohn, 2018). 
DAMPs have been shown to be associated with a number of human diseases such as: autoimmune 
(rheumatoid arthritis); cardiovascular (atherosclerosis); metabolic (type 2 diabetes mellitus) and 
neurodegenerative (Parkinson’s) diseases (Foell et al., 2007; Frostegard, 2013; Land, 2015; Shin 
et al., 2015).  
            PRRs are the hallmark of the innate immune response and are absolutely necessary for the 
proper functioning of the immune system. There are four major families of PRRs: Toll-like 
receptors (TLRs); C-type lectin receptors (CLRs); Retinoic acid-includible gene (RIG)-I-like 
receptors (RLRs) and nucleotide-binding oligomerization domain-like receptors (NLRs) 
(Takeuchi and Akira, 2010). TLRs and CLRs are transmembrane proteins that are present on the 
cell surface, where RLRs and NLRs are cytoplasmic proteins that act as intercellular sensors of 
PAMPs and DAMPs.  
            TLRs are evolutionarily conserved type 1 transmembrane proteins that are homologs of the 
Drosophila Toll protein. The extracellular domain of TLRs contains leucine rich repeats (LRRs), 
which are involved in ligand binding and mediate PAMP recognition. The cytoplasmic tail region 
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contains a highly conserved Toll/IL-1 receptor (TIR) domain that initiates downstream signal 
transduction upon receptor activation (Armant and Fenton, 2002). TLRs dimerize upon ligand 
binding and initiate downstream signaling cascades through recruitment of adapter proteins like 
Myeloid Differentiation primary response 88 (MyD88) or TIR-domain-containing 
adapter-inducing interferon-b (TRIF) via their cytoplasmic TIR domain. These signaling cascades 
ultimately lead to activation of various transcription factors like nuclear factor kappa B (NF-kB), 
activator protein-1 (AP-1), interferon-regulatory factor (IRF)-3, which translocate into the nucleus 
and induce expression of a number of pro-inflammatory genes. The TLR superfamily is comprises 
of 10 genes (TLR1-TLR10) in humans and 12 genes (TLR1-TLR9, TLR11-TLR13), with TLR10 
homolog being a pseudogene, in mice (Beutler, 2004). The pattern recognition repertoire of TLRs 
is expanded by its ability to form heterodimers with one another. For example, TLR2/TLR6 
heterodimers are required for recognizing diacylated lipoproteins whereas TLR1/TLR2 
heterodimers interact with triacylated lipoproteins on the bacterial cell wall (Ozinsky et al., 2000).  
            TLRs are broadly subdivided into two groups based on their localization: cell surface TLRs 
and intracellular TLRs. TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10 are expressed on cell 
surfaces, whereas intracellular TLR subfamily comprises TLR3, TLR7, TLR8 and TLR9 
(Kawasaki and Kawai, 2014). Each TLR family member can recognize a distinct but limited 
repertoire of conserved microbial molecules. Microbial membrane components such as lipids, 
lipoproteins, and proteins are predominantly recognized by cell surface TLRs. TLR2 along with 
either TLR1 or TLR6 can recognize a variety of PAMPs from the cell surface of Gram-positive 
bacteria (Kawai and Akira, 2010). TLR4 is mainly activated by LPS, whereas TLR5 recognizes 
bacterial flagellin (Akira et al., 2006). Intracellular TLRs generally recognize bacterial and viral 
nucleic acids as well as host-nucleic acids in some disease conditions (Blasius and Beutler, 2010). 
TLR3 largely responds to double-stranded viral RNA, whereas TLR7 and TLR8 are responsible 
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for the detection of single-stranded viral RNA (Kawasaki and Kawai, 2014). Finally, TLR9 is 
implicated in detecting unmethylated CpG bacterial and viral DNA (Kumagai et al., 2008).  
            CLRs are a part of a large transmembrane receptor superfamily that is responsible for 
recognizing carbohydrates on microorganisms such as viruses, bacteria, and fungi (Hoving et al., 
2014). These receptors are generally calcium-dependent and contain at least one carbohydrate-
binding domain. CLRs initiate intracellular signaling either via their dual-tyrosine ITAM 
(Immunoreceptor tyrosine-based activation motif) or adaptor proteins containing ITAM domains 
such as fragment crystallizable (Fc) receptor g chain or DAP12 (Geijtenbeek and Gringhuis, 2009). 
RLRs are a family of cytosolic receptors that recognize viral RNA and activate type I interferons 
and NF-kB dependent pro-inflammatory cytokines. These receptors contain the N-terminal 
caspase recruitment domain (CARD) that mediate downstream signaling, a central DEAD box 
helicase/ATPase domain that binds viral RNA and a regulatory C-terminal domain (Loo and Gale, 
2011). RNA viruses are generally recognized by a specific member of the RLRs family based on 
viral RNA length (Kato et al., 2008).  
            NLRs are intracellular sensors that can sense microbial invasion and cellular stress through 
the recognition of cytosolic PAMPs and DAMPs. NLRs are characterized by an N-terminal 
effector domain such as CARD, a central nucleotide-binding oligomerization domain (NOD) that 
is critical for activation and a C-terminal LRR domain that detects conserved molecular patterns. 
There are 23 NLR family members in humans that are classified by their N-terminal effector 
domain (Kanneganti et al., 2007). NLRs play an important role in the cytoplasmic/non-membrane 
processing of precursor pro-IL1b and pro-IL18. NALP3, one of the NLR proteins containing pyrin 
domain 3, can sense metabolic and cellular ‘danger signals’ such as potassium efflux and 
extracellular Adenosine triphosphate (ATP) that are released from dying cells due to infection or 
sterile inflammation. These metabolic stressors can activate NALP3 leading to its association with 
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the adaptor protein apoptosis-associated speck-like protein containing CARD (ASC). The 
NALP3:ASC complex through the CARD domain of ASC protein recruits pro-caspase-1 leading 
to the formation of an active inflammasome complex (Abderrazak et al., 2015; Latz et al., 2013). 
The active inflammasome leads to autocatalytic cleavage of pro-caspase-1 into active caspase-1 
which will then cleave pro-IL1b and pro-IL18 into their mature biological active forms. These 
biological active cytokines are important mediators of the inflammatory response and are released 
from the cells via a non-classical secretion pathway (Dinarello, 2009). 
 
1.3. Human Interleukin-1 Beta Gene 
            Interleukin 1b (IL-1b) is a key mediator of inflammation and innate immunity. It plays a 
crucial role in host-defense response to infection and injury stimuli. It is encoded by the IL1B gene 
located on human chromosome 2 (Webb et al., 1986) within an IL1B super-family gene cluster at 
band 2q13. There are 11 members in the IL1B gene super-family (9 members at band 2q13 and 
one each at 9p24.1 and 11q23.1), of which seven are associated with pro-inflammatory and four 
with anti-inflammatory responses (Dinarello, 2018). TLR-activated monocytes/macrophages, as 
well as related myeloid lineage cells, act as the primary source of IL-1b in humans. Apart from 
being an important mediator of the inflammatory response, IL-1b is involved in a variety of cellular 
functions such as cell proliferation, cell maturation, and apoptosis. But the increased and sustained 
expression of IL-1b is associated with many auto-inflammatory diseases such as sepsis, osteo- and 
rheumatoid arthritis, inflammatory bowel disease, Crohn’s disease, gout and asthma (Braddock 
and Quinn, 2004). Every year, severe sepsis, alone, affects more than a million people in the United 
States (Hall et al., 2011). It is estimated that about 28 to 50 percent of these people die, which is 
far more than the deaths from AIDS, prostate cancer and breast cancer combined (Wood and Angus, 
2004). Apart from these diseases, IL-1b is also known to play a role in atherosclerosis, stroke, 
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chronic obstructive pulmonary disease, cancer, multiple sclerosis, Alzheimer’s disease and 
diabetes (Braddock and Quinn, 2004). 
            IL1B is an immediate-early (IE) gene with a rapid increase in mRNA levels within 15 
minutes after the LPS dependent TLR4-activation of monocytes (Dinarello, 2018). IL1B gene 
transcription has two distinct phases with an IE rapid-vigorous phase followed by a decreased 
continuous expression that lasts for several hours (Adamik et al., 2013). Unlike other classic IE 
genes, like TNF and FOS, IL1B lacks many canonical core promoter elements such as Initiator 
(Inr), Downstream Promoter Element (DPE) and Downstream Core Element (DCE) sequences, 
which are specifically recognized by protein components of the transcription Pre-Initiation 
Complex (PIC) (Nogales et al., 2017). The absence of these sequence elements may be the reason 
why the IL1B gene promoter does not have pre-bound TATA-Binding Protein (TBP) and RNA 
Polymerase II (Pol II), but instead has the Spi-1/PU.1 (Spi1) transcription factor pre-bound to the 
promoter region before TLR-4 activation (Adamik et al., 2013). Spi1 is a monocytic cell lineage-
determining factor that belongs to the ETS family of transcription factors and is absolutely required 
for IL1B gene transcription in monocytes (Adamik et al., 2013). Spi1 constitutively binds to the 
IL1B promoter between -50 to -39 and may also bind to a site at -115 to -97, relative to the 
transcription start site (TSS) (Kominato et al., 1995). The inducible regulatory region of the IL1B 
gene is multi-partite, consisting of a short 14 base pair (bp) signal-dependent mini-enhancer 
located approximately 300 bp upstream of the TSS, which binds the NF-kB transcription factor 
upon TLR-4 activation (Figure 1). In addition, the IL1B gene also has a 400 bp-long far-upstream 
super enhancer (UIS: Upstream Induction Sequence) that is essential for a high level of IL1B 
transcription in LPS-activated monocytes (Gray et al., 1993; Shirakawa et al., 1993). This 
super-enhancer located approximately 3 Kbp upstream of the TSS and binds various constitutively 
expressed and TLR4-activated transcription factors (Tsukada et al., 1994; Unlu et al., 2007). Of 
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all the transcription factors that can bind to this upstream region, the majority of the LPS-dependent 
activity is contributed by the co-operative effect of a 9 bp C/EBPb-dependent heterodimer binding 
sequence (Tsukada et al., 1994) and a 21 bp IRF8 dependent heterotrimeric sequence (LILRE: 
LPS/IL1B response element) (Unlu et al., 2007). Previous studies have reported that by long-range 
LPS-dependent chromatin looping the DNA binding domain (DBD) of C/EBPb (bound to the UIS 
enhancer) can directly interact with the Spi1 DBD (located at promoter) (Adamik et al., 2013; 
Listman et al., 2005; Tsukada et al., 1994; Yang et al., 2000). These complex transcription factors 
interactions and their binding to different regulatory regions along the gene results in the tight 
regulation of the IL1B gene.  
 
Figure 1. Regulatory regions of IL1B. Schematic of IL1B gene structure showing the relative 
locations of important transcription factor binding sites. Key transcription factor binding sites are 
indicated. These include: the -300 NF-kB site; Region I binding site for the critical C/EBPb dimer; 
LILRE site for an IRF8:Spi1:Stat1 ternary complex; and two Spi1 sites at the IL1B promoter. This 
figure is courtesy of Dr. Philip E. Auron. 
 
            IL-1b is first translated into a 31-kDa precursor protein with very low biological activity 
(proIL-1b), which is subsequently processed into 17-kDa mature highly-active IL-1b either 
intracellularly by the caspase-1 inflammasome or extracellularly by other proteases (Dinarello, 
2011).  Intracellular processing and secretion generally require a second danger signal, such as 
extracellular ATP via the P2X7 purinoceptor, potassium efflux, uric acid or reactive oxygen 
species (Hoffman, 2009). This results in a non-classical secretion for cytoplasmic IL-1b that 
bypasses the classic ER/Golgi glycosylation secretion pathway. Recent studies have shown that 
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the pyroptosis regulator Gasdermin D (GSDMD) facilitates secretion of IL-1b from macrophages 
that have activated inflammasome (Evavold et al., 2018). Once GSDMD is cleaved by the 
inflammasome-associated proteases (Kayagaki et al., 2015), its N-terminal fragment oligomerizes 
and forms large permeability pores in the plasma membrane through which IL-1b is released 
(Heilig et al., 2018).  
 
1.4. CD4 T Lymphocytes 
            CD4 T cells are essential modulators of an effective adaptive immune response. They play 
a central role in various immunological processes, such as activation of cytotoxic T cells, 
maturation of B cells into plasma cells and memory cells, enhancing microbiocidal activity of 
macrophages, recruiting neutrophils, eosinophils and basophils to site of inflammation as well as 
a crucial role in mediating tolerance and suppression of inflammatory responses (Luckheeram et 
al., 2012; Zhu and Paul, 2008). T cell precursors develop from common lymphoid progenitors in 
the bone marrow and migrate to the thymus for maturation. These T cell precursors rearrange their 
chromosomal DNA in order to generate a large repertoire of T cell receptor specificities, followed 
by a series of selection processes resulting in maturation into two distinct subsets, CD4 and CD8 
T cells. The mature, receptor-specific T cells leave the thymus and circulate in the blood and 
secondary lymphoid organs, constantly “looking” for antigens. T cells that have not been exposed 
to antigen are termed as naïve. Human naïve CD4 T cells can be identified by the expression of T-
Cell Receptor (TCR), CD4 co-receptor along with the expression of the surface molecule CD45 
long isoform (CD45RA) and/or absence of the short isoform (CD45RO) (Berard and Tough, 2002).  
            The unique TCR receptor of each naïve CD4 T cell is responsible for its specificity and 
only recognizes peptides presented by MHC class II molecules. Naïve CD4 T cells require two 
signals for successful activation. The first signal is generated by the engagement of the TCR on 
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the naïve T cell with appropriate foreign peptide bound to the MHC class II molecule on the APCs. 
The second signal is provided by co-stimulatory molecules such as B7 proteins (CD80 and CD86) 
on the APCs that interact with CD28 co-receptor on the T cells (Smith-Garvin et al., 2009). This 
second signal promotes the survival and clonal expansion of the T cells following the activation 
process (Acuto and Michel, 2003). During TCR activation, the CD4 T cells depending mainly on 
the particular cytokine microenvironment can differentiate into several CD4 subsets such as T 
Helper 1 (Th1), Th2, Th17, T regulatory cells and follicular helper T cells with a variety of immune 
functions (Zhu et al., 2010).  
            Monocytes, macrophages and dendritic cells are the major sources of IL-1b (Asgari et al., 
2013). Recent studies have shown that under specific conditions, both the Human and Mouse CD4 
T cells express low levels of the proIL-1b protein (Arbore et al., 2016; Doitsh et al., 2014; Martin 
et al., 2016). However, these reports have not explored the transcriptional status of the IL1B gene 
in the CD4 T cells. Previous studies have reported that the Spi1 transcription factor that is 
absolutely necessary for IL1B gene expression in monocytes is expressed in double-negative 
CD4/8 T cells, but it is lost in double-positive and naïve CD4 T cells (Rothenberg et al., 2013). 
Upon differentiation, Spi1 is shown to be re-expressed in Th2 (Chang et al., 2005) and Th9  (Chang 
et al., 2010) CD4 T cells. Yet, it has not been known whether IL1B gene expression in CD4 T cells 
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            Interleukin 1β is a pro-inflammatory cytokine important for both normal immune responses 
and chronic inflammatory diseases. The regulation of the 31 kDa proIL-1β precursor coded by the 
IL1B gene has been extensively studied in myeloid cells, but not in lymphoid-derived CD4 T cells. 
Surprisingly, we found that some CD4 T cell subsets express higher levels of proIL-1β than 
unstimulated monocytes, despite relatively low IL1B mRNA levels. We observed a significant 
increase in IL1B transcription and translation in CD4 T cells upon ex vivo CD3/CD28 activation, 
and a similar elevation in the CCR5+ effector memory population compared to CCR5− T cells in 
vivo. The rapid and vigorous increase in IL1B gene transcription for stimulated monocytes has 
previously been associated with the presence of Spi-1/PU.1 (Spi1), a myeloid-lineage transcription 
factor, pre-bound to the promoter. In the case of CD4 T cells, this increase occurred despite the 
lack of detectable Spi1 at the IL1B promoter. Additionally, we found altered epigenetic regulation 
of the IL1B locus in CD3/CD28–activated CD4 T cells. Unlike monocytes, activated CD4 T cells 
possess bivalent H3K4me3+/H3K27me3+ nucleosome marks at the IL1B promoter, reflecting low 
transcriptional activity. These results support a model in which the IL1B gene in CD4 T cells is 
transcribed from a low-activity bivalent promoter independent of Spi1. Accumulated cytoplasmic 
proIL-1β may ultimately be cleaved to mature 17 kDa bioactive IL-1β, regulating T cell 










            ProIL-1β, the interleukin 1β protein precursor, is encoded by the IL1B gene within an IL1 
family gene cluster located on human chromosome 2. ProIL-1β is principally produced by 
activated monocytes/macrophages. These cells become activated by pathogen-associated molecule 
patterns (PAMPs) recognized by pattern recognition receptors (PRRs), and/or secondary damage 
signals (DAMPs, danger-associated molecular patterns) (Eder, 2009; Petrilli et al., 2007). 
Following activation, proIL-1β is synthesized as a precursor protein with very low biological 
activity. It is then processed into highly active mature IL-1β, either intracellularly by the caspase-
1 inflammasome or extracellularly by other proteases (Dinarello, 2011; Dubyak, 2012; Malhotra, 
2013). Most of our current understanding of IL1B transcriptional and translational regulation stems 
from studies of myeloid-lineage cells. IL1B gene expression has not extensively been examined in 
lymphoid cells. 
            Spi-1/PU.1 (Spi1) is a transcription factor involved in genome-wide development and 
maintenance of cells in the macrophage lineage (Lawrence and Natoli, 2011). Spi1 often associates 
with inducible transcription factors, such as NF-kB and C/EBPβ, on lipopolysaccharide (LPS)-
responsive promoters and enhancers in human and murine macrophages (Ghisletti et al., 2010; 
Heinz et al., 2010). In the monocyte/macrophage lineage, Spi1 constitutively binds to the IL1B 
promoter at two distinct sites located between -50 to -39 and -115 to -97 relative to the transcription 
start site (Adamik et al., 2013; Kominato et al., 1995).  In non-myeloid cells, its ectopic expression 
can result in IL1B transcription in the presence of an activation signal for NF-kB and C/EBPβ 
(Adamik et al., 2013; Kominato et al., 1995; Shirakawa et al., 1993). Additionally, Spi1 can act as 
a “pioneer factor”, binding nucleosome-occluded DNA and facilitating chromatin accessibility for 
LPS-responsive transcription factors in activated monocytes (Marecki et al., 2004; Natoli, 2012). 
Further, it directly recruits TATA-binding protein (TBP), which is involved in forming the pre-
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initiation complex (PIC) that helps to recruit RNA Polymerase II (Pol II) to gene promoters 
(Adamik et al., 2013; Hagemeier et al., 1993). 
            IL-1b is expressed at extremely high levels in myeloid-derived cells in response to 
microbial invasion and tissue injury (Adamik et al., 2013). Although activated monocytes are a 
major source of IL-1b; NK cells, B cells, dendritic cells, fibroblasts, and epithelial cells also 
express this protein, but at much lower levels (Libby et al., 1986). ProIL-1β has been previously 
detected in human lymphoid CD4 T cells expressing chemokine receptor 5 (CCR5+) (Doitsh et 
al., 2014). This proIL-1β can be cleaved and released as highly active mature IL-1β following 
abortive HIV infection. Recent reports have further shown that stimulation of the T cell antigen-
receptor (TCR), when combined with varied co-stimulation can induce the production of proIL-1b 
in CD4 T cells. Specifically, mouse CD4 T cells that were TCR-activated in vitro by CD3/CD28 
crosslinking were found to produce proIL-1b mRNA and protein (Martin et al., 2016). Human 
CD4 T cells also produced high levels of proIL-1β when CD3 stimulation was combined with anti-
CD46 complement receptor activation (Arbore et al., 2016). This study further showed that NLRP3 
inflammasome activation in these cells caused cleavage of proIL-1β to highly bioactive mature 
IL-1b form, supporting polarization of type-1 T-helper cells in an autocrine manner (Arbore et al., 
2016). While these studies highlight the biologic importance of lymphocyte-derived IL-1β, little 
is known about the regulation of the IL1B gene in CD4 T cells. 
            As stated above, IL1B transcription depends on the Spi1 transcription factor, which is 
highly expressed in monocytes. However, it is not known whether proIL-1b expression depends 
on Spi1 in CD4 T cells. The status of IL1B gene transcription and its epigenetic landscape in 
lymphoid CD4 T cells is also unknown. Thus, we set out to measure the regulation of IL1B in 
lymphoid-derived CD4 T cells, including Pol II and Spi1 engagement and specific epigenetic 
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marks on IL1B chromatin, in both ex vivo CD3/CD28-activated CD4 T cells and in vivo 




2.3.1. Human lymphoid T cells express proIL-1b after T cell antigen-receptor activation.  
            To better understand the process of proIL-1b expression in lymphoid CD4 tonsillar T cells, 
anti-CD3/CD28 beads were used in order to stimulate the T cell antigen receptors. After three days 
of activation, IL1B mRNA substantially increased in the ex vivo-activated tonsillar CD4 T cells, 
as compared to unstimulated T cells and the THP-1 human monocytic cell line, a well-studied 
benchmark population for IL1B gene expression, as well as the negative control human kidney 
epithelial HEK293 (Figure 2A). The mRNA kinetic profile for IL1B revealed highest transcription 
after 3 days following the CD3/CD28 activation (Figure 3A). However, LPS-treated THP-1 cells 
expressed approximately 500-fold more IL1B mRNA than the 3-day CD3/CD28 activated CD4 T 
cells. Of note, the level of SPI1 mRNA, which encodes Spi1, a myeloid-lineage transcription factor 
required for vigorous IL1B gene expression in activated monocytes (Adamik et al., 2013), was 
slightly increased following the activation of CD3/CD28 on CD4 T cells (Figure 2B and 3B), 
although Spi1 protein was undetectable (Figure 2C). By contrast, THP-1 monocytes expressed 




Figure 2. CD4 T cells express proIL-1β following TCR stimulation. Relative mRNA expression 
for (A) IL1B and (B) SPI1 in purified CD4 T cells from human lymphoid tissue (two individual 
patient donors), stimulated for 3 days with anti-CD3/CD28 beads, compared to resting CD4 T cells, 
HEK293 cells, and THP-1 cells (unstimulated or LPS-treated for 1.5 h). Data were normalized to 
the HEK293 cell sample; Standard error for each donor from lymphocyte populations represents 
technical replicates, and control cell lines (HEK293 and THP-1) represents biological replicates. 
(C) Western blot analysis of proIL-1β and Spi1 proteins from samples shown in A and B. The 
proIL-1β and Spi1 blots are shown at short and long exposures to illustrate the relative abundance 
of these proteins in CD4 T cells. Membranes were stripped and re-probed for β-actin. Note that 
the β-actin levels vary between cell types and increases with TCR stimulation. Sample inputs for 
western blots were normalized by cell equivalents: 1.5x105 for all lanes. For conciseness and 
clarity, only cropped western blot images are displayed. The full-length images of these blots are 




Figure 3. CD4 T cells express maximal IL1B mRNA after 3 days of TCR activation. Kinetic 
mRNA profile for (A) IL1B and (B) SPI1 in CD4 T cells following the TCR activation for indicated 
time. The values were normalized to HEK293 negative control cells. For comparison, unstimulated 




            Western blot analysis revealed that CD3/CD28 activated T cells expressed substantially 
higher levels of proIL-1b compared to their unstimulated counterparts (Figure 2C). Importantly, 
unstimulated THP-1 monocytes did not express proIL-1b protein (Figure 2C). As expected, CD4 
T cells expressed much lower levels of proIL-1b protein than LPS-treated THP-1 monocytes. 
Together, these results demonstrate that antigen receptor stimulation of human CD4 lymphocytes 
can induce de novo expression of IL1B gene transcription and protein synthesis. Flow cytometry 
analysis for proIL-1b revealed maximal protein after 3 days of CD3/CD28 activation with 
significant increase in induction over naïve T cells after 1 day of activation (Figure 4D).  This flow 
cytometry analysis also revealed that increase in proIL-1b production in activated CD4 T cells is 
likely from majority of the T cells expressing the protein at low levels and not from few high 
producers (Figure 4E). Interestingly, among the CD3/CD28 activated T cells, proIL-1b is produced 
by both CCR5+ and CCR5− cells (Figure 4F). 
 
 
Figure 4. Characterization of ex vivo differentiated CD4 T cells. (A) Fresh human PBMCs 
were isolated and analyzed by flow cytometry and compared to CD4 T cells, which were 
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magnetically purified by negative selection from tonsil. Note the lack of monocytes in CD4 T cell 
preparations. (B&C) Purified CD4 T cells from tonsil, stimulated with anti-CD3/28 beads or 
resting for 3 days of culture were surface-stained for CD45RO (memory marker), CCR5, and 
CD25. TCR stimulation induces an activated memory phenotype, including upregulation of CD25 
and CD45RO, and homogenous increase of CCR5. (D) Time course showing increasing proIL-1β 
following CD3/CD28 activation (blue traces). Cells were stimulated with anti-CD3/28 beads for 
time indicated, then treated with GolgiPlug (BD Biosciences) for two hours, surface stained as 
described in Methods, then fixed and permeabilized (eBiosciences Cytofix/Perm). Intracellular 
proIL-1β was stained using Alexa647 anti-IL-1β (BioLegend). Shown here are representative 
cytograms from one donor, representative of four individual donors. (E) Increase in proIL-1β 
production among the activated T cells is likely from almost all cells; not the result of a few high 
producers. (F) Among CD3/CD28 activated T cells, proIL-1β is produced by both CCR5+ and 
CCR5- cells (gated as in E). 
            Previous work has shown that CCR5+ cells express proIL-1b protein, which can be cleaved 
and released during pyroptotic cell death (Doitsh et al., 2014). In vivo CCR5+ CD4 T cells are 
predominantly effector memory cells, expanded from previous antigen-mediated activation. 
Lymphoid-derived CCR5+ and CCR5− CD4 T cells were purified from fresh human tonsil tissue 
by sequential magnetic and flow sorting (Figure 5A). All preparations of these cells were 
completely devoid of monocytes (Figure 4A). Cells from six donors were combined and compared 
with negative control HEK293 cells, as well as both unstimulated and LPS-stimulated THP-1 cells. 
IL1B mRNA was approximately 15-fold higher in CCR5+ CD4 T cells than their CCR5− 
counterparts (Figure 5B). Interestingly, IL1B mRNA was much lower in CCR5+ T cells than 
unstimulated THP-1 monocytes, which express measurable levels of IL1B mRNA (Kaspar and 
Gehrke, 1994). SPI1 mRNA was also slightly higher in CCR5+ cells than in CCR5− T cells (Figure 
5C). As previously described (Adamik et al., 2013), THP-1 monocytic cells expressed high levels 
of constitutive SPI1 mRNA, independent of LPS stimulation. Western blot analysis revealed that 
CCR5+ T cells expressed higher levels of proIL-1b protein than CCR5− T cells, unstimulated 
THP-1, and HEK293 cells (Figure 5D). Anticipating that LPS-treated THP-1 cells would produce 
high levels of proIL-1b protein, lysate for this positive control was loaded at one-tenth of that used 
for all other samples. This revealed an intense band for proIL-1b protein at ~31 kDa for LPS-
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treated THP-1. Again, proIL-1b protein was completely undetectable in unstimulated THP-1 cells 
but was present in CCR5+ CD4 T cells (Figure 5D). This result contrasts with the 25-fold greater 
abundance of IL1B mRNA in unstimulated THP-1 compared to CCR5+ T cells (Figure 5B), 
reflecting different mechanisms of post-transcriptional regulation of IL1B mRNA between these 
two cell types. 
 
 
Figure 5: in vivo differentiated CCR5+ CD4 T cells express proIL-1b. (A) Shown is a 
representative flow-sort from an individual CCR5+ CD4 T cell isolation. Cells were sorted from 
the CCR5+ and CCR5- gates as shown, after performing negative-selection magnetic enrichment 
of CD4 T cells from fresh human tonsil. Relative mRNA expression levels for (B) IL1B and (C) 
SPI1 from CCR5+ and CCR5- CD4 T cells, HEK293 cells, and both unstimulated and LPS-
stimulated THP-1. For mRNA analysis, multiple donors were pooled and the standard error 
represents technical replicates. The standard error for THP-1 and HEK293 reference samples were 
calculated from biological replicates.  (D) Western blot for proIL-1b from cells prepared as above 
described for two individual patient donors. Samples were normalized by cell equivalents: 1.5x104 
cell equivalents for THP-1+LPS and 1.5x105 in all other lanes. Membranes were stripped and re-
probed for β-actin. The β-actin band for LPS stimulated THP-1 is not visible on the blot because 
only 1/10th of the cells were added to prevent over-saturation of pro-IL1β band. For conciseness 
and clarity, only cropped western blot images are displayed. The full-length images of these blots 




2.3.2. Spi1 is not a detectable regulator of IL1B gene transcription in activated T cells.  
            To further understand de novo transcription of IL1B after CD3/CD28 activation of CD4 T 
cells, the presence of Pol II and Spi1 on the IL1B gene was investigated using chromatin 
immunoprecipitation-quantitative PCR (ChIP-qPCR). Amplicons for chromatin 
immunoprecipitation (ChIP) were designed to span the IL1B promoter and structural gene in order 
to measure the enrichment profile for Pol II and Spi1, as previously described (Adamik et al., 2013) 
(Figure 6A). We found that RNA Polymerase II (Pol II) on the IL1B gene in ex vivo CD3/CD28-
activated T cells was substantially enriched at the promoter and throughout the gene body, 
compared with unstimulated CD4 T cells (Figure 6B). Pol II engagement was not detected on the 
IL1B gene in negative control HEK293 cells. As expected, LPS-treated THP-1 monocytes had the 
highest levels of Pol II at both the promoter and throughout the body of the gene. 
 
Figure 6. Occupancy of Pol II and Spi1 on the IL1B gene. (A) Gene schematics with exons 
labeled as Roman numerals, and qPCR amplicons indicated by Arabic numbers referenced to 
positions listed in Table 2. (B) Pol II and (C) Spi1 ChIP for indicated CD4 T cell populations. For 
comparison, IL1B-refractory HEK293 cells were used as a negative control, and THP-1 cells 
stimulated with LPS for 1.5 hours were used as a positive control. CD4 T cells were purified from 
human lymphoid tissue and activated for 3 days with anti-CD3/CD28 beads and compared to 
unstimulated CD4 T cells. Promoter-proximal amplicons are shown as green bars, whereas 
downstream amplicons are shown as gray scale bars. Standard error for each donor from 
lymphocyte populations represents technical replicates, and control cell lines from cultured 
biologic replicates. (D) Histone H3 nucleosome ChIP at IL1B promoter in ex vivo CD3/CD28-
activated and unstimulated CD4 T cells as described within, are qualitatively compared to the 
previously reported Spi1 binding site and nucleosome distribution at the IL1B promoter in THP-1 
cells (Adamik et al., 2013). This reveals that a nucleosome is positioned over the Spi1 recognition 
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site in T cells. It has also been reported that Spi1-binding displaces this histone in THP-1 cells, but 
not in both Spi1-negative 293 cells and the HUT102 T cell line (Adamik et al., 2013). The qPCR 
amplicons used are listed in Table 2. 
 
 
Figure 7. The Spi1 independent IL1B gene for in vivo differentiated CCR5+ CD4 T cells 
exhibits similar bivalent H3K4me3+/H3K27me3+ epigenetic marks as ex vivo TCR-activated 
CD4 T cells. (A) Shown is a flow-sort from six individual donors pooled together to separate 
CCR5+ and CCR5- CD4 T cells for ChIP analyses. Cells were sorted from the CCR5+ and CCR5- 
gates as shown, after performing negative-selection magnetic enrichment of CD4 T cells from 
fresh human tonsil. (B) Pol II and (C) Spi1 ChIP on IL1B gene was performed in these CD4 T cell 
populations. For sake of comparison, Pol II and Spi1 ChIP data for HEK 293 and LPS stimulated 
THP-1 cells are included. (D&E) Actively transcribing HIST1H4K gene from the same chromatin 
was used as control. Histone modification ChIP on IL1B and HIST1H4K genes in CCR5+ and 
CCR5- CD4 T cell populations: (F) H3K9Ac; (G) H3K4me3; (H) H3K27me3; and (I) H3K36me3. 
Gene schematics for IL1B and HIST1H4K genes with exons labeled as Roman numerals are 
provided in Figure 6A and 8A respectively. Promoter-proximal amplicons are shown as green bars, 
whereas downstream amplicons are shown as gray scale. 
 
            In monocytes, Spi1 constitutively binds at the IL1B promoter and is required for 
transcription (Adamik et al., 2013). Because SPI1 mRNA was slightly up-regulated in CD4 T cells 
after ex vivo CD3/CD28 activation, Spi1 protein engagement at the IL1B promoter was measured. 
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Spi1 protein was not enriched at the promoter region of IL1B in either CD3/CD28-activated or 
CCR5+ CD4 T cells, when compared to the body of the gene (Figure 6C and 7C). This is supported 
by the lack of detectable Spi1 protein in T cells (Figure 2C). Spi1 was also not substantially 
enriched at the promoter in IL1B-refractory HEK293 cells. However, Spi1 was more abundant at 
the promoter of LPS-stimulated THP-1 cells than at the downstream gene body (Figure 2C). 
Histone H3 ChIP nucleosome profiles were also generated for the IL1B promoter in activated CD4 
T cells and compared to THP-1 cells from our previous work (Adamik et al., 2013). These revealed 
that both unstimulated and stimulated primary T cells, like HEK293 and Hut102 T cells (Adamik 
et al., 2013), possess a nucleosome positioned over the Spi1 binding site, supporting a Spi1-
independent model for IL1B gene transcription in CD4 T cells (Figure 6D). 
 
2.3.3. IL1B is transcribed from a bivalent H3K4me3/H3K27me3 promoter in CD3/CD28-
activated T cells.  
            The ex vivo CD3/CD28-activated lymphoid CD4 T cells were examined for the presence 
of chromatin marks that correlate with either permissive/active or repressed/inactive genes at the 
IL1B locus. Specifically, H3K4me3 and H3K9ac at promoter-proximal regions are generally 
associated with actively transcribed genes (Wang et al., 2008), whereas H3K27me3 is generally 
associated with inactive genes (Hansen et al., 2008). Additionally, H3K36me3 located at 
downstream regions of genes is generally associated with active transcript elongation by Pol II 




Figure 8. CD3/CD28-stimulation of CD4 T cells induces bivalent H3K4me3+/H3K27me3+ 
marks. Histone modification ChIP analysis of IL1B in CD3/CD28-activated and unstimulated 
CD4 T cell populations from two donor samples as indicated: (A) H3K9Ac; (B) H3K4me3; (C) 
H3K27me3, and (D) H3K36me3. The qPCR amplicon designations for panels A-D are as 
described in Figure 6A. Histone modification ChIP of the HIST1H4K (H4) gene in ex vivo 
CD3/CD28-activated and resting CD4 T cell populations as indicated: (F) H3K9Ac; (G) 
H3K4me3; (H) H3K27me3; and (I) H3K36me3. The qPCR amplicon designations for panels F-I 
are as shown in (E). Promoter-proximal amplicons are shown as green bars, whereas downstream 
amplicons are shown as gray scale. H3K9ac levels at the IL1B promoter are approximately half of 
HIST1H4K in activated CD4 cells. H3K4me3 is much lower on IL1B. Note that the inhibitory 
mark, H3K27me3, is substantially reduced on the IL1B gene following TCR activation, but not as 
low as it is on HIST1H4K in the same cells. Standard error for each donor represents technical 
replicates. 
 
            Following ex vivo CD3/CD28 activation, the H3K9ac and H3K4me3 marks substantially 
increased (Figure 8A and B), consistent with transcriptional activity. The H3K27me3 repressive 
mark only slightly decreased (Figure 8C), while the H3K36me3 mark increased along the length 
of the gene, indicating ongoing transcription (Figure 8D). However, comparing these IL1B histone 
modifications to those of constitutively expressed “housekeeping” HISTH4K gene in the same 
cells, the activating H3K9ac and H3K4me3 marks were approximately 2- and 4-fold lower, 
respectively, on IL1B than HISTH4K (Figure 8F and G). Also, the repressive H3K27me3 mark is 
10 to 12-fold higher on IL1B in activated T cells than on HISTH4K in the same cells (Figure 8H). 
 
 26 
Together, these findings of intermediate levels for both activating and inhibitory marks support a 
“bivalent” status for the IL1B promoter in CD4 lymphocytes following activation.   
            The epigenetic status of the IL1B gene in CCR5+ and CCR5− CD4 T cells was also 
investigated; revealing a slightly enriched H3K9 acetylation at the IL1B promoter in CCR5+ CD4 
T cells (Figure 7F). Both active H3K4me3 and repressive H3K27me3 were also enriched in 
CCR5+ CD4 T cells (Figure 7G and H), a characteristic of low-activity bivalent promoters (Voigt 
et al., 2013). In contrast, CCR5− CD4 T cells exhibited the H3K27me3, but not the active 
H3K4me3 mark at the IL1B promoter. Histone H3K36me3 was not substantially different on IL1B 
in either CCR5+ or CCR5− populations (Figure 4I). The control “housekeeping” HIST1H4K gene 
for both activated CCR5+ and naïve CCR5− cells revealed a promoter signature characteristic of 
actively expressed genes (H3K4me3+/H3K27me3Low), with CCR5− revealing higher levels of 
H3K4me3 than CCR5+ (Figure 7G and H). Histone H3K36me3 revealed the classic increase of 
gene body over promoter at the transcriptionally active HIST1H4K gene (Figure 7I). 
 
2.4. DISCUSSION  
 
            Recent findings of proIL-1b production and functionality in CD4 T cells highlight the 
importance of lymphocyte-derived IL-1b, a previously unappreciated phenomenon. We set out to 
investigate the regulation of the IL1B gene expression in CD4 T cells, as previous reports have all 
focused on these processes in myeloid-lineage cells. In the absence of stimulation, low-level IL1B 
transcription in resting monocytic cells does not result in IL-1b protein expression because of a 
specific post-transcriptional translation blockade (Kaspar and Gehrke, 1994) (Figure 2). 
LPS-TLR-stimulation of THP-1 cells causes a massive increase in IL1B transcription, overcoming 
the post-transcriptional block, resulting in abundant translation of proIL-1b. By contrast, the vast 
majority of unstimulated lymphoid CD4 T cells have little or no IL1B transcription, while TCR 
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activation causes de novo transcription and translation of IL1B to proIL-1b (Figure 2A and C, 
Figure 3A). It is important to note that the low expression of proIL-1b protein in CD4 T cells is 
not from few high producers but from a majority of the activated cells expressing the protein at 
low levels (Figure 4E). Interestingly, both CCR5+ and CCR5− CD4 T cells are expressing 
proIL-1b after 3 days of CD3/CD28 activation. Thus, it is likely that proIL-1b expression is 
induced independently of CCR5, following TCR activation. 
            Previous studies demonstrated that vigorous IL1B transcription in activated monocytes has 
an absolute requirement for the myeloid lineage-determining Spi1 transcription factor (Adamik et 
al., 2013). Although Spi1 is expressed in early stage, pre-commitment (CD4/8 double-negative) 
thymocytes, it is lost in CD4/8 double-positive and single-positive naïve T cells (Rothenberg et al., 
2013). Spi1 can be re-expressed in polarized Th2 (Chang et al., 2005) and Th9 (Chang et al., 2010) 
cells, suggesting that it may play a role in the regulation of IL1B gene expression following 
activation of CD4 T cells. Accordingly, we sought to compare the status of Spi1 involvement in 
IL1B gene transcription for activated CD4 T cells. Although, a slightly higher level of SPI1 mRNA 
was observed in activated T cells, when compared to resting T cells and HEK293 cells, Spi1 
protein was not detected in any of these cells (Figure 2C). Consistent with the role of Spi1 as a 
required monocyte-macrophage lineage commitment factor for IL1B transcription (Adamik et al., 
2013), its basal expression in both unstimulated and LPS-treated THP-1 monocytes were very high 
when compared to HEK293 and CD4 T cells. The very low level of proIL-1b protein in activated 
T cells, as compared to LPS-treated THP-1 monocytes, suggested a potentially distinct mechanism 
for IL1B gene transcription in T cells. The significant increase of Pol II at the promoter and body 
of the IL1B gene in activated T cells revealed by ChIP-qPCR provides further support for de novo 
IL1B transcription following TCR activation (Figure 5B). Consistent with the mRNA observations, 
this level of Pol II engagement at the IL1B gene is much lower than that observed on LPS-treated 
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THP-1 cells, resulting in substantially lower IL1B gene transcription in T cells than in activated 
monocytes. Additionally, Spi1 ChIP did not reveal enrichment at the IL1B promoter in activated 
T cells, arguing that transcription of IL1B in lymphocytes is Spi1-independent. This result is in 
striking contrast to monocytes, for which IL1B gene expression is absolutely dependent on Spi1 
and THP-1 cells exhibit a robust constitutive presence of Spi1 at the canonical DNA recognition 
site on the IL1B promoter (Adamik et al., 2013) (Figure 5C).  
            Additionally, the IL1B promoter in both unstimulated and activated T cells reveals strong 
nucleosome enrichment positioned directly over the Spi1 DNA binding site (Figure 6D), consistent 
with the lack of involvement of Spi1 in CD4 T cell transcription of IL1B. We have previously 
reported the presence of a stable nucleosome directly over the Spi1 binding site at the IL1B 
promoter in the Hut102 T cell line that does not express IL1B mRNA (Adamik et al., 2013). The 
winged helix-turn-helix (wHTH) DNA binding domain of Spi1, like other wHTH proteins 
(Iwafuchi-Doi et al., 2016), possesses potential “pioneer” activity for opening chromatin by 
nucleosome displacement. Consequently, the presence of a strong nucleosome signal over the high 
avidity Spi1 DNA binding sequence at the IL1B promoter is consistent with the absence of Spi1 
activity in CD4 T cells. 
            As previously demonstrated (Doitsh et al., 2014), the majority of CD4 T cells producing 
proIL-1b in vivo are marked by expression of the chemokine receptor CCR5 (Figure 5D). 
Interestingly, the relative IL1B mRNA expression in CCR5+ lymphocytes, though 15-fold higher 
than their CCR5− counterparts, was lower than that of unstimulated THP-1 monocytes. This 
observation is consistent with previous studies demonstrating that the IL1B gene is transcribed 
from a Spi1-poised promoter in unstimulated THP-1 monocytes (Adamik et al., 2013) that 
expresses a low basal level of IL1B mRNA (Chanput et al., 2010). Despite active transcription of 
IL1B in unstimulated THP-1 cells, the intracellular proIL-1b protein level in CCR5+ CD4 T cells 
 
 29 
was higher. This finding is not surprising, since unstimulated monocytes are known to exhibit a 
constitutive background level of IL1B mRNA transcript in the absence of detectable protein, due 
to a translational blockade that is reversed by LPS treatment (Kaspar and Gehrke, 1994). Therefore, 
if CCR5+ CD4 T cells lack a post-transcriptional blockade, a low-level translation of proIL-1b 
may occur as a result of a low level of IL1B transcription. Supporting a model of low IL1B 
transcription rate in CCR5+ cells, we detected only slight Pol II enrichment at IL1B promoter-
proximal regions, as compared to CCR5− CD4 T cells (Figure 7B), but differences in Pol II 
enrichment between these T cells populations were not detected throughout the length of the IL1B 
gene body, as observed in CD3/CD28 ex vivo activated T cells. The same chromatin samples were 
also evaluated for the actively transcribed HIST1H4K housekeeping gene. Both CCR5+ and 
CCR5− cells showed significant engagement of Pol II on HIST1H4K (Figure 7D). Although Pol 
II is likely transcribing IL1B at a very low level, over time, accumulation from low-rate 
transcription/translation could explain the substantial pool of intracellular proIL-1b detected in 
CCR5+ CD4 T cells (Figure 5D).  
            As observed following ex vivo CD3/CD28 activation, SPI1 gene mRNA levels were 
slightly higher in CCR5+ cells than in both CCR5− and HEK293 cells. However, in light of the 
lack of detectable Spi1 in activated CD4 T cells (Figure 2C) and negative detection of Spi1 on the 
IL1B promoter in CCR5+ CD4 T cells (Figure 7C), it is unlikely that Spi1 is responsible for the 
low level IL1B transcription observed in CCR5+ CD4 T cells in vivo.  
            It is well established that CCR5+ CD4 T lymphocytes are the primary cellular targets of 
HIV infection (Bleul et al., 1997; Eckstein et al., 2001; Jekle et al., 2003; Roy et al., 2005; 
Schweighardt et al., 2004). However, in ex vivo cultures from fresh human tonsil or spleen tissues 
(Glushakova et al., 1995), the majority of these cells are non-permissive for HIV replication, with 
the cytosolic viral DNA intermediates initiating an innate immune response that leads to the 
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activation of caspase-1. This results in abortive HIV infection (Doitsh et al., 2010), along with the 
death of abortively-infected CD4+ T-cells via caspase 1-mediated pyroptosis (an inflammatory 
form of programmed cell death) (Doitsh et al., 2014). As a result, dying CCR5+ CD4 T cells 
release mature IL-1β protein into the extracellular space, potentially driving a localized 
inflammatory response (Doitsh et al., 2014). Such an inflammatory response likely drives a vicious 
pathogenic cycle, where pyroptotic CD4 T cells release bioactive IL-1b and inflammatory 
mediators including chemokines that attract more cells into the infected lymph nodes to die, 
driving even more inflammation (Doitsh and Greene, 2016).  
            Resident CCR5+ CD4 T cells in lymphoid tissues are primarily memory cells. Unlike naïve 
CD4 T cells (which do not express CCR5), these CCR5+ CD4 T cells have previously undergone 
TCR activation before developing into activated/memory T cells. As our results show that 
CD3/CD28 activation of resting CD4 cells drives proIL-1β expression, it is likely that CCR5+ 
cells express proIL-1β as a consequence of prior, in vivo TCR activation. Memory CD4 T cells 
continually recirculates within lymphoid tissues, scanning for presentation of their cognate antigen 
(Lanzavecchia and Sallusto, 2000; Mackay, 1993; Sallusto et al., 1999). CCR5 expression has 
been previously characterized as a marker of Th1 lymphocytes (Loetscher et al., 1998). CCR5+ 
CD4 T cells could contribute substantially to chronic inflammation through activation of caspase-
1 and release of bioactive IL-1b.  
            Our previous work explored epigenetic regulation of IL1B in myeloid cells (Adamik et al., 
2013). Genes in embryonic and hematopoietic stem cells (Roh et al., 2006; Shen and Orkin, 2009; 
Vaquerizas and Torres-Padilla, 2016), as well as differentiated T cells (Roh et al., 2006), have 
been previously reported to be marked by active and repressive histone modifications, with the 
ratio of these marks modulating gene transcription. The new evidence presented in this study 
suggests that the IL1B gene in CD4 T cells following TCR-activation is modified to a bivalent 
 
 31 
H3K4me3+/H3K27me3+ status (Figure 8) that likely supports of a low level of transcriptional 
activity (Voigt et al., 2013). By contrast, the IL1B gene in unstimulated T cells is marked solely 
by high levels of monovalent H3K27me3 (i.e., no detectable promoter-localized H3K4me3). This 
supports the observed lack of IL1B transcription in naïve/unstimulated T cells. Additionally, a 
substantially higher level of H3K9ac is observed at the IL1B promoter in activated CD4 T cells, 
supporting active transcription. Finally, progressively increasing H3K36me3 through the IL1B 
gene body is consistent with ongoing, de novo Pol II transcription (Adamik et al., 2013). These 
marks in activated CD4 T cells differ from myeloid cells: unstimulated THP-1 cells possess 
monovalent H3K4me3, the active mark, which increases along with H3K9ac when stimulated with 
LPS (Adamik et al., 2013).  
            Validation of our results is found in the epigenetic analysis of the short, intronless 
HIST1H4K gene from the same chromatin samples. This “housekeeping” gene is actively 
transcribed, displaying high-level monovalent H3K4me3, with minimal enrichment of H3K27me3 
in both resting and activated T cells (Figure 8). Also, as expected for a constitutively active gene, 
strong enrichment for H3K9ac was observed at the HIST1H4K promoter, and H3K36me3 
increased towards the 3’ end of the gene body. Notably, the histone marks associated with 
transcriptional activity were all substantially higher on the constitutively expressed HIST1H4K 
gene than the IL1B gene from the same activated T cell chromatin samples. The repressive 
H3K27me3 histone mark at the IL1B promoter is much higher than that on the HIST1H4K gene, 
supporting the model that IL1B in activated T cells is transcribed from a low-activity bivalent 
H3K4me3+/H3K27me3+ promoter. The Spi1-independent nature of T cell IL1B expression may 




            Furthermore, the epigenetic study of CCR5+ T cells also reveals a bivalent profile at 
(H3K4me3+/H3K27me3+) of the IL1B promoter. Similar to unstimulated CD4 T cells, the IL1B 
gene in CCR5− cells contains only high levels of monovalent H3K27me3, the transcriptional 
repressive mark (Figure 7G and H). Also, the H3K36me3 comparison did not reveal a progressive 
increase toward the 3’ end of the IL1B, as was observed in ex vivo activated T cells. H3K36me3 
did present a classic profile for the HIST1H4K gene in both CCR5+ and CCR5− cell types. It is 
striking that the relative level of modification for this mark throughout IL1B in both CCR5+ and 
CCR5− T cells is comparable and appears elevated throughout the gene with respect to that of 
HIST1H4K. Interestingly, literature suggests that H3K36me3 modification patterns are not 
exclusively associated with gene activation, and can be related to other processes (Wagner and 
Carpenter, 2012). Consequently, although the pattern of this modification did not provide 
information on the transcriptional status of IL1B in either CCR5+ or CCR5− T cells, it is not 
evidence against active IL1B transcription in CD4 T cells. Generally, the epigenetic studies of 
CCR5+ vs. CCR5− CD4 T cells were limited by the low amounts of primary T cell chromatin 
samples with six donor samples being pooled in order to generate sufficient material for analysis. 
            In conclusion, we have extended the current understanding of IL1B gene transcription in 
human CD4 T lymphocytes, by investigating the involvement of Spi1 and the nature of chromatin 
organization for the IL1B gene in these newly recognized cellular sources of IL-1b protein 
expression. The proposed model argues that the IL1B gene in TCR-activated CD4 T cells is 
transcribed from a low-activity bivalent (H3K4me3+/H3K27me3+) promoter in a 
Spi1-independent fashion that results in the accumulation of intracellular proIL-1b (Figure 9). By 
contrast, myeloid cells transcribe the IL1B gene constitutively at a low level in a Spi1-dependent 
manner but have a post-transcriptional block on translation. TLR activation of monocytes drives 
extreme transcription of Spi1-dependent IL1B, while releasing translation inhibition. These 
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findings are highly relevant to further our understanding of adaptive immunity, since CD4 
lymphocytes, as a source of IL-1b, can shape immune response polarization and inflammation in 
disease. 
   
 
  
Figure 9. Monocytes and T cells have distinct mechanisms for IL1B gene regulation. LPS-
treated monocytes have high levels of active monovalent H3K4me3 ( ) but lack inhibitory 
H3K27me3 ( ) epigenetic histone modifications at the IL1B promoter. These modifications, along 
with activated NF-kB and C/EBPβ (Adamik et al., 2013), drive a vigorous Pol II engagement with 
extremely high transcriptional activity ( ) and correspondingly high levels of cytoplasmic proIL-
1β protein (•••). Unstimulated monocytes contain lower levels of monovalent H3K4me3 at the 
IL1B promoter and are deficient in inhibitory marks, resulting in weak Pol II engagement and 
extremely low transcription levels compared to stimulated monocytes. Accumulation of proIL-1β 
in these cells is inhibited due to a translational blockade (X). The myeloid competence factor, Spi1 
( ), is constitutively bound at a constant level to the IL1B promoter in these cells (Adamik et al., 
2013).  In contrast to the immediate-early LPS responsive IL1B gene in monocytes, slowly-
activated developmentally-regulated genes possess bivalent promoters with both active H3K4me3 
and inhibitory H3K27me3 epigenetic histone modifications. The IL1B promoter in lymphoid 
CCR5+ CD4 T cells contains such a bivalent H3K4me3+/H3K27me3+ mark, resulting in decreased 
Pol II engagement and substantially lower (~25‑times) transcription activity, as compared to 
resting monocytes. Interestingly, despite such a low level of transcription, intracellular proIL-1β 
accumulates in CCR5+ CD4 T cells in amounts higher than unstimulated monocytes. CCR5- CD4 
T cells exclusively contain the inhibitory H3K27me3, which does not support active IL1B 





2.5. MATERIALS AND METHODS 
2.5.1. Cell Culture, Reagents and Treatment Conditions 
          Cell lines were obtained from American Type Culture Collection (ATCC). THP-1 cells were 
cultured in RPMI media (Cellgro) supplemented with 10% heat-inactivated fetal bovine serum 
(Hyclone), 1% Penicillin/Streptomycin Solution (Cellgro) and 500 μl of 2-mercaptoethanol 
(Invitrogen). HEK293 cells were grown in EMEM (Cellgro) containing 10% heat-inactivated fetal 
bovine serum and 1% Penicillin/Streptomycin Solution. In mRNA and ChIP analysis, THP-1 cells 
were stimulated with 1ug/ml of E.coli 055:B5 Lipopolysaccharide (LPS) (L2880, Sigma-Aldrich) 
for 1.5 hours. Human tonsils were obtained from the Cooperative Human Tissue Network and 
processed as previously described (Doitsh et al., 2014; Galloway et al., 2015). Briefly, single cell 
suspensions were prepared and purified by density gradient-centrifugation with Ficoll-Paque 
Hypaque (GE Healthcare Life Sciences). CD4 T cells were enriched by negative selection using 
EasySep Human CD4+ T Cell Enrichment Kits (STEMCELL Technologies), per the 
manufacturer’s protocol. Following isolation, cells were cultured in RPMI (Gibco), plus 10% heat-
inactivated FBS (Atlas) and 1X Penicillin/Streptomycin/L-Glutamine (Gibco). For CD3/CD28 
stimulation, anti-CD3/CD28 magnetic beads (Dynabeads, Thermo Fisher Scientific) were added 
at a ratio of one bead per cell. Ex vivo anti-CD3/CD28 treatment of CD4 T cells results in antigen-
independent activation of the CD3 T cell receptor and the CD28 co-receptor. This is in contrast to 
normal in vivo activation involving cellular presentation of antigen by major histocompatibility 
complex II to the T cell receptor complex, in the context of costimulatory and cytokine signals. 
 
2.5.2. Cell Sorting and Flow Cytometric Analysis 
          Human tonsils were obtained from the Cooperative Human Tissue Network and processed 
as previously described (Doitsh et al., 2014; Galloway et al., 2015). These tissue specimens are 
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de-identified before receipt by the laboratory and have been classified exempt from human 
subject’s research by the Human Research Protection Program Institutional Review Board of the 
University of California, San Francisco. Briefly, single cell suspensions were prepared and purified 
by density gradient-centrifugation with Ficoll-Paque Hypaque (GE Healthcare Life Sciences). For 
ChIP analyses, CD4 T cells were isolated from HLAC by positive selection using CD4 microbeads 
(Miltenyi) per manufacturer’s protocol. Isolated CD4 T cells were stained with APC-CD4, 
APC/Cy7-CD3, and PE-CCR5 (clone 2D7/CCR5) (BD Biosciences) on ice for 3 hours. Stained 
cells were sorted using FACSAriaII (BD Biosciences) to isolate CD3+CD4+CCR5+, and 
CD3+CD4+CCR5− T cell populations.  
            For ChIP analyses the sorted cells were cross-linked immediately with 1% formaldehyde 
(as described below) and pellets were stored at -80 °C. For mRNA analyses cells were lysed in 
TRIzol (Invitrogen). For protein analyses, CD4 T cells were enriched by negative selection using 
EasySep Human CD4+ T Cell Enrichment Kits (STEMCELL Technologies), per the 
manufacturer’s protocol. The CD4 T cells were labelled on ice for 30 minutes with APC/Cy7-CD3, 
PE/Cy7-CD4, and Brilliant Violet 421-CCR5 (BioLegend). The cells were then FACS sorted as 
above. Sorted cells were lysed with RIPA buffer: 50mM Tris (Sigma), 150 mM NaCl (Sigma), 
0.1% SDS (BioRad), 0.5% sodium deoxycholate (Sigma), 1% Triton X100 (Sigma), and Complete 
protease inhibitor (Roche), and the lysates were frozen at -80°C.  
 
2.5.3. Western Blot Analysis 
            Cell lysates prepared as above were loaded in 4-12% Bis-Tris NuPAGE gels 
(ThermoFisher) for gel electrophoresis and transferred to PVDF membrane (EMD Millipore). 
Membranes were blocked for 1 hour at room temperature in blocking buffer: PBS + 0.05% 
Tween20 (Sigma) + 5% non-fat dry milk (BioRad). Primary antibodies were diluted in blocking 
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buffer and incubated overnight at 4°C. ProIL-1b was detected by a C-terminal-reactive mAb at 1 
µg/mL (mAb 201, R&D Systems). Blots were washed and probed with secondary Goat Anti-
Mouse IgG, Human ads-HRP (SouthernBiotech), diluted 1:20,000 in PBS + 0.05% Tween20 + 5% 
bovine serum albumin (Axenia BioLogix) for 2 hours at room temperature. HRP was detected 
using Western Lightning ECL Pro Enhanced Luminal Reagent (PerkinElmer) and Hyperfilm ECL 
(GE/Amersham).  
 
2.5.4. mRNA Expression Analysis 
            1x106 THP-1 and HEK293 cells were plated into 6-well plates (Thermo Fisher). Following 
the LPS treatments, cells were pelleted and supernatant was removed. The cell pellet was re-
suspended in 500 μl of TRIzol reagent (Invitrogen). For ex vivo differentiation experiments, naïve 
or anti-CD3/CD28-treated T cells were cultured for 3 days, counted, and 5x106 cells were 
resuspended in 500 µL of TRIzol reagent. For in vivo analyses, T cells were sorted, as described 
above, and 5x106 CCR5− cells and 2x106 CCR5+ cells were immediately resuspended in 500 μl 
of TRIzol reagent. Following the addition of 170 μl of Chloroform (Fisher), the samples were 
vortexed well and incubated at room temperature for 15 minutes. Then, the samples were 
centrifuged at 13200 RPM for 15 minutes at 4oC. Aqueous layer was transferred into a fresh tube 
and combined with 500 μl of isopropanol (Fisher) and 1 μl of Glycogen (Ambion). The samples 
were incubated at room temperature for 10 minutes and then centrifuged at 13200 RPM for 10 
minutes at 4oC. The RNA pellets were washed with 500 μl of 75% Ethanol (Pharmaco-AAPER) 
and centrifuged for 10 min in room temperature at 14000 RPM. Then, the ethanol was aspirated, 
and the pellets were allowed to air-dry for 10-15 minutes. Air-dried pellets were re-suspended in 
25 μl of DEPC-treated water (Ambion). The samples were incubated at 65oC for 10 minutes and 
subjected to DNAse treatments using Turbo DNA-free reagents (Ambion) according to the 
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manufacturer instructions in order to eliminate genomic DNA contamination. RNA concentration, 
260/280 and 260/230 values were measured using NanoDrop 1000 spectrophotometer (Thermo 
Fisher). mRNA was converted into cDNA using GoScript Reverse Transcription System (A5001, 
Promega). cDNA was analyzed using quantitative PCR (qPCR) carried out in a StepOnePlus 
Applied Biosystems Real Time Instrument (Thermo Fisher). Relative expression levels were 
calculated using DCt method. Primer Sequences used for mRNA analysis are indicated in Table 1. 
Gene Forward Primer Reverse Primer 
hIL1B TCCAGGGACAGGATATGGAG TCTTTCAACACGCAGGACAG 
hSpi1 CCAGCTCAGATGAGGAGGAG AGGCGGATCTTCTTCTTGCT 
 
Table 1. Primer sequences used for mRNA analysis. Table shows qPCR forward and reverse 
primers used for Human IL1B and Spi1 mRNA expression analysis.   
 
2.5.5. Chromatin Immuno-precipitation (ChIP)  
            ChIP was performed using a modification of the Millipore/Upstate protocol 
(MCPROTO407). In brief, a total of 1x107 THP-1 monocytes, 2.5x107 naïve CD4 T cells, 2.5x107 
CD3/CD28-activated CD4 T cells, 5.9x107 CCR5− CD4 T cells and 1.58x107 CCR5+ CD4 T cells 
were fixed in 1% formaldehyde (Fisher) for 10 min at room temperature. Cross-linking was 
inhibited by addition of glycine to a final concentration 0.125 M. Cell pellets were washed twice 
with ice cold PBS and resuspended in SDS Lysis Buffer (1% SDS, 10 mM EDTA, 50 mM Tris, 
pH 8.1) supplemented with Protease inhibitor cocktail (Sigma) and 1mM phenylmethylsulfonyl 
fluoride (PMSF, Fluka). Samples were sonicated (to generate DNA fragments of 250 base pairs 
(bp) average length) on ice using a Fisher Scientific Sonic Dismembrator (Model 100), as follows: 
15x25 strokes at 100% power followed by 3x25 stokes at 50% power and centrifuged at 12000 
RPM for 10 min. Chromatin was diluted 7-fold in ChIP Dilution Buffer (0.01% SDS, 1.1% Triton 
X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH8.1, 167 mM NaCl. Total equivalence of 3x106 
 
 38 
cells was used for Pol II and Spi1 pull downs for both ex vivo and in vivo CD3/CD28-activated T 
cells. For histone modifications ChIP analyses, 3x106 cells were used for ex vivo whereas 1.5x106 
cells were used for in vivo CD3/CD28-activated CD4 T cells. Supernatants were incubated at 4°C 
overnight with Santa Cruz antibodies Pol II (sc-899x), PU.1 (sc-352x), control IgG (sc-2027x); 
Active Motif antibodies H3K9ac (61251), H3K4me3 (39915), H3K27me3 (39155), H3K36me3 
(61101) and Cell Signaling Technology antibody Histone 3 (9715S). Aliquots for INPUT and non-
specific IgG control samples were included with each experiment. Samples were precipitated using 
25 µl of Magna ChIP Protein A+G Magnetic beads, at 4°C for 3 hours, and subsequently washed 
with following solutions: once with Low-Salt Buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 
20 mM Tris-HCl, pH 8.1, 150 mM NaCl), once with High-Salt Buffer (0.1% SDS, 1% Triton X-
100, 2mM EDTA, 20 mM Tris-HCl, pH 8.1, 550 mM NaCl), once with LiCl Wash Buffer (0.25 
M LiCl, 1% IGEPAL-CA630, 1% deoxycholic acid, 1mM EDTA, 10 mM Tris, pH 8.1), and twice 
with TE Buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). Immunocomplexes were eluted for 4 
hours at 65°C with 200 µl of ChIP Elution Buffer (1% SDS, 0.1M NaHCO3). To reverse the cross-
linking, eluted samples were treated with 10 µl of 5 M NaCl and subsequently incubated at 65°C 
for ≥4 hours. DNA was purified using a GeneJET PCR Purification kit (K0702, Thermo Scientific). 
Primer Sequences used for ChIP analysis are indicated in Table 2. The size of the PCR products 
ranges between 80 and 150 bp. Twenty micro liter qPCR reactions containing 2x Maxima SYBR 
Green/ROX qPCR Master Mix (Thermo Scientific), 250 nM of primers, and 3 µl of precipitated 
DNA were set up in Fast 96-Well Reaction Plates (Applied Biosystems). qPCR reactions were 
carried out in a StepOnePlus Applied Biosystems Real Time Instrument.  Fold enrichment was 
calculated based on Ct as 2(DCt), where DCt = (Ct Input – Ct IP). Final enrichment values were adjusted 








Forward Primer Reverse Primer 
  -279 TGTGTGTCTTCCACTTTGTCCCAC CCTGACAATCGTTGTGCAGTTGAT
G 
  -223 TGTGGACATCAACTGCACAACG TTCATGGAAGGGCAAGGAGTAGC
A 
  -155 TTGCTACTCCTTGCCCTTCCATGA GAGTATTGGTGGAAGCTTCTTAG
GG 
   -91  





  -19  





 +36  
























+3325      






+5389   






+6268   












  +35   




   (8) 
GGTGCTGAAGGTGTTCCTGG CGCTTGGCGTGCTCTGTA 
 
 +382  






Table 2. Primer sequences used for ChIP analysis. Table shows Human IL1B and HIST1H4K 
primer sequences used for ChIP. Numbers indicate the midpoint of amplicons in relation to the 
Transcription start site. Arabic numbers in red indicate the amplicons number in reference to gene 
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3.1. ABSTRACT  
 
            We previously reported that transcription of the human IL1B gene, encoding the 
proinflammatory cytokine interleukin 1b, depends on long-distance chromatin looping that is 
stabilized by a mutual interaction between the DNA-binding domains (DBDs) of two transcription 
factors, Spi-1 proto-oncogene (Spi1) at the promoter and CCAAT enhancer–binding protein b 
(C/EBPb) at a far-upstream enhancer. We have also reported that the C-terminal tail sequence 
beyond the C/EBPb leucine zipper is critical for its association with Spi1 via an exposed residue 
(Arg-232) located within a pocket at one end of the Spi1 DNA-recognition helix. Here, combining 
in vitro interaction studies with computational docking and molecular dynamics of existing X-ray 
structures for the Spi1 and C/EBPb DBDs, along with the C/EBPb C-terminal tail sequence, we 
found that the tail sequence is intimately associated with Arg-232 of Spi1. The Arg-232 pocket 
was computationally screened for small-molecule binding aimed at IL1B transcription inhibition, 
yielding L-arginine, a known anti-inflammatory amino acid, revealing a potential for disrupting 
the C/EBPb:Spi1 interaction. As evaluated by chromatin immunoprecipitation, cultured 
lipopolysaccharide (LPS)-activated THP-1 cells incubated with L-arginine had significantly 
decreased IL1B transcription and reduced C/EBPb’s association with Spi1 on the IL1B promoter. 
No significant change was observed in direct binding of either Spi1 or C/EBPb to cognate DNA 
and in transcription of the C/EBPb-dependent IL6 gene in the same cells. These results support the 
notion that disordered sequences extending from a leucine zipper can mediate protein–protein 







            Human interleukin 1β (IL-1β), a member of the IL-1 family of cytokines coded by the IL1B 
gene, is an important mediator of inflammation in response to microbial invasion and tissue injury. 
Many rapidly induced/immediate early (IE) genes such as FOS and EGR1 (Donner et al., 2010), 
TNF (Adamik et al., 2013) and a majority of the 6,511 protein genes in human K562 cells (Pugh 
and Venters, 2016) possess prebound RNA Polymerase II (Pol II) co-present with TATA Binding 
Protein (TBP) and TFIIB transcription pre-initiation factors paused 30-50 bp upstream of the 
transcription start site. In contrast, we previously reported that the human IL1B gene promoter is 
deficient in prebound Pol II and constitutively binds the Spi1/PU.1 (Spi1) transcription factor in 
the almost complete absence of TBP and Pol II (Adamik et al., 2013). Spi1, which is required for 
IL1B gene expression in monocytes (Adamik et al., 2013), is a myeloid cell lineage-determining 
factor that has a C-terminal ETS family winged Helix-Turn-Helix (wHTH) DNA binding domain 
(DBD) and an N-terminal transactivation domain (TAD). We also reported that the DNA binding 
domain of constitutively promoter-bound Spi1 directly interacts by long-range chromatin looping 
(Adamik et al., 2013) with the DBD of the C/EBPβ transcription factor, which in-turn binds to a 
far upstream super-enhancer following Lipopolysaccharide (LPS)/Toll-Like Receptor 4 (TLR4) 
signaling. The critical protein–protein interaction between Spi1 and C/EBPβ in monocytes occurs 
along with TBP and Pol II recruitment, gene expression, and an apparent chromatin loop 
stabilization (Adamik et al., 2013; Listman et al., 2005; Yang et al., 2000). We have also reported 
that the C-terminal tail extension of the C/EBPb basic leucine zipper (bZIP) is critical for 
C/EBPb:Spi1 association via an exposed arginine residue (Arg-232) within a pocket at one end of 
the DNA-recognition helix in the Spi1-DNA X-ray structure (Listman et al., 2005) previously 
reported by others (Kodandapani et al., 1996). 
            In an attempt to investigate the molecular nature of this critical protein–protein interaction, 
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computational docking of the existing independent X-ray structures for the C/EBPb and Spi1 
DBDs yielded a conformation reminiscent of a C/EBPb:cMyb X-ray structure previously reported 
by others (Tahirov et al., 2002). Although the cMyb structure provided a basis for a C/EBPb:Spi1 
interaction, the absence of the C/EBPb C-terminal tail suggested a distinct binding mode for 
C/EBPb with Spi1. In vitro interaction studies between the DBDs of the two proteins argues for a 
larger surface footprint on Spi1 than would be expected for a cMyb-like interaction with C/EBPb. 
Our docking of the isolated C/EBPb C-terminal tails to Spi1 revealed an intimate association of 
the terminal cysteine carboxylate of the tail with Arg-232 of Spi1. A composite C/EBPb:Spi1 
structure was then generated and evaluated by molecular dynamics simulation, revealing a stable 
structure consistent with the new and previously reported data. 
            In order to test the computational model, the Arg-232 pocket in the Spi1:DNA X-ray 
structure (Kodandapani et al., 1996) was used to screen known small molecules for competitive 
potential. L-arginine, a known anti-inflammatory, was computationally identified to bind in this 
pocket, suggesting a potential for disrupting the C/EBPb:Spi1 interaction. Subsequent ex vivo 
studies using LPS-activated THP-1 cells incubated with L-arginine demonstrated a significant 
decrease in IL1B transcription in parallel with a reduction in C/EBPb association with Spi1 on the 
IL1B promoter, as evaluated by chromatin immunoprecipitation. No significant change was 
observed for parallel transcription of the Spi1-independent/ C/EBPb-dependent IL6 gene.  
Importantly, direct binding of Spi1 and C/EBPb to cognate DNA was unaffected. These results 
are consistent with an L-arginine-dependent decrease in IL1B gene expression being due to its 
ability to inhibit the protein–protein interaction between C/EBPb and Spi1 in the absence of any 




3.3. RESULTS AND DISCUSSION 
3.3.1. Computational modeling predicts interaction between the C/EBPβ leucine zipper 
C-terminus and the Spi1 DNA binding domain 
            Our previous reports described a long-range DNA loop-mediated promoter-proximal 
protein–protein interaction between the Spi1 winged Helix-Turn-Helix (wHTH) DNA binding 
domain (DBD) and the carboxyl end of the C/EBPβ leucine zipper dimer DBD that is critical for 
IL1B gene transcription (Adamik et al., 2013; Listman et al., 2005; Yang et al., 2000). This 
interaction is similar to that which we reported for Human Cytomegalovirus (HCMV) IE2 protein 
with Spi1 (Wara-aswapati et al., 1999) and by others for C/EBPa with GABPa (Shimokawa et al., 
2010; Shimokawa et al., 2013; Shimokawa and Ra, 2005). Although the structure of HCMV IE2 
protein is unknown, the structures of the Spi1 and GABPa DBDs are known and represent the two 
most distantly related ETS wHTH DBDs of the 12 ETS domain homology types (Hollenhorst et 
al., 2011). The ETS family of DNA binding proteins all contain a common ETS DBD localized to 
either end or the middle of the overall protein sequence (Hollenhorst et al., 2011). The structure of 
several ETS domains have been solved, all of which contain three interacting a-helices, one of 
which serves as a DNA sequence recognition element, along with two loops closed by antiparallel 
b-strands that constitute a wing motif that provides additional DNA backbone interactions. An 
HTH structure is also found in other DNA binding domains that possess a similar 3 a-helix 
backbone without b-strands and minimal sequence conservation with the ETS subfamily. Three 
tandem copies of the non-ETS HTH domains are contained within the cMyb DNA binding protein, 
which also binds the C/EBPβ leucine zipper dimer. The X-ray crystal structure of the C/EBPβ 
leucine zipper coiled-coil attached to its basic (i.e., positively charged) DNA binding sequence 
interacting with DNA-bound cMyb (a DNA:bZIPC/EBPβ:HTHcMyb:DNA complex) reveals a 
C/EBPβ bZIP dimer interaction with a single cMyb HTH domain (Tahirov et al., 2002). In this 
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structure, the short C-terminal peptide tails that extend beyond each of the leucine zipper 
monomers were deleted, resulting in the C-terminal glutamate of one bZIP monomer and a second 
glutamate within the body of the zipper generating salt bridges to one cMyb DBD (Figure 10). 
 
Figure 10. Three rotational views of the DNA:bZIPC/EBPβ HTHcMyb:DNA interaction 
generated from the RCSB-deposited coordinates using transformations provided in the 1H89 
PDB file. The C/EBP bZIP homodimer (Chain A, Green & Chain B, Blue) joins two separate 
DNA duplexes (Grey) by directly interacting with one of the two DNA-bound cMyb HTH domains 
(Red) via both truncated C-terminal ends of the leucine zipper dimer (aa296 to 336) in the absence 
of the 9 amino acid C-terminal extra-zipper tails (aa337 to 345), while also interacting via the bZIP 
basic DNA binding domain (aa259 to 295) to a second DNA. Chain B also makes direct contact 
with a DNA backbone phosphate, indicated by an arrow in the upper right structure. 
 
            The structure of the C/EBPβ:cMyb complex provides a potential paradigm for other 
bZIP:HTH domain interactions. This resulted in our earlier studies aimed at exploring the 
involvement of the C/EBPβ leucine zipper C-terminal glutamate (Listman et al., 2005) and a 
detailed inspection of the contact surface between the two domains that were generated from the 
RCSB-deposited X-ray coordinates using transformations described within the 1H89 PDB file 
(Figure 10). The C/EBPβ:cMyb contact surface consists of an asymmetric interaction between the 
C-terminus of the C/EBPβ leucine zipper dimer and a single cMyb HTH domain involving 4 side 
chain, 1 backbone and 9 van der Waals contacts with the bZIP Chain A, along with 5 backbone, 2 
van der Waals contacts and 2 DNA salt-bridge interactions with the bZIP Chain B (Tahirov et al., 
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2002; Tsukada et al., 2011). Strikingly, the leucine zipper dimer extra-ZIP C-terminal peptides, 
each consisting of 9 residues beyond the terminal Glu-336 were deleted from the molecule used 
for crystallography, providing circumstantial evidence that complex formation did not require 
sequences beyond the structural terminus of the bZIP dimer. This conclusion appeared to agree 
with the hypothesis provided in our previous report (Listman et al., 2005) that suggested Glu-336 
might directly interact with Arg-232 of Spi1 for the C/EBPβ:Spi1 interaction, although the 
importance of the Chain B DNA contact was never addressed. Consequently, we set out to attempt 
computational docking in order to evaluate possible requirements for the C/EBPβ:Spi1 interaction. 
            The initial computational approach took advantage of the ZDOCK webserver (Pierce et al., 
2014), which uses rigid-body protein–protein docking via a fast Fourier transform algorithm that 
relies on a combination of shape complementarity, electrostatics and statistical potential. The 
C/EBPβ bZIP, basic leucine zipper, sequence from aa266 to 336 was docked to the Spi1 DBD. 
Figure 11 displays models for the 8 top-ranking zipper dimer interactions, all of which reveal tight 
clustering to a localized target on the surface of Spi1 for the carboxyl ends of the C/EBPβ zipper 
dimer coiled-coil. Six of these ZDOCK predictions involve at least one salt-bridge between 
C/EBPβ and Spi1, three of which are with the terminal C/EBPβ Glu-336. All of these interactions 
absolutely depend upon the terminal Glu-336 residue, since C/EBPβ aa266 to 335, missing this 
residue, did not yield a consistent result (Figure 12). This docking geometry, lacking the extra-ZIP 
C-terminal unstructured peptides, resembles the C/EBPβ:cMyb interaction (Tahirov et al., 2002) 
and did not provide structural evidence for the involvement of Arg-232 (Figure 11, red arrow), 




Figure 11. Computational docking using the ab initio ZDOCK server. Six different views of a 
composite backbone ribbon structure presenting the general orientation of the top eight C/EBPb 
leucine zipper coiled-coil dimers (long Blue coils representing aa296 to 336) with an invariant 
Spi1 DBD, represented as three a-helices (short Blue coils) and four b-strands (Red bands). The 
Spi1 a3 DNA-recognition helix in two views is labeled with a red arrow pointing to the location 
of Arg-232 (R232). A green arrow locates the position of the amino end of the Spi1 DBD (residue 
171). The first 170 N-terminal residues of the full length Spi1 protein Transactivation domain 
(TAD) is not contained within the solved X-ray structure. The four structures in the top row are 
related by incremental 90o rotations, whereas the lower row presents top and bottom views. Due 
to its flexible behavior in the absence of DNA, the aa266 to 295 DNA-binding basic regions of the 
bZIP, is not shown in the figure. 
 
 
Figure 12. ZDOCK docking between Glu 336-deficient C/EBPβ (aa296 to 335) and Spi1. The 




            Since the ZDOCK prediction does not rely on experimental data, we employed the 
HADDOCK webserver, which provides a data-driven approach to docking by requiring a list of 
residues that are either Active (involved) or Passive (potentially involved) in contact as part of the 
data input (de Vries et al., 2010). Data for HADDOCK was obtained using an in vitro glutathione-
S-transferase (GST) interaction approach, as we had previously used for gross mapping of DNA-
independent Spi1 interactions with HCMV IE2 (Wara-aswapati et al., 1999) and seven other 
proteins (Adamik et al., 2013). The GST results (Figure 13A and B) collectively suggest that the 
C/EBPβ leucine zipper independently targets specific substructures within the Spi1 wHTH ETS 
domain. In particular, we focused on helix a3, which contains Arg-232 (Figure 13A, white band), 
and the wing loop component interaction between the b3 and b4 anti-parallel strands. An 
additional interaction may also localize to the b1 and b2 antiparallel strands, which together with 
b3 and b4 constitute a complete wHTH wing module (Figure 13B). Figure 13C presents these 
interacting regions as backbone (Top) and space-filling (Bottom) views of the Spi1 DBD bound 
to DNA and color coded with respect to indicated regions in Figure 13A, revealing that one side 
of the structure may be the most relevant for C/EBPb interaction (Figure 14). This information 
was used to specify Active and Passive residues for HADDOCK docking between the full-length 
aa259-336 bZIP dimer (that included the N-terminal basic DNA-binding motif) and the Spi1 
wHTH domain, as described in Materials and Methods. The C/EBPβ C-terminal 7 amino acids (aa) 
of the leucine zipper dimer (aa330-336), which terminates at Glu-336, was defined as active, 
whereas the N-terminal DNA-binding region (aa259-295) was defined as passive. The Spi1b3/b4 
anti-parallel strands that include the interpositioned loop located between aa243 and aa254 were 
defined as active, while the sequence between aa171 and aa219 was made passive. The resulting 
HADDOCK interaction appeared similar, but not identical, to that obtained with ZDOCK (Figure 
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15), once again supporting a C/EBPβ:cMyb-like interaction. In particular, salt bridges between 
Glu-336 in C/EBPβ Chains A and B with the sidechains of Lys-248 and Lys-244 in Spi1, 
respectively, are consistent with both the cMyb tail-less mode of docking and the ZDOCK result 
in the absence of Glu-336 (Figure 12). Unfortunately, neither ZDOCK nor HADDOCK provide 
direct evidence for the involvement of the C-terminal tails and, specifically, Arg-232. However, 
the GST interaction results (Figure 13) suggest that the Spi1 a3 helix, containing Arg-232, may 
be a part of an extended contact surface for the Chain B C-terminal tail.  
 
Figure 13. Summary of Glutathione-S-Transferase (GST) interaction studies between the 
C/EBPb leucine zipper (aa259 to 345) and the Spi1 DBD. The location of Arg-232 in the a3 
helix is indicated by a white band. (A) Schematic representation and relative binding of GST-Spi1 
ETS-domain DBD fragments to 35S-methionine-labeled C/EBPb leucine zipper. (B) SDS 
polyacrylamide gels presenting the degree of interaction by autoradiography (Top). The relative 
amount of input protein by staining with Coomassie Brilliant Blue is shown (Bottom).  (C) X-ray 
crystal structure (RCSB 1PUE) of Spi1 bound to DNA (Grey space-filled) presenting specific GST 
protein–protein interaction results shown as blue and green structural elements, as indicated in A, 
with their general location on backbone ribbon (Top) and space-filling (Bottom). The Arg-232 





Figure 14. Rotational views of Spi1:DNA correlating specific GST protein-protein 
interaction results. The single structural view in Figure 13C is expanded in order to present 
multiple views more clearly demonstrating the asymmetrical interaction of C/EBPβ on Spi1. The 
interacting regions are shown as blue and green structural elements in A with their general location 
on backbone ribbon (Top) and space-filling models of Spi1 bound to DNA (Grey space-filled). 




Figure 15. Computational docking using the data-driven HADDOCK server. Two views of 
the top four docking solutions for the C/EBPb leucine zipper coiled-coil dimer (Red coils) to Spi1 
(Pink surface) bound to DNA (Grey surface). The diagram to the right presents the interactions 
between Spi1 DBD and each C/EBPb (aa266 to 336) chain. 
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3.3.2. A critical salt bridge between C/EBPβ and Spi1 is stable throughout the NAMD 
simulation  
            In order to model the Arg-232 interaction, an independent approach was used for docking 
of the C/EBPβ C-terminal extra-zipper tails. This involved the use of LowMode MD (Labute, 
2010), a method of short molecular dynamics simulations to predict the likely orientation of protein 
loops. The resulting LowMode MD docking of the C/EBPβ C-terminal extra-zipper tails revealed 
a salt-bridge between the side-chain guanidinium group of Arg-232 in the Spi1 a3 helix and the 
C-terminal carboxylate group of Cys-345 on the Chain B C/EBPβ tail (Figure 16A), consistent 
with our previous report suggesting that Arg-232 on Spi1 is critical for the interaction between the 
two proteins (Listman et al., 2005). The Chain A tail docked into a pseudo-symmetrical location 
on the Spi1 a3 Helix, interacting with Lys-224 (Figure 16B).  
 
Figure 16. LowMode Molecular Dynamics docking of C/EBPβ extra-leucine zipper C-
terminal tail to DNA-bound Spi1. (A, Left) The Spi1 DBD and the C/EBPβ 20 amino acid 
peptide sequence from T326 to C345, which includes the last eleven amino acids of the leucine 
zipper and the nine amino acids of the C-terminal tail, are presented as a ribbon/coil backbone with 
sidechain sticks. DNA is shown as a grey surface. Spi1 R232 and C/EBPβ C345, which constitute 
the specific interaction between the two proteins, are presented as ball & stick atoms. (A, Right) 
Interaction schematics present the contact environment of the terminal Chain B C345 of C/EBPβ 
in the Spi1 pocket. (B, Left & Right) Similar LowMode MD for docking of the C/EBPβ Chain A 




            The LowMode MD Docking of the C/EBPβ C-terminal extra-zipper tails to the Spi1 DBD 
was executed in the absence of the C/EBPβ leucine zipper:cMyb-like interaction in order to test 
whether the two contacts were independent, an hypothesis derived from the apparent independent 
targeting of specific substructures within the Spi1 wHTH ETS domain revealed by the in vitro 
GST studies (Figure 13). Superimposition of the Chain A LowMode MD C/EBPβ C-terminal tail 
structure revealed significant coincidence with the C/EBPβ Chain A leucine zipper monomer from 
HADDOCK, permitting manual manipulation of the backbone in order to generate a peptide bond 
(Figure 17). The Chain B LowMode MD Spi1 C-terminal tail structure was also reasonably close 
to the Glu-336 terminus of the HADDOCK C/EBPβ Chain B, which was also computationally 




Figure 17. General structural geometry relationships among the HADDOCK, Low Mode 
MD and NAMD docked C/EBPβ:bZIP structures. (A) Display of two merged Spi1 DBD 
structures associated with either the Chain A C-terminal extra-zipper tail (aa332 to 345) LowMode 
docking result (Green) or the ChainA:Chain B leucine zipper dimer derived from HADDOCK 
docking (Red), showing the Chain B Glu336 interaction with Lys244 of Spi1. (B) Two 90o 
rotational views, each displaying two merged Spi1 DBD associated with either the Chain A 
(Green):Chain B (Red) leucine zipper dimer with C-terminal extra-zipper tails, derived from the 
completed NAMD simulation or just the Chain A (aa332 to 345) LowMode docking, as indicated. 
The dotted double-headed arrow indicates the distance between the Chain A Lys332 a-carbons 
from the two models.   
 
            The resulting composite structure, consisting of: 1) the HADDOCK-derived bZIP dimer 
docked to Spi1; 2) the two peptide-bonded LowMode-docked C-terminal extra-zipper tails; and 3) 
both fragments of double-stranded DNA from the two original X-ray crystal structures was then 
energy minimized. This resulted in the loss of the Chain A leucine zipper Glu-336 salt bridge and 
a rotational movement of this chain with respect to Chain B. Since the in vitro data and LowMode 
MD docking supported an interaction between Cys-345 of C/EBPb and Arg-232 of Spi1, the Chain 
B tail was computationally replaced with the LowMode MD tail structure and the 
Cys-345:Arg-232 contact constrained prior to energy minimization and solvation, following which 
the constraints were removed and the structure was subjected to 104 ns of NAMD simulation. 
Strikingly, the Glu-336 salt bridges that appeared critical for C/EBPb:cMyb-like docking in the 
absence of the C-terminal tails were both destabilized in the presence of the Arg-232-docked Chain 
C-terminal tail. The loss of the salt bridges was accompanied by a 13 Å displacement of the leucine 
zipper dimer from its original HADDOCK location toward the Arg-232 side of the Spi1 DBD 










Figure 18. NAMD simulation for the solvated completely docked Spi1:C/EBPβ with 
C-terminal tails that generated the final structure shown in Figure 20A. (A) The inter-atom 
distances for different conformations of the salt-bridge between Zeta carbon of Arg232 on Spi1 
(Chain C) and C-terminal carboxylate carbon of Cys345 on C/EBPβ Chain B during the NAMD 
run. The inter-atom distance between: (B) the Zeta 1 nitrogen of Lys224 on Spi1 (Chain C) and 
backbone carboxylate carbon of Cys345 on C/EBPβ Chain A; (C) the Zeta nitrogen of Lys198 on 
Spi1 (Chain C) and backbone carboxylate carbon of Cys345 on C/EBPβ Chain A; and (D) the Zeta 




Figure 19. Detail of C/EBPβ:Spi1 contact surface showing the individual sub-interactions. 
The 1481 Å2 surface consists of 928 Å2 from Chain B and 578 Å2 from Chain A (See Table 3). 
The zipper-only contact is 274 Å2, while the Chain A and Chain B tails represent 320 and 912 Å2, 
respectively. Overall, the Chain B tail that terminates in the critical Spi1 Arg 232 interaction 
represents approximately 60% of the contact surface. 
 
            The stability of the Chain B interaction between Arg-232 of Spi1 and Cys-345 at the 
C/EBPβ C-terminus was maintained (Figure 18A) vs that for the Chain A tail, which rapidly 
destabilized during the first 20 ns of the simulation (Figure 18B) and folded into a compact domain 
that directly interacted with the Spi1 DBD, providing 320 Å2 of buried contact surface (Figure 19) 
along with a compensatory C-terminal Cys-345 salt bridge to Lys-198 of Spi1 (Figure 18C). The 
resulting dynamically stable Chain B-biased model (Figure 20 and 21) is not only compatible with 
our previously reported mutational (Listman et al., 2005) and GST (Figure 13) in vitro results, but 
also suggests that the HADDOCK and Chain B interactions could be cooperative in a two-step 
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docking model. This involves an initial HADDOCK cMyb-like C/EBPb Glu-336 ionic-driven 
interaction, followed by reconfiguration to a more stable conformation involving the Chain B 
C-terminal tail interaction with Arg-232 along with the increased excluded-water contact surface 
and compensatory salt bridge of Chain A. In addition, the inability of the C/EBPβ Chain A 
C-terminal tail to readily conform to the LowMode MD prediction during the NAMD simulation 
conforms not only with the in vitro data, but also with reports of Spi1 interactions with C/EBPβ 
homotypic heterodimers. These closely related CREB-CREM bZIP family heterodimers, which 
possess a highly divergent collection of bZIP C-terminal extensions, binding to the IL1B gene 
(Gray et al., 1993; Tsukada et al., 1994). 
 
Figure 20. Details of the interaction between Spi1 and C/EBPβ resulting from NAMD 
simulation. (A) Shows three views of the DNA-Spi1DBD:C/EBPbbZIP+Tails-DNA structure at 
the end of the 104 ns NAMD simulation. The white dotted box in the bottom-side view locates the 
region where the major Arg-232:Cys-345 and Arg-235:His-344 interactions occur between Spi1 
and C/EBPb. The C/EBPb A and B chains are colored Red and yellow, respectively. Spi1 is 
colored Blue. (B) Detailed structure of the interaction between Arg-232 of the Spi1 with Cys-345 
at the C-terminus of C/EBPb Chain B and Arg-235 of Spi1 with His-344 of C/EBPb Chain B at 
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the end of the NAMD run. Backbone colors are as described for Panel A. (C) Specific atomic 
distances tracked during the NAMD simulation. The first plot (left) tracks inter-atom distances 
between the Zeta carbon of Arg-232 on Spi1 and C-terminal carboxylate carbon of Cys-345 on the 
C/EBPβ Chain B. The second plot (right) tracks inter-atom distances between the Eta1 nitrogen of 
Arg-235 on Spi1 (Chain C) and the backbone carboxylate oxygen of His-344 on C/EBPβ Chain B. 
(D) A modified figure derived from our previously published report (Listman et al., 2005) 
demonstrating the relative importance of Arg-232 and Arg-235 as revealed by in vitro protein–
protein interaction studies. 
 
            The final NAMD conformation for the complex, including DNA fragments representing 
the IL1B gene promoter and super-enhancer, reveals (Figure 20A) how the C/EBPβ:Spi1 
interaction might stabilize a 2.8 Kbp chromatin loop between the IL1B promoter and its 
super-enhancer (Adamik et al., 2013). In addition to the Arg-232:Cys-345 C-terminal C/EBPβ 
interaction with Spi1, a proximal contact exists between His-344 of C/EBPβ and Arg-235 of Spi1 
(Figure 20B). The NAMD reveals that both of these interactions are stable over the last 98 ns of 
the simulation, with the Arg-232(Cz):Cys-345(CCO) contact stabilizing before that of 
Arg-235(Nh1):His-344(OCO) (Figure 20C). This supports the kinetic importance of the 
Arg-232:Cys-345 contact over that of Arg-235:His-344 and is consistent with our previous report 
(Listman et al., 2005) experimentally demonstrating that mutation of Arg-232 in Spi1 was 
substantially more critical for complex stability with C/EBPβ than Arg-235, as referenced in 
Figure 20D. This previous study revealed that an Arg-232 point mutation alone reduced 
C/EBPb:Spi1 interaction by about 80% (Listman et al., 2005). Figure 20B shows the 
Arg-232:Cys-345 and Arg-235:His-344 interactions between Spi1 and C/EBPβ and their 
respective O-N bond lengths at the end of the NAMD run. A weak salt bridge was observed 
between Chain A of C/EBPβ (Cys-345) and Spi1 (Lys-198) only towards the end of NAMD 
simulation (Figure 18C). Along with these interactions, some non-polar and hydrogen bonds were 




Figure 21. The Spi1:C/EBPβ interaction surface. (A) Structural interaction diagram shows the 
key interacting residues in: C/EBPβ Chain A (Blue); C/EBPβ Chain B (Green); and Spi1 (Red). 
The overall contact surface is marked by a yellow swath. H-bonds are indicated by black dots and 
electrostatic interactions by blue dashes. (B) Summary of all intermolecular interactions between 
Spi1 and C/EBPb. 
  
            The total 1481Å2 of buried surface area between Spi1 and C/EBPβ (Table 3) is within the 
range of values that have been observed for other functional protein–protein interactions (Janin et 
al., 2007). In particular, the C-terminal residues (337-345) of C/EBPβ Chain B contribute more 
than half of the average buried surface area (912Å2) as compared to Chain A terminal residues, 
whose average buried surface area with Spi1 is only 320Å2 (Table 3 and Figure 19). The interaction 
between the guanidinium side chain of Arg-232 and the C-terminal carboxylate of Cys-345 is 
noteworthy as a result of both its geometry and electrostatics. First, the arginine side chain has the 
highest pKa (~12.48) of any amino acid, while the terminal cystine carboxylate presents the lowest 
a-carboxyl pKa (~1.71), providing the strongest potential for a unitary salt bridge. In addition, the 
bifurcated nature of the carboxylate-guanidinium interaction provides for a cooperative bidentate 
linear geometry that has been exploited by many proteins (SAPSE and RUSSELL, 1984), with 
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stabilities that can approach -3.6 kcal/mol (Linton and Hamilton, 1999) and argued to provide 
enzymatic active site stability in thermophilic organisms (Lam et al., 2011). Consequently, it may 
not be surprising that the Arg-232:Cys-345 guanidinium:carboxylate interaction between the Spi1 
DBD and the C/EBPβ Chain B C-terminal bZIP extension is a singularly critical component of the 
observed complex stability (Listman et al., 2005). Strikingly, in contrast to the extended nature of 
the Chain B interaction that positions Cys-345 in the DNA-protein pocket at the end of the Spi1 
a3 DNA-recognition helix, the NAMD simulation positions the C-terminal extension of Chain A 
beyond Glu-336 with the backbone of the following residue folded upon itself to form a globular 
structure from Pro-337 through the terminal Cys-345 carboxylate that forms a salt bridge to Lys-
198 of Spi1 (Figure 21A). Globular folding of a C-terminal bZIP extension for protein–protein 
interaction has previously been reported for the Epstein-Bar virus ZEBRA bZIP (Petosa et al., 
2006). 
 
Table 3: Buried Surface area between C/EBPβ and Spi1. Shows the total buried surface area 
between different regions of C/EBPβ and Spi1 at the end of the NAMD run in comparison to 
previous reported buried surface area for C/EBPβ:cMyb (Tahirov et al., 2002) and other functional 
protein-protein interactions (Janin et al., 2007). 
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3.3.3. L-arginine reduces C/EBPβ binding to Spi1 on the IL1B gene promoter 
            The critical importance of Spi1 in TLR4-dependent induction of the human IL1B gene 
(Adamik et al., 2013) suggests a unique and specific role in promoter regulation that could be 
targeted for inhibition. Although specific inhibition of Spi1 binding to DNA by small molecules 
has been explored (Munde et al., 2014), this approach suffers from its inability to discriminate 
among the highly conserved Spi1-DNA binding sites, an important issue because Spi1 regulates 
at least 219 genes (Turkistany and DeKoter, 2011) almost exclusively as a functional enhancer–
binding factor. However, the involvement of Spi1 as a promoter, rather than an enhancer, factor 
for IL1B, as well as its unique mode of action in physically integrating C/EBPb bound to the far-
upstream C/EBPb super-enhancer into the promoter, suggests that disruption of this interaction 
could provide a highly specific target for disrupting Spi1 action at the IL1B promoter. 
            Consequently, we used the Arg-232 interaction pocket between Spi1 and the C/EBPβ 
Chain B extra-zipper C-terminal tail to screen existing public database libraries for small 
compounds. It is important to note that this screening was conducted with the original 1PUE Spi1-
DNA X-ray structure (Kodandapani et al., 1996), independent of our C/EBPb docking models. 
Only those compounds capable of competitive binding to this interaction pocket, without affecting 
direct/cognate Spi1-DNA binding, were selected. One of the highest-scoring compounds resulting 
from multiple computational docking trials was L-arginine, a common semi-essential amino acid. 
Figure 22 presents interaction diagrams for one of the highest-scored L-arginine binding modes 
docked into the Spi1:C/EBPβ Chain B interaction pocket. Interestingly, this mode involves 
contacts with Arg-232 and Asn-236, closely mimicking the Cys-345 interaction with Spi1 from 






Figure 22. A Potential binding mode for L-arginine docked into the Spi1:C/EBPβ Chain B 
interaction pocket. (A) Two-dimensional interaction schematic and (B) three perspective views. 
Locations of relevant amino acids, DNA backbone phosphates, and L-arginine are labeled. (C) 
Pharmacophore model demonstrating the favorable accessibility and chemical interaction potential 
for C/EBPβ Chain B over Chain A. 
 
            This potential inhibitory interaction of L-arginine with Spi1 was tested by examining TLR-
dependent de novo IL1B gene expression in cultured THP-1 cells in L-arginine-deficient RPMI 
1640 media. The titration of L-arginine in the presence and absence of a 2.5 hr 1 μg/ml LPS 
treatment revealed an inhibitory trend of IL1B gene expression between 5 and 50 mM L-arginine, 
beyond the 1.15 mM concentration of conventional RPMI media. A 10 mM concentration was 
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chosen for subsequent experiments because the lowest concentration generating a significant 
change was 10 mM. At the highest concentration of 50 mM, cells exhibited an altered morphology, 
although retaining viability (Figure 23A). Figure 23B demonstrates inhibition of IL1B 
transcription with 10 mM L-arginine at various concentrations of LPS. In contrast to IL1B, the IL6 
gene does not possess a Spi1-dependent promoter but is otherwise activated via similar TLR-
activated transcription factors as IL1B (Baccam et al., 2003). Consequently, IL6 mRNA was 
assayed in parallel with IL1B, revealing no significant decrease in the presence of L-arginine 
(Figure 23B). Chromatin immunoprecipitation (ChIP) revealed an L-arginine-dependent decrease 
in C/EBPβ binding to Spi1 at the critical promoter-proximal Spi1 binding site (Adamik et al., 2013) 
on the human IL1B gene promoter. As a control, C/EBPb binding to promoter-bound Spi1 was 
compared to a downstream site on the IL1B gene that does not bind either C/EBPβ or Spi1. The 
PCR amplicon covering the Spi1 binding site on the IL1B promoter is centered at 19 nucleotides 
upstream of the transcription start site (-19 relative to the TSS), while the PCR amplicon control 
site is centered at +4858 nucleotides downstream of the TSS. Direct C/EBPβ binding to DNA was 
also evaluated by ChIP at a well-known avid C/EBPβ binding site (Zhang et al., 1994) with a PCR 
amplicon centered at -77 of the IL6 gene in the same cells. Incubation of THP-1 cells in the 
presence of 10 mM L-arginine decreased C/EBPβ association with Spi1 at the critical -19 site on 
the IL1B gene promoter following 2.5 hr LPS treatment (Figure 23C). Under these conditions there 
was no significant effect on direct binding of C/EBPβ to its cognate DNA at position -77 of the 
IL6 gene promoter. Strikingly, direct binding of constitutively bound Spi1 to its DNA site at -19 
on the IL1B promoter increased significantly under these conditions (Figure 23D), suggesting the 
possibility of L-arginine stabilization of Spi1 DNA binding. No enrichment of either C/EBPβ or 
Spi1 was observed at the downstream +4858 control site on IL1B. These ChIP studies provide 
evidence that the L-arginine-dependent decrease in IL1B mRNA expression is due to its ability to 
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inhibit the protein–protein interaction between C/EBPβ and Spi1 on the IL1B gene promoter, 
without having any inhibitory effect on either direct DNA binding of C/EBPβ or another C/EBPβ-
dependent gene (IL6). 
 
Figure 23. L-arginine inhibits recruitment of C/EBPb to Spi1 and transcription of the IL1B 
gene in living cells. (A) Relative mRNA expression levels for the IL1B gene in THP-1 cells treated 
with 1µg/ml LPS for 2.5hr following 12hr pretreatment with indicated concentrations of 
L-arginine. (B) Relative mRNA expression levels for the IL1B and IL6 genes in THP-1 cells 
titrated with LPS, as indicated, for 2.5hr following the 12hr pretreatment with 10 mM L-arginine. 
The mRNA data presented is relative to unstimulated THP-1 cells (vehicle) and was normalized 
to cells treated with 1µg/ml LPS for 2.5hr following 12hr pretreatment with 0 mM L-arginine. 
ChIP studies on the IL1B gene for (C) C/EBPb and (D) Spi1 in THP-1 cells that are treated with 
1µg/ml LPS for 2.5hr following 12hr pretreatment with 10 mM L-arginine. The amplicon -19 on 
IL1B gene is Spi1 binding site and +4858 (IL1B) is downstream background control. The amplicon 
-77 on IL6 gene is direct C/EBPb binding site. The ChIP data was normalized to amplicon -19 on 
IL1B gene in unstimulated THP-1 cells. The primer sequences are indicated in Table 5. The 
standard error for all significant samples is representative of at least three biological replicates with 





            Our prior understanding of the mechanism for transcriptional regulation of the human IL1B 
gene was based on the realization that its transcription depends on a cell-type-specific transcription 
start site promoter and a far-upstream inducible super-enhancer (Shirakawa et al., 1993). This was 
followed by the identification of TLR rapid activation of C/EBPβ homo- and hetero-dimer binding 
to the enhancer (Tsukada et al., 1994) and constitutive Spi1 binding to the IL1B promoter 
(Kominato et al., 1995) as key elements of function. However, it remained unclear how these two 
important gene regulatory elements, separated by almost 3 Kbp of DNA sequence might, 
mechanistically cooperate. One hint was that the two proteins are capable of a direct interaction 
that depends upon the carboxyl terminus of C/EBPβ and the integrity of a single amino acid in the 
Spi1 DBD (Listman et al., 2005). Our report of a long-range chromatin loop that positions the 
enhancer in close proximity to the promoter prior to gene induction, that rapidly increases in 
stability after TLR signaling in human monocytes along with concomitant recruitment of TBP and 
Pol II, provided a reasonable mechanistic model (Adamik et al., 2013). What still remained elusive 
was the nature of the structural interaction between C/EBPβ and Spi1 and how it contributes to 
TBP and Pol II recruitment. Using computational docking, in vitro interaction, and a predicted 
inhibitory compound, a reasonable molecular structure is now envisioned for a complex that 
anchors the enhancer to the promoter (Figure 24). The interaction is distantly related to that of 
C/EBPβ:cMyb in that the C/EBPβ leucine zipper interacts with a DNA-distal surface of the Spi1 
wHTH domain by involving the same two chains that bind to cMyb, but is also dependent upon 
the entire length of the Chain B tail in order to provide a critical interaction with Arg-232 of Spi1. 
Therefore, it is interesting to speculate whether cMyb might support an interaction mode similar 
to that of C/EBPβ with Spi1, if it were crystallized with intact tails. This is because a salt bridge 
between Glu-336 of C/EBPβ Chain B with Lys-248 of Spi1 in our initial ZDOCK and HADDOCK 
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structures, which destabilized early in the NAMD simulation (Figure 18D), is similar to the 
reported Glu-336 salt bridge to Arg-114 of cMyb (Tahirov et al., 2002). This suggests that the 
C/EBPβ:cMyb structure may be representative of the first stage of a two-step docking mode for 
C/EBPβ with Spi1 in which a less stable cMyb-like leucine zipper-only docking provides both an 
anchor as well as an increased effective concentration that supports increased collision and 
sampling by the Chain B tail. The proximity of the Chain B tail increases the probability of 
Arg-232 interaction with the terminal Cysteine 345 of C/EBPb. This interaction may also be 
preferred because of the asymmetry of chemical interaction accessibility associated with the Chain 
B pocket formed by the Spi1:DNA interaction (Figure 22C). It should also be noted that the 
C/EBPβ interaction with cMyb, in contrast to Spi1, includes one direct and one water-mediated 
salt bridge with a DNA backbone phosphate, possibly abrogating the requirement for C-terminal 
tail interactions.  
 
Figure 24. Four rotational views of the final DNA:C/EBPb:Spi1:DNA composite model. 
Showing the locations of the two bZIP chains and the Spi1 wHTH DBD, along with the likely 
long-range Enhancer-Promoter DNA interaction, are shown for four 90o rotational views in 




            The presence of the C-terminal tails and the absence of a nucleic acid salt bridge between 
C/EBPβ and Spi1 is consistent with the ability of this interaction to be DNA independent during 
in vitro GST pulldown experiments, a situation also reported for C/EBPa with GABPa 
(Shimokawa et al., 2010; Shimokawa et al., 2013; Shimokawa and Ra, 2005). This also reflects 
the conservation between the leucine zippers of C/EBPa and C/EBPβ, as well as the ETS domains 
of Spi1 and GABPa (Figure 25). 
 
Figure 25. Homology alignments for (A) C/EBPa and C/EBPβ leucine zippers and 
C-terminal tails. The leucine zipper coiled-coil extends to the glutamate residues immediately 
preceding the C-terminal tail. Key leucine zipper heptad sites are indicated by black boxes and 
sites of direct interaction with wHTH proteins are indicated by arrows. (B) Sequence of C/EBPb 
bZIP basic charged DNA-binding sequence and leucine zipper coiled-coil dimerization composite 
domain. (C) Schematic representations and homology alignments for the GABPa and Spi1 wHTH 
domains. Structural elements are indicated for a-helices and b-sheets. 
 
            It is also noteworthy that our data-supported computational model positions the final 
C/EBPβ tailed structure on a surface of the 102 amino acid Spi1 DBD that is 180° removed from 
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the attachment point of the 170 amino acid Spi1 transactivation domain (TAD) (labeled as K171 
in Figure 24). This is important because it places the C/EBPβ docking site in a region that is more 
likely to be free of permanent obstruction from the substantial mass of the Spi1 amino terminus. 
One might speculate that the TLR4-dependent docking of C/EBPβ might maintain the Spi1 TAD, 
which is reported to directly recruit TBP (Hagemeier et al., 1993), in an open conformation 
essential for TBP and subsequent Pol II recruitment, consistent with the kinetics associated with 
IL1B gene induction (Adamik et al., 2013). 
            The anti-inflammatory properties of L-arginine are well known (Fritz, 2013). However, the 
complexities of L-arginine metabolism have resulted in a vast array of possible targets (Morris, 
2016). Our results suggest that L-arginine can block C/EBPβ recruitment by Spi1 at the human 
IL1B gene promoter, resulting in decreased TLR4-dependent induction of gene transcription and 
suggesting one mode of action for its use as an anti-inflammatory therapeutic. This report deals 
with the involvement of L-arginine in a specific transcription mechanism and suggests one possible 
target that may serve as a model for the design of a novel and specific pro-inflammatory gene 
inhibitor. The central involvement of IL-1β protein in numerous pro-inflammatory acute diseases 
and cancer has underscored the importance of antibody therapy (Everett et al., 2018; Ridker et al., 
2017). However, antibody therapy targets the huge number of IL-1β protein molecules that are 
derived from IL1B gene transcription in each activated cell. Blocking transcription provides an 
upstream target that precedes the amplified “storm” of IL-1β protein expression and can 
theoretically provide a much more effective method for inhibition. Of course, such inhibition 
requires both a reasonable efficiency for cell permeation as well as high specificity for a target. 
Unfortunately, virtually all protein-coding genes use a common promoter transcription initiation 
mechanism and most transcription factors function as pleiotropic enhancer–binding proteins with 
broad gene activity that obviates therapies that depend on either direct promoter inhibition or 
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specific enhancer DNA binding. This is certainly the case for Spi1, which predominantly functions 
as an enhancer–binding factor. Our observation that the human IL1B gene promoter utilizes a 
unique protein–protein interaction at a core promoter that can be selectively targeted and repressed, 
offers the potential for a correspondingly novel therapeutic mode targeting protein–protein, rather 
than protein–DNA, interaction within the cell. It also begs the question whether there are other 
genes that are similarly regulated either by Spi1 or by other transcription factors that function both 
as enhancer-dependent activators, as well as core promoter general transcription factors. 
Regardless, our results demonstrate that at least one gene can be selectively repressed by inhibition 
of protein–protein interaction at a core promoter. 
 
3.5. MATERIALS AND METHODS 
3.5.1. Cell Culture, Reagents and Treatment Conditions 
            THP-1 cell line (ATCC, TIB-202) was initially cultured in RPMI-1640 media (Corning, 
10-040-CV) supplemented with 10% heat-inactivated fetal bovine serum (Hyclone, SH30070.03), 
1% Penicillin/Streptomycin Solution (Corning, 30-002-Cl) and 500 μl of 2-mercaptoethanol 
(Gibco, 21985023). RPMI-1640 media lacking amino acid L-leucine, L-lysine and L-arginine was 
purchased from Sigma, R1780. This media was supplemented with 50mg/L of L-leucine (Sigma, 
L8912) and 40mg/L of L-lysine monohydrochloride (Sigma, L8662), which is same amount of 
these amino acids in classic RPMI-1640 media but without L-arginine. It was also supplemented 
with 10% heat-inactivated fetal bovine serum (Hyclone, SH30070.03), 1% 
Penicillin/Streptomycin Solution (Corning, 30-002-Cl) and 500 μl of 2-mercaptoethanol (Gibco, 
21985023). For mRNA and ChIP analyses, the THP-1 cells grown in classic RPMI-1640 media 
were washed and transferred into RPMI-1640 media lacking L-arginine. These cells were pre-
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treated with different concentrations of L-arginine (Sigma, A8094) for 12 hours prior to E. coli 
055:B5 Lipopolysaccharide (LPS) (L2880, Sigma) stimulation for 2.5 hours. 
 
3.5.2. Small Molecule Docking with MOE 
            Two potential binding pockets proximal to our amino acid residue of interest, Arg-232, on 
opposite sides of DNA-bound Spi1 from RCSB 1PUE (Berman et al., 2000; Kodandapani et al., 
1996) (resolution: 2.1 Å; R-value free: 0.287; R-value work: 0.225) were identified with Molecular 
Operating Environment’s (MOE) SiteFinder (Edelsbrunner, 1992; Edelsbrunner et al., 1995). 
Conformations of small molecule drugs (78-180g/mol) from DrugBank (Law et al., 2014) were 
docked to both pockets using MOE’s Amber10:EHT (Extended Hückel Theory parameterization) 
force field (Gerber and Muller, 1995) and induced fit docking protocol, which relaxes the structure 
as it docks. The potential binding sites were identified using dummy atoms defining the binding 
pockets, potential poses were determined via the Alpha Triangle match method, and initially the 
poses were scored with the Affinity dG method. Each pose and the pocket atoms (residues greater 
than 6 Ångstroms from the pocket are not included in the energy minimization or the energy 
evaluation; backbone atoms are held fixed) were energy minimized using the Generalized Born 
solvation model (GB/VI) (Wojciechowski and Lesyng, 2004). After energy minimization, the 
poses are rescored with the GBVI/WSA dG method. Top ranked compounds with established links 
to IL-1B or inflammation in literature were selected as compounds of interest. 
 
3.5.3. Protein–Protein Docking 
            The protein–protein docking of the Spi1:C/EBPβ DNA-bound complex used the murine 
Spi1 and human C/EBPβ structures found in RCSB entries 1PUE (Kodandapani et al., 1996) and 
1H88 (Tahirov et al., 2002) (resolution: 2.8 Å; R-value free: 0.277; R-value work: 0.222), 
 
 71 
respectively. A series of docking runs was performed using the ZDOCK server (Pierce et al., 2014), 
using a fast Fourier transform-based docking algorithm that takes into account pairwise shape 
complementarity, desolvation, electrostatics, and statistical potential. When both proteins were 
DNA-unbound and also when Spi1 was DNA-bound and C/EBPβ unbound with its bZIP marked 
as passive at residues 315 and below, ZDOCK results reliably indicated that the C/EBPβ bZIP 
domain associates with the Spi1 β-turn domain in an orientation notably not proximal to the residue 
of interest, Arg-232. 
            To reinforce the results from ZDOCK, additional docking was performed using the 
HADDOCK webserver (Dominguez et al., 2003; van Zundert et al., 2016), which incorporates 
biochemical interaction data to drive docking. The Easy Interface was used with active (involved 
in contact) and passive (solvent accessible neighbors) residues entered based on previous 
experimental data. For Spi1 (des-DNA), actives were 243, 245-254 (β3/β4 strands and loop) and 
passives were 171-219 (α helices not in contact with DNA and β1/β2 strands and loop). On 
C/EBPβ, the dimer chains were combined into one and the residues of one chain were renumbered, 
with active 330-336 and passive 276-293. Again, results showed the C/EBPβ bZIP domain docked 
to the Spi1 β turn domain in the same orientation.  
            Because C/EBPβ did not dock particularly close to Spi1 Arg-232, it was suggested that the 
disordered 9-residue C-terminus end strands, which are not found in the C/EBPβ 1H88 crystal 
structure, could be associating with Arg-232 on one or both sides of the complex. The strands were 
appended to the docked protein–protein structure on both chains of C/EBPβ and LowModeMD 
(Labute, 2010), a dynamics simulation method to predict the orientation of protein loops, was used 





3.5.4. mRNA Expression Analysis 
            1x106 THP-1 cells in RPMI-1640 media lacking L-arginine were plated into 6-well plates 
(Thermo Fisher BioLite, 130184). Following the L-arginine and LPS treatments, cells were 
pelleted and supernatant was removed. The cell pellet was re-suspended in 500 μl of TRIzol 
reagent (Invitrogen, 15596026). Following the addition of 170 μl of Chloroform (Fisher, C606-1), 
the samples were vortexed well and incubated at room temperature for 15 minutes. Then, the 
samples were centrifuged at 13200 RPM for 15 minutes at 4oC. Aqueous layer was transferred into 
a fresh tube and combined with 500 μl of isopropanol (Fisher, BP2632-4) and 1 μl of Glycogen 
(Ambion, AM9510). The samples were incubated at room temperature for 10 minutes and then 
centrifuged at 13200 RPM for 10 minutes at 4oC. The RNA pellets were washed with 500 μl of 
75% Ethanol (Pharmaco-AAPER, 111ACS200) and centrifuged for 10 min in room temperature 
at 14000 RPM. Then, the ethanol was aspirated, and the pellets were allowed to air-dry for 10-15 
minutes. Air-dried pellets were re-suspended in 25 μl of DEPC-treated water (Ambion, AM9920). 
The samples were incubated at 65oC for 10 minutes and subjected to DNase treatments using Turbo 
DNA-free reagents (Ambion, AM1907) according to the manufacturer instructions in order to 
eliminate genomic DNA contamination. RNA concentration, 260/280 and 260/230 values were 
measured using NanoDrop 1000 spectrophotometer (Thermo Fisher, ND-1000). mRNA was 
converted into cDNA using GoScript Reverse Transcription System (Promega, A5001). cDNA 
was analyzed using quantitative PCR (qPCR) carried out in a StepOnePlus Applied Biosystems 
Real Time Instrument (Thermo Fisher, 4376600). Relative expression levels were calculated using 
DDCt method with GAPDH (Reference gene) and unstimulated THP-1 cells as a control. Primer 





Gene Forward Primer Reverse Primer 
IL1B TCCAGGGACAGGATATGGAG TCTTTCAACACGCAGGACAG 
IL6 AGGAGACTTGCCTGGTGAAA CAGGGGTGGTTATTGCATCT 
GAPDH ACACCCACTCCTCCACCTTT CCCTGTTGCTGTAGCCAAAT 
 
Table 4. qPCR primer sequences for mRNA analysis. Table shows the forward and reverse 
primer sequences used for mRNA analysis.  
 
 
3.5.5. Chromatin Immuno-precipitation 
            ChIP was performed using a modification of the Millipore/Upstate protocol 
(MCPROTO407). Following treatments, a total of 1x107 THP-1 monocytes in RPMI-1640 media 
lacking L-arginine were fixed in 1% formaldehyde (Fisher, F79-500) for 10 min at room 
temperature. Cross-linking was inhibited by addition of glycine (Fisher, G46-1) to a final 
concentration 0.125 M. Cell pellets were washed twice with ice cold PBS and resuspended in SDS 
Lysis Buffer (1% SDS, 10 mM EDTA, 50 mM Tris, pH 8.1) supplemented with Protease inhibitor 
cocktail (Sigma, P8340) and 1mM phenylmethylsulfonyl fluoride (Sigma, 93482). Samples were 
sonicated (to generate DNA fragments of 250 base pairs (bp) average length) on ice using a Fisher 
Scientific 120 Sonic Dismembrator (Fisher Scientific, FB-120) as follows: 30 seconds ON and 30 
seconds OFF at 50% amplitude for 12 cycles on ice and centrifuged at 12000 RPM for 10 min. 
Chromatin was diluted 7-fold in ChIP Dilution Buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM 
EDTA, 16.7 mM Tris-HCl, pH8.1, 167 mM NaCl. Total equivalence of 3x106 cells was used for 
both C/EBPb and Spi1 pull downs. Supernatants were incubated at 4°C overnight with Santa Cruz 
antibodies C/EBPb (sc-150X, sc-56637), Spi1 (sc-352X, sc-22805X) and control IgG (sc-2027X). 
For the C/EBPb pull downs, both the sc-150X and sc-56637 antibodies were mixed in equal 
amounts. Similarly, for the Spi1 pull downs sc-352X and sc-22805X were mixed. Aliquots for 
Input and non-specific IgG control samples were included with each experiment. Samples were 
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precipitated using 25 µl of Magna ChIP Protein A+G Magnetic beads (EMD Millipore, 16-663), 
at 4°C for 3 hours, and subsequently washed with the following solutions: once with Low-Salt 
Buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl), 
once with High-Salt Buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20 mM Tris-HCl, pH 8.1, 
550 mM NaCl), once with LiCl Wash Buffer (0.25 M LiCl, 1% IGEPAL-CA630, 1% deoxycholic 
acid, 1mM EDTA, 10 mM Tris, pH 8.1), and twice with TE Buffer (10 mM Tris-HCl, 1 mM EDTA, 
pH 8.0). Immunocomplexes were eluted for 4 hours at 65°C with 200 µl of ChIP Elution Buffer 
(1% SDS, 0.1M NaHCO3). To reverse the cross-linking, eluted samples were treated with 10 µl of 
5 M NaCl and subsequently incubated at 65°C for ≥4 hours. DNA was purified using a GeneJET 
PCR Purification kit (Thermo Scientific, K0702). Primer Sequences used for ChIP analysis are 
indicated in Table 5. The size of the PCR products ranges between 80 and 150 bp. 20 μl qPCR 
reactions containing 2x Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scientific, 
K0223), 250 nM of primers, and 3 µl of precipitated DNA were set up in Fast 96-Well Reaction 
Plates (Applied Biosystems, 4346907). qPCR reactions were carried out in a StepOnePlus Applied 
Biosystems Real Time Instrument (Thermo Fisher, 4376600).  Fold enrichment was calculated 
based on Ct as 2(DCt), where DCt = (CtInput - CtIP). Final enrichment values were adjusted by 
subtraction of the nonspecific IgG antibody binding.  
 
Position Forward Primer Reverse Primer 
-77 IL6 TGCACTTTTCCCCCTAGTTG TCATGGGAAAATCCCACATT 





Table 5. Human IL6 and IL1B ChIP primer sequences. Primer sequences used for ChIP 




3.5.6. In vitro studies  
            The C/EBPβ pCDNA3.1 (Tsukada et al., 1994), Spi1 pRC/CMV (Galson et al., 1993) and 
Spi1 deletion (Wara-aswapati et al., 1999) expression vectors were constructed as previously 
described. All constructs were verified by DNA sequencing. Purification of fusion proteins and 
DNA-independent glutathione-S-transferase (GST) pull-down assays were as we described 
previously (Listman et al., 2005). This approach was used because DNA-independent Spi1 
protein–protein interactions correlate with Spi1-dependent gene regulation (Adamik et al., 2013; 
Listman et al., 2005; Meraro et al., 1999; Nagulapalli et al., 1995; Perkel and Atchison, 1998; 
Wara-aswapati et al., 1999; Yang et al., 2000). 
 
3.5.7. Nanoscale Molecular Dynamics (NAMD)  
I. System Preparation 
            The Spi1-C/EBPb-DNA system used in the MD simulations was constructed from two 
published crystal structures. The binary C/EBPb-DNA portion of the system was taken from the 
ternary complex in RCSB 1H89 (Tahirov et al., 2002) (resolution: 2.45 Å; R-value free: 0.267; R-
value work: 0.229). A second crystal structure, RCSB 1PUE, was used for the Spi1 structure 
(Kodandapani et al., 1996). Using sequences for C/EBPb gathered from the Uniprot (The UniProt, 
2017) entry for human CEBPb, tails were added to the non-interacting C-termini of the binary 
C/EBPb-DNA structure in 1H89. These tails enable enhanced binding of C/EBPb to the Spi1-
DNA complex. This system was prepared from the two crystal structures and the aforementioned 
tail sequences using Visual Molecular Dynamics (VMD) (Humphery et al., 1996). The tails were 
attached to the termini of both chains of C/EBPb using the psfgen module in VMD. A 76×70×150 
Å solvation box contained 22,623 water molecules was placed around the protein–DNA complex 




II. Simulation Details 
            The NAMD software package (Phillips et al., 2005) was used to perform MD simulations 
on the Spi1:C/EBPb-DNA complex. The CHARMM36 force field (Huang and MacKerell, 2013) 
was used for all simulations to assign atomic partial charges, calculate forces, and potential 
energies. Constant volume, temperature, and number of atoms (NVT) were maintained during the 
preliminary equilibration simulations, and volume was allowed to vary while pressure was held 
constant (NPT) during the final equilibration run and data production simulations. All simulations 
were carried out at 300 K, and 1.01325 atm was maintained during NPT simulations. The velocity 
Verlet algorithm was used for MD integration with a 1 fs timestep. For nonbonded interactions, 
pair lists were maintained for pair distances less than 12 Å with an interaction cutoff distance of 
10 Å, and a switching function was applied at a distance of 8 Å. All positional constraints 
mentioned below were held with a 0.5 kcal Å-1 mol-1 force constant. Full system electrostatics was 
calculated with the particle mesh Ewald summation (Darden et al., 1993) method. The TIP3P water 
model (Jorgensen et al., 1983) was used for explicit water solvation, and cubic periodic boundary 
conditions were utilized. A Langevin thermostat and piston were used to maintain constant 
temperature and pressure respectively. 
 
III. MD Simulations. 
            Conjugate gradient minimization was performed for 5000 steps with positional constraints 
placed on protein/DNA heavy atoms, followed by 5000 more steps of minimization without 
constraints. An NVT equilibration (Jorgensen et al., 1983) was then performed for 2 ns with 
position of the protein/DNA backbone heavy atoms constrained, and 2 ns with these constraints 
removed to enable the solvent to relax before the larger molecules. Throughout all the simulations 
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carried out, positional constraints were maintained on the terminal residues of the DNA chains, to 
disable the system from shifting in a manner than would disrupt the periodic boundary conditions. 
Otherwise, DNA chains were allowed to freely move. Following the NVT equilibration, NPT 
equilibration was carried out for 5 ns with no additional constraints. 104 ns of data production MD 
simulation was performed under the NPT ensemble, with trajectory and observable data being 
recorded at 2 ps intervals. 
 
IV. Data Analysis 
            All data analysis was performed with VMD. Inter-atomic distance time traces for the 
various residue pairs discussed in this work were calculated each step from the DCD trajectory 
with Tcl analysis scripts. Buried surface areas discussed in this work were calculated for each 
frame of the MD trajectory by subtracting the solvent accessible surface areas (SASA) for the 
individual protein chains from the SASA of the complex, which is a commonly used method to 
calculate this metric. Mathematically, an example of this protocol to calculate the buried surface 
area of complex ABC is given as: 
 
𝑆𝐴#$%&'()*+ = (𝑆𝐴𝑆𝐴) + 𝑆𝐴𝑆𝐴* + 𝑆𝐴𝑆𝐴+) − 𝑆𝐴𝑆𝐴)*+ 
 
where 𝑆𝐴#$%&'()*+  is the buried surface area for the complex ABC and 𝑆𝐴𝑆𝐴1  is the solvent 
accessible surface area for chain N. Buried surface area calculations were carried out using Tcl 
scripts in VMD. 
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Chapter 4: Molecular Insights into IL1B gene 
regulation 
 
This Chapter contains a series of preliminary studies that either require more supporting 
experiments to derive a conclusion or more experimental/biological replicates before consideration 
for publication.   
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            Interleukin 1b (IL-1b) and Tumor Necrosis Factor (TNF) are important mediators of 
inflammatory responses and intracellular communication in the body against microbial infection. 
To understand the transcriptional kinetics of these pro-inflammatory cytokines, the mRNA kinetic 
profile in THP-1 monocytes following LPS or Phorbol 12-Myristate 13-Acetate (PMA) 
stimulation was analyzed. The IL1B and TNF genes showed distinct mRNA profiles with LPS 
and/or PMA stimulation. Following LPS stimulation, the TNF gene was rapidly induced with an 
absence of expression in the late phase, while refractory to LPS re-stimulation. The IL1B gene 
showed a rapid-vigorous induction, followed by a decreased continuous expression, which can be 
re-induced with LPS stimulation. In contrast to LPS, PMA generated a lower-level of sustained 
IL1B expression in the late phase, with only a minute induction of TNF. Furthermore, the addition 
of both LPS and PMA together revealed super-induction of the IL1B gene in the late phase, 
indicating the synergistic effect of LPS and PMA. The addition of PMA to LPS-activated THP-1 
cells did not show any significant induction of the TNF gene. ChIP analysis revealed that in 
TLR4-activated monocytes, NF-κB is necessary for both the initial and continuous, late, 
expression of the IL1B gene, with C/EBPβ being important only for the rapid initial expression. 
TNF gene expression was mostly dependent on NF-κB, with minimal involvement of C/EBPβ. 
Late phase expression of the IL1B gene with PMA was dependent on both NF-κB and C/EBPβ. 
Super-induction of the IL1B gene with LPS+PMA was associated with continuous strong binding 
of both NF-κB and C/EBPβ to the IL1B promoter and enhancer. Our preliminary studies have 
shown that extracellular succinate, likely acting through the SUCNR1/GCPR91 receptor, can 
potentially enhance LPS induced re-stimulation of the IL1B gene. The Spi1 transcription factor is 
constitutively expressed and absolutely necessary for IL1B gene transcription in monocytes. Using 
luciferase reporter assays and mRNA expression studies, we have shown that serine 
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phosphorylation in both the Transcription Activation Domain (TAD) and PEST phosphorylation 
target domain of Spi1 play an important role in the LPS-dependent activation of Spi1. These 
preliminary studies provide new molecular insights into IL1B gene regulation in TLR4-activated 
monocytes.     
 
4.2. INTRODUCTION 
            Innate immune cells are the first cellular components of the immune system that comes 
into contact with invading pathogens. A number of innate immune genes are required to rapidly 
respond (Immediate Early Genes) to a wide variety of external stimuli from pathogenic microbes. 
Immediate Early (IE) genes are rapidly transcribed within minutes following stimuli independent 
of de novo protein synthesis (Bahrami and Drablos, 2016). It is widely believed that all IE rapidly 
induced genes depend upon paused RNA Polymerase II (Pol II) located at 50 bp downstream the 
TSS before the appropriate stimuli release the paused Pol II to start active transcription (Adelman 
et al., 2009; Jonkers and Lis, 2015; Liu et al., 2015). Classical IE genes like TNF and FOS have 
pre-bound TBP and Pol II at their respective promoters prior to gene induction (Adamik et al., 
2013; Ryser et al., 2007). These IE genes have many canonical core promoter elements like 
Initiator (Inr), Downstream Promoter Element (DPE) and Downstream Core Element (DCE) 
sequences that recruit TFIID and the RNA Polymerase II Pre-Initiation Complex (PIC) to the 
promoter site. However, recent studies have shown that not all IE genes have paused Pol II and 
pre-bound TBP at the promoter prior to gene induction (Adamik et al., 2013; Gupte et al., 2013). 
Unlike classical IE genes, the IL1B gene promoter does not possess canonical core promoter 
elements and is devoid of pre-bound TBP and Pol II but has a constitutively bound myeloid 
lineage-specifying Spi1 transcription factor. Previous studies have demonstrated that Spi1 is 
absolutely necessary for IL1B gene transcription in TLR4-activated monocytes (Adamik et al., 
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2013; Kominato et al., 1995; Tsukada et al., 1997; Unlu et al., 2007). The Spi1 binding site is 
immediately adjacent to the TBP binding site on the IL1B gene promoter, and it has been reported 
that Spi1 can directly recruit TBP via its amino-terminal transactivation domain (Hagemeier et al., 
1993). Previous studies have also reported that the IL1B gene has a decreased, prolonged, 
expression after the initial TLR4-activation, and can be re-induced with secondary activation 
(Adamik et al., 2013). This contrasts the TNF gene, which is both completely shut-down after 
initial rapid induction and is refractory to re-stimulation (Adamik et al., 2013). Therefore, to 
understand the distinct molecular mechanism regulating the IL1B gene, as compared to TNF, the 
transcription factors responsible for the IL1B and TNF gene kinetics were examined. The roles 
played by extracellular succinate in the re-stimulation phase of the IL1B gene and LPS-dependent 
serine phosphorylation of Spi1 to prime IL1B gene induction were also investigated. The studies 
included in this chapter, exploring the molecular mechanisms of IL1B gene expression, are 
preliminary, requiring either additional supporting experiments or biological replicates.  
 
 
4.3. RESULTS AND DISCUSSION 
4.3.1. The IL1B gene exhibits sustained expression in TLR4-activated monocytes 
            To understand the IL1B and TNF gene activation kinetics, we took advantage of the short 
half-lives of these messages (Brooks et al., 2004; Fenton et al., 1988) by using mRNA levels as a 
readout for gene transcription. Distinct mRNA expression profiles were observed for IL1B and 
TNF, when the THP-1 monocytes were stimulated with LPS, PMA (Phorbol 12-Myristate 13-
Acetate), or LPS+PMA at various time points over 24 hours. Unlike, LPS which is present on 
outer bacterial membranes and activates TLR4 receptors on monocytes, PMA mimics 
Diacylglycerol which activates Protein Kinase C, resulting in a downstream signaling cascade 
(Castagna et al., 1982; Traore et al., 2005). With LPS treatment alone (shown in green in Figure 
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26A), IL1B showed two distinct phases: an IE rapid-vigorous phase followed by a decreased 
continuous expression. In contrast, TNF showed only a rapid-transient IE induction followed by a 
complete shut-down at the later stage. PMA treatment (shown in blue in Figure 26A) resulted in a 
delayed, but sustained, lower level of expression for IL1B, with only a minute effect on TNF. The 
addition of both LPS+PMA together (shown in brown in Figure 26A) resulted in super-induction 
of IL1B gene expression, only displaying a curve for TNF that was similar to that of LPS, 
demonstrating once again that PMA has only a minimal effect on TNF expression. These mRNA 
results support and expand on previous studies showing that IL1B and TNF have distinct gene 
activation kinetics. The sustained expression of the IL1B gene is associated with many 
auto-inflammatory diseases such as sepsis, rheumatoid arthritis, inflammatory bowel disease, 
asthma along with heart disease, cancer, Alzheimer’s disease and diabetes (Braddock and Quinn, 
2004). Understanding the molecular mechanisms that contribute to this sustained expression of the 
IL1B gene might provide insights into developing new therapeutic approaches to tackle diseases 
that are caused by chronic expression of IL-1b. 
 
Figure 26. IL1B and TNF have distinct mRNA expression profiles. A) Shows the relative 
mRNA expression levels of the IL1B and TNF genes in THP-1 cells stimulated with LPS, PMA, 
and LPS+PMA for various times over 24 hours. Error bars represent three biological replicates. 
B.) Composite figure showing the morphological changes in THP-1 monocytes once stimulated 





            LPS and PMA treatments also resulted in morphological changes in THP-1 cells over 24 
hours (Figure 26B). Unstimulated cells remained round in shape and barely attached to the surface 
of the plate. LPS stimulated cells acquired ruffled edges and adhered to the plate. PMA stimulated 
cells showed strong adherence to the surface of the plate, with some cells becoming polarized and 
macrophage-like at 24 hours. The addition of both LPS+PMA to THP-1 cells also generated strong 
attachment to the plate, along with a higher percentage of polarized macrophage-like cells. These 
results nicely agree with many previous studies revealing that LPS increases the expression of cell 
adhesion molecules (CAMs) such as ICAM-1, V-CAM-1 and E-selectin, whereas PMA 
upregulates P-selectin, LFA-1 and ICAM-1 facilitating monocyte/macrophages cell adherence 
(Sellak et al., 1994; Takamatsu, 2018). CAM upregulation upon activation is essential for 
adherence of monocytes to endothelial cells and transmigration to sites of infection/inflammation 
(Hmama et al., 1999). LPS and PMA treatments are also known to support actin cytoskeleton 
reorganization that alters the morphology of monocytes upon activation (Takamatsu, 2018; 
Williams and Ridley, 2000).  
 
4.3.2. NF-κB and C/EBPβ are both required for IL1B gene expression in TLR-4 activated 
monocytes 
            To identify the roles of NF-κB and C/EBPβ in IL1B and TNF gene expression, we 
performed a screen using relatively specific transcription factor inhibitors (BMS: IKK inhibitor 
for NF-κB and U0126: C/EBPβ p38 MAPK inhibitor) for immediate-early (IE) and late phases of 
gene expression. THP-1 cells treated with LPS and specific transcription factor inhibitors 
demonstrated that the rapid-vigorous IE expression and continuous late expression of IL1B 
depended upon both NF-κB and C/EBPβ (Figure 27). In contrast, TNF early phase IE expression 
appeared to be almost exclusively dependent on NF-κB, with minimal involvement of C/EBPβ 
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(Figure 27). The relative mRNA expression studies for THP-1 cells treated with PMA and specific 
transcription factor inhibitors revealed that the lower-level early expression, as well as sustained 
late expression for IL1B, was dependent on both NF-κB and C/EBPβ (Figure 27). The TNF gene 
did not show any significant expression with PMA treatment. Finally, when the cells were treated 
with both LPS+PMA, along with specific transcription factor inhibitors, the early and the late 
phase IL1B gene expression was dependent on both NF-κB and C/EBPβ (Figure 27). In contrast, 
the early phase expression of the TNF gene with both LPS+PMA treatment was mostly dependent 




Figure 27. Expression of IL1B and TNF genes is dependent on both NF-κB and C/EBPβ. The 
figure shows IL1B and TNF mRNA expression kinetics in THP-1 cells treated with either LPS, 
PMA or LPS+PMA, along with specific transcription factor inhibitors (BMS: IKK inhibitors for 
NF-κB; U0126: C/EBPβ p38 MAPK inhibitor) in immediate-early (IE) and late phases of gene 
expression. Error bars represent two biological replicates.  
 
            Next, to directly verify the involvement of these transcription factors, Chromatin 
Immunoprecipitation (ChIP) was conducted in early (1.5hr) and late (7hr) phase treatments. A 
significant enrichment of NF-κB was observed after 1.5hr of LPS stimulation, both at the 
mini-enhancer NF-κB (-279) and Spi1 binding sites (-91) at the IL1B gene promoter, as compared 
to a downstream control (+4858) (Figure 28). At 7 hours, there was decreased NF-κB binding at 
both sites, as compared to 1.5 hours, but still demonstrated a significant enrichment over the 
downstream control (Figure 28). Consistent with the inhibitor data, these ChIP results indicate that 
NF-κB is required for both early and decreased late expression of the IL1B gene in TLR4-activated 
monocytes. When LPS binds to the TLR4 receptor, it activates NF-κB through the recruitment of 
an adaptor protein, Myeloid Differentiation Primary Response Gene 88 (MyD88). The initial 
activation of NF-κB through MyD88 is very rapid, and an increased NF-κB binding on the IL1B 
promoter can be observed as early as 30 minutes post TLR-4 activation by LPS (Adamik et al., 
2013). Recent studies have shown that LPS activation of TLR4 can induce NF-κB in the late phase 
via TIR-domain-containing adapter-inducing interferon-b (TRIF)-mediated signal transduction 
(Cheng et al., 2015; Tan et al., 2015). After the initial activation of the TLR4 receptor, CD14 has 
been shown to mediate the internalization of TLR4 into endosomes (Zanoni et al., 2011). Once the 
TLR4 receptor is recruited into endosomes, the internalized receptor engages the TRIF adaptor 
which is known to activate NF-κB. Since the activation of the TRIF pathway by TLR4 is late 
compared to rapid MyD88 activation, it would be interesting to inhibit TRIF signaling in 
LPS-activated monocytes and analyze the IL1B mRNA kinetic profile. If the TRIF signaling 
pathway is important only for the late activation of NF-κB, a decreased IL1B mRNA expression 
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would be observed in the late phase with TRIF inhibitor, and the resulting IL1B mRNA profile 
should look more like TNF, with only an initial peak and minimal late phase gene expression. 
These inhibitor studies can be followed-up with NF-κB ChIP assays on the IL1B gene in 
LPS-activated monocytes with TRIF inhibitor. 
 
Figure 28. Late phase super-induction of the IL1B gene with LPS+PMA requires continuous 
binding of both NF-κB and C/EBPβ. The figure shows NF-κB and C/EBPβ ChIP results for the 
THP-1 cells stimulated with either LPS, PMA or LPS+PMA in immediate-early (IE) and late 
phases of IL1B gene expression. Error bars represent two biological replicates.  
 
            C/EBPβ binding was observed only at the early phase (1.5hr) of LPS stimulation at both 
the IL1B promoter (-155, -91) and UIS enhancer (-2790) regions (Figure 28). Consistent with 
PMA-induced IL1B mRNA expression, a weak but significant enrichment of NF-κB at both the 
promoter (-91) and mini enhancer site (-279) was observed only in the late induction phase. 
Similarly, C/EBPβ enrichment following PMA treatment was also observed only in the late phase, 
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both at the promoter and UIS enhancer sites on IL1B. These results indicate that in the case of 
PMA activation, both NF-κB and C/EBPβ contribute to the delayed, sustained IL1B gene 
expression. As indicated by the inhibitory mRNA studies, LPS+PMA treatment showed 
enrichment for both NF-κB and C/EBPβ in the early and late phases at their respective binding 
sites (Figure 28). These LPS+PMA ChIP results suggest that the super-induction of the IL1B gene 
might be due to strong continuous binding of both the NF-κB and C/EBPβ transcription factors.   
 
Figure 29. Both NF-κB and C/EBPβ effect TNF gene expression. The figure shows NF-κB and 
C/EBPβ ChIP results for the THP-1 cells stimulated with either LPS, PMA or LPS+PMA in early 
(IE) and late phases of TNF expression. Error bars represent two biological replicates.  
 
            In the case of TNF, significant binding of NF-κB was observed at the enhancer NF-κB site 
(-600) as compared to the promoter site (-128) after 1.5hr of LPS stimulation (Figure 29). 
Decreased NF-κB binding was observed at the later 7hr time point, even though there was no TNF 
expression in the late phase. Previous studies from our laboratory have shown that the +1 
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nucleosome on the TNF gene is re-deposited by 5-hours (late phase) after the initial TLR4 
activation thereby impeding TNF gene expression (Adamik et al., 2013). But in the case of the 
IL1B gene, the nucleosome binding at the +1 position remained low in the late phase accompanied 
by active gene transcription. The exact molecular mechanism contributing to the increased +1 
nucleosome enrichment at the TNF promoter is unknown. C/EBPβ binding to the TNF promoter 
site (-128) was observed only in the early phase of LPS stimulation (Figure 29). Consistent with 
TNF mRNA expression profile, NF-κB binding was not observed on the TNF gene following PMA 
treatment (Figure 29). Interestingly, a slight enrichment of C/EBPβ was observed at the TNF 
promoter site (-128) in the late phase with PMA treatment. Finally, NF-κB enrichment on the TNF 
gene with LPS+PMA treatment was very similar to the LPS only treatment, with significant NF-κB 
binding in the early phase at the enhancer site, along with a decreased binding in the later phase. 
Both in the early and late phase of LPS+PMA treatment, C/EBPβ was enriched at the TNF 
promoter site (Figure 29). These results, along with the inhibitory studies, argue that C/EBPβ has 
a minor effect on TNF gene expression. 
  
4.3.3. Extracellular succinate supports LPS induction of IL1B gene expression 
            Previous studies from our lab have shown that the IL1B gene, unlike that of TNF, is less 
sensitive to endotoxin tolerance (re-induction) and can be re-activated upon secondary LPS 
stimulation (Adamik et al., 2013). Consequently, kinetic mRNA studies were performed in order 
to compare the expression of IL1B with the endotoxin tolerant TNF gene, following secondary 
stimulation (2o) of THP-1 cells with LPS. Therefore, THP-1 cells were first treated for 24 hours 
with LPS, followed by re-stimulation with the same LPS dose for various time points over 24 
hours, without washing the cells between stimulation treatments. These studies revealed that the 
IL1B mRNA expression profile for re-stimulation was similar to the initial LPS profile, with a 
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rapid transient expression, followed by a sustained decreased expression (Figure 30). In contrast, 
the TNF gene revealed a much lower level of absolute re-stimulation with secondary LPS treatment, 
as compared to the IL1B gene.  
 
Figure 30. LPS re-stimulation profile for IL1B is similar to that of primary LPS treatment. 
The figure shows IL1B and TNF mRNA expression profiles with LPS-only stimulation (1o) in blue 
and LPS re-stimulation (2o) in red for the indicated time points. Error bars represent two technical 
replicates for LPS-only treatment and two biological replicates for LPS re-stimulation samples.  
 
            Succinate, an intermediate metabolite in the Tricarboxylic acid cycle is well established as 
an important onco-metabolite that drives the Warburg effect in cancer cells (Selak et al., 2005). 
However, recent studies have shown that succinate also plays an important role in inflammation 
through the upregulation of the pro-inflammatory cytokine, IL-1β, in LPS-stimulated macrophages 
(Mills et al., 2016; Tannahill et al., 2013). Activated macrophages can upregulate the expression 
of extracellular succinate receptor SUCNR1/GPCR91 and secrete succinate which can act in an 
autocrine and paracrine manner to stimulate the SUCNR1 receptor on macrophages to increase 
proIL-1β expression (Littlewood-Evans et al., 2016; Rubic-Schneider et al., 2017; van Diepen et 
al., 2017). Since, previous studies have demonstrated that washing the cells prior to secondary LPS 
challenge decreases the re-stimulation of the IL1B gene (Adamik et al., 2013), we hypothesized 
that the wash step removes extracellular succinate in the media that might be necessary for 
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secondary stimulation of the IL1B gene. After the initial LPS stimulation, THP-1 cells were 
subjected to secondary LPS challenge with or without washing the cells with serum-free 
RPMI-1640 in the presence or absence of extracellular succinate. Washing the cells prior to 
re-stimulation decreased the IL1B gene expression but did not completely negate the IL1B gene 
response to re-stimulation (Figure 31). The addition of extracellular succinate along with a 
secondary LPS dose, following the wash step, slightly increased IL1B gene expression, when 
compared to the same treatment without extracellular succinate. These preliminary trend data 
suggest that washing the cells prior to secondary stimulation may remove the extracellular 
succinate which might otherwise support LPS induction of the IL1B gene in monocytes. However, 
additional biological replicates and supporting experiments are required to provide conclusive 
evidence that extracellular succinate plays a role in LPS re-stimulation of the IL1B gene. It should 
be noted that these studies were conducted with a very high concentration of LPS (1 µg/ml). The 
co-operative effect of extracellular succinate on IL1B gene expression may be more striking if the 




Figure 31. Extracellular Succinate supports LPS re-stimulation of IL1B. The figure shows the 
effect of extracellular succinate on IL1B in LPS-treated THP-1 monocytes. Error bars represent 
two biological replicates. 
 
4.3.4. LPS dependent serine phosphorylation is required for Spi1 transcription factor 
activation of the IL1B gene promoter 
            Previous studies have demonstrated that LPS activates casein kinase II, which in turn 
phosphorylates serine residues on the Spi1 transcription factor (Lodie et al., 1997). We 
hypothesized that this phosphorylation event for pre-bound Spi1 may be required for its activation 
of IL1B gene transcription in TLR-4 activated monocytes. To test this hypothesis, the luciferase 
reporter assay with the IL1B XT-Luc expression vector was performed on various Spi1 point 
mutants and deletions in HEK293T cells. HEK293T cells do not express TLR4 receptor, but can 
transcribe the IL1B gene when TRAF6, IRF8 and wild-type Spi1 are ectopically expressed, which 
our group previously demonstrated (Adamik et al., 2013; Wang et al., 2006). Figure 32A shows 
the schematic of Spi1 domains with various known serine phosphorylation sites that were mutated 
to alanine (Celada et al., 1996). The Serine to Alanine point mutants in the TAD domain (S41A, 
S45A and S41A+S45A) and the PEST domain (S148A) showed a significant decrease (about 60%) 
in luciferase activity (Figure 32B). The PEST domain deletion also showed similar levels of 
luciferase activity as the point mutants. The D1-100 (TAD) and D8-29 (TBP binding region) 
domain deletions were used as negative controls. No significant activity was detected in these 
deletions over the background. These luciferase assay results suggest that serine phosphorylation 
of both the TAD and PEST domains play a significant role in Spi1 activation. In order to validate 
the luciferase assay results, the IL1B mRNA expression levels were analyzed using the same 
expression vectors as the luciferase reporter studies, with the exception of the XT-Luc vector, in 
HEK293 cells. These mRNA studies reveal a 1000 to 2500-fold decrease in IL1B gene 
transcription with the Spi1 point mutants, as compared to the Wild-type Spi1 (Figure 32C). The 
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S148A Spi1 mutant revealed the highest decrease (~2500 fold) in IL1B gene expression among 
the point mutants. The PEST domain serine mutation showed an approximately 2-fold lower 
mRNA expression than the TAD domain mutations. Once again, there was no significant IL1B 
mRNA detected in D1-100 and D8-29 deletions (negative controls) over the background. These 
mRNA results agree with the luciferase reporter studies in that these point mutations have an effect 
on the Spi1 activation event and IL1B gene transcription in TLR4-activated monocytes. Since 
previous studies have demonstrated that Spi1 through its amino-terminal transactivation domain 
can recruit TBP (Adamik et al., 2013; Hagemeier et al., 1993), it would be interesting to test the 
ability of these Spi1 serine mutants to recruit TBP and Pol II to the IL1B gene promoter relative to 
the wild type Spi1 in an HEK293T system using ChIP analysis.  
  
Figure 32. Phosphorylation of serine residues on Spi1 likely plays an important role in IL1B 
gene expression. (A) Shows the schematic of wild-type Spi1 with various domains and previously 
reported putative serine phosphorylation sites (Celada et al., 1996). The Spi1 schematic is courtesy 
of Dr. Philip E Auron. (B) The luciferase assay results for Spi1 point mutants and deletion vectors 
as compared to Wild-type Spi1 transfected into HEK293T cells. (C) Relative IL1B mRNA 
expression in HEK293T cells transfected with Spi1 point mutants and deletion vectors. Error bars 





4.4. MATERIALS AND METHODS 
4.4.1. Cell Culture, Reagents and Treatment conditions 
            Cell lines were obtained from American Type Culture Collection (ATCC). THP-1 cells 
were cultured in RPMI media (10-040-CV, Cellgro) supplemented with 10% heat-inactivated fetal 
bovine serum (SH30070.03, Hyclone), 1% Penicillin/Streptomycin Solution (30-002-CI, Cellgro) 
and 500 μl of 2-mercaptoethanol (21985-023, Invitrogen). HEK293T cells were grown in EMEM 
(10-010-CV, Cellgro) containing 10% heat-inactivated fetal bovine serum (SH30070.03, Hyclone) 
and 1% Penicillin/Streptomycin Solution (30-002-CI, Cellgro). For mRNA and ChIP studies, 
THP-1 cells were stimulated with 1µg/ml of E.coli 055:B5 Lipopolysaccharide (LPS) (L2880, 
Sigma-Aldrich) and/or with 30ng/ml of Phorbol 12-Myristate 13-Acetate (PMA) (Sigma) for 
indicated time periods. For transcription factor inhibitor mRNA studies, the THP-1 cells were 
pre-treated with specified inhibitor one hour prior to LPS stimulation. 10 µM of IKK inhibitor III 
(BMS-345541, Calbiochem) was used as an NF-κB inhibitor and 10 µM of U0126 (V1121, 
Promega) was used as an C/EBPβ inhibitor. For LPS re-stimulation experiments, THP-1 cells were 
first treated with 1µg/ml of LPS for 24 hours and then re-stimulated with 1µg/ml of LPS with or 
without washing with serum-free RPMI media for indicated time periods. For extracellular 
succinate treatment experiments, sodium succinate dibasic hexahydrate (S9637, Sigma) was used 
at the indicated concentration.  
 
4.4.2. Transfection constructs 
            Wild-type TRAF6 vector has been described previously (Wang et al., 2010). Luciferase 
reporter XT-Luc IL1B and wild-type IRF8 were as described (Unlu et al., 2007). Expression 
vectors containing full-length and Spi1 mutant constructs (D8-29, DPEST (D112-166), Serine to 
Alanine substitutions: S41A, S45A, S41A S45A, S148A) were a gift from Richard Maki (The 
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Scripps Research Institute, La Jolla, California). The plasmid expressing the D1-100 Spi1were 
constructed as described (Kominato et al., 1995) 
 
4.4.3. Cell transfection 
            HEK293T cells were seeded into either 6-well plates (mRNA studies) or 24-well plates 
(luciferase reporter assays) to 60-70% confluency. Expression plasmids were transfection into 
HEK293T cells with FUGENE 6 transfection reagent (11814443001, Roche) in a ratio of 3:1 (3 
µl of reagent per 1 µg if DNA), according to the manufacturer’s instructions. For luciferase 
reporter assays, expression vectors were transfected into HEK293T cells in 24-well plates as 
follows: 50 ng of Spi1 wild-type or mutants and 100 ng of wild-type TRAF6, wild-type IRF-8 and 
XT-Luc IL1B reporter vector. pECE (empty vector) plasmid was used to maintain a constant 
amount of total transfected DNA into each sample. For endogenous IL1B mRNA expression 
studies, the expression vectors were transfected into HEK293T cells in 6-well plates as follows: 
150 ng of Spi1 wild-type or mutants and 300 ng of wild-type TRAF6 and wild-type IRF-8.  
 
4.4.4. Luciferase Reporter Assays 
            The luciferase assay system (Promega, E-1501) was used for luciferase reporter assays. 
After 24 hours of transfection, cells were then lysed with 60 µl of cell lysis buffer (Promega) in 
each well of the 24-well plates and continuously shaken for 20 minutes at room temperature. 20 
µl of cell lysate from each well was used to determine the luciferase activity using VERITAS 






4.4.5. mRNA Expression Analysis 
            1x106 THP-1 cells in RPMI-1640 media were plated into 6-well plates (Thermo Fisher 
BioLite, 130184). Following treatments, cells were pelleted and the supernatant was removed. The 
cell pellet was re-suspended in 500 μl of TRIzol reagent (Invitrogen, 15596026). For endogenous 
IL1B mRNA expression studies, HEK293T cells were plated into 6-well plates (Thermo Fisher 
BioLite, 130184) and transfected as indicated at 60-70% cell confluency. The RNA was isolated 
and converted into cDNA as previously described (Pulugulla et al., 2018a; Pulugulla et al., 2018b). 
cDNA was then analyzed using quantitative PCR (qPCR) carried out in a StepOnePlus Applied 
Biosystems Real Time Instrument (Thermo Fisher, 4376600). Relative expression levels were 
calculated using the DDCt method with GAPDH (Reference gene) and unstimulated THP-1 cells 
as a control. Primer Sequences used for mRNA analysis are indicated in Table 6. 
Gene Forward Primer Reverse Primer 
IL1B TCCAGGGACAGGATATGGAG TCTTTCAACACGCAGGACAG 
TNF CGTCTCCTACCAGACCAAGG GGAAGACCCCTCCCAGATAG 
GAPDH ACACCCACTCCTCCACCTTT CCCTGTTGCTGTAGCCAAAT 
 
Table 6. Primer sequences for mRNA expression analysis. The table shows the forward and 
reverse primer sequences used for mRNA analysis.  
 
 
4.5.6. Chromatin Immuno-precipitation 
            ChIP was performed using a modification of the Millipore/Upstate protocol 
(MCPROTO407). Following treatments, a total of 1x107 THP-1 monocytes in RPMI-1640 media 
were fixed in 1% formaldehyde (Fisher, F79-500) for 10 min at room temperature. ChIP and DNA 
isolation were performed as previously described (Pulugulla et al., 2018a; Pulugulla et al., 2018b). 
Primer Sequences used for ChIP analysis are indicated in Table 7. The size of the PCR products 
ranges between 80 and 150 bp. 20 μl qPCR reactions containing 2x Maxima SYBR Green/ROX 
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qPCR Master Mix (Thermo Scientific, K0223), 250 nM of primers, and 3 µl of precipitated DNA 
were set up in Fast 96-Well Reaction Plates (Applied Biosystems, 4346907). qPCR reactions were 
carried out in a StepOnePlus Applied Biosystems Real Time Instrument (Thermo Fisher, 4376600).  
Fold enrichment was calculated based on Ct as 2(DCt), where DCt = (CtInput - CtIP). Final enrichment 
values were adjusted by subtraction of the nonspecific IgG antibody binding.  
















+4858 IL1B AGTAGCCAAAGCCTCTGCAC CCGATTCCAAAGAAACAGGA 






















Chapter 5: Conclusion and Future Directions 
 
            This dissertation focuses on the examination of various molecular mechanisms that 
regulate IL1B gene expression. The first major finding highlighted in chapter 2 focused on 
understanding IL1B gene expression and its chromatin status in human tonsillar CD4 T cells. Our 
mRNA expression studies demonstrate that TCR-activation of CD4 T cells results in IL1B gene 
expression in these cells. Interestingly, the IL1B gene in TCR-activated CD4 T cells is 
slowly-induced with maximal expression after 72 hours, contrasting that of TLR4-activated 
monocytes, where the IL1B gene is expressed both at much higher levels (~1000-fold greater) and 
with rapid maximal gene expression within the first 3-4 hours. In order to explore whether distinct 
mechanisms regulate IL1B gene expression in CD4 T cells and monocytes, we examined the 
epigenetic status of IL1B in TCR-activated CD4 T cells, showing that, in contrast to monocytes, 
the IL1B gene in CD4 T cells is expressed from a low-activity bivalent promoter containing both 
active H3K4me3 and repressive H3K27me3 gene expression nucleosome marks. 
            In monocytes, Spi1 is known to broadly act as a “pioneer factor” possessing the ability to 
associate with nucleosomal DNA and either physically remodel or displace nucleosomes (Barozzi 
et al., 2014; Calo and Wysocka, 2013; Iwafuchi-Doi et al., 2016), and likely also opens chromatin 
that our laboratory has reported for the IL1B promoter (Adamik et al., 2013). We have reported 
that Spi1, which is absolutely necessary for IL1B gene expression in monocytes and macrophages, 
is absent in TCR-activated CD4 T cells. A nucleosome is present at the Spi1 binding site of the 
IL1B promoter in unstimulated and TCR-activated CD4 T cells, supporting the argument that IL1B 
gene expression in CD4 T cells is independent of Spi1. The absence of Spi1 might be one of the 
reasons for the low-level induction of IL1B in CD4 T cells in comparison to TLR4-activated 
monocytes. For future studies, it would be informative to ectopically express Spi1 in CD4 T cells 
prior to TCR-activation to determine whether the presence of Spi1 in these cells results in an 
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increased and immediate-early IL1B gene induction, similar to that of monocytes. In order to 
evaluate whether Spi1 is generally capable of inducing IL1B transcription in other T cells, similar 
studies could also be conducted in either A3.01 or Jurkat T cell line. Chromatin 
Immunoprecipitation could be used to determine whether ectopically expressed Spi1, functioning 
as a pioneer factor, can displace the single nucleosome that we reported to be blocking the Spi1 
binding site on the IL1B promoter in CD4 T cells (Pulugulla et al., 2018a). Moreover, the 
transcription factors responsible for IL1B gene induction in CD4 T cells after TCR-activation is 
unknown. Previous studies have shown that TCR-activation can induce NF-κB activity 
(Coudronniere et al., 2000; Thaker et al., 2015; Wang et al., 2004), which is known to be important 
in IL1B gene expression in monocytes (Adamik et al., 2013). Using relatively specific transcription 
factor inhibitors and ChIP studies, it should be able to be determined whether NF-κB plays a role 
in IL1B gene induction in CD4 T cells, similar to that which it plays in TLR-4 activated monocytes. 
Other than NF-κB, transcription factors like IRF-4 (Klein et al., 2015; Zhang et al., 2008), IRF-8 
(Unlu et al., 2007), AP-1 (Roman et al., 2000) and C/EBPβ (Adamik et al., 2013) that are known 
to be important for IL1B gene expression in monocytes can also be evaluated in TCR-activated 
CD4 T cells. 
            The third chapter of this dissertation focuses on understanding the molecular structure of a 
critical long-range protein-protein interaction between Spi1 and C/EBPβ at the IL1B promoter and 
its upstream enhancer using a combination of computational and experimental approaches. We 
have reported the predicted structure of the Spi1:C/EBPβ interaction on the IL1B promoter using 
computational docking and molecular dynamic simulations. These computational and in vitro 
approaches revealed that the C-terminal Cysteine (Cys-345) of C/EBPβ is involved in a strong 
critical salt-bridge with Arg-232 located within the DNA-recognition helix of Spi1. A pocket 
surrounding Arg-232 was computationally screened in order to identify small molecules that might 
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disrupt the Spi1:C/EBPβ interaction. L-Arginine was one of the highest-scoring small molecules 
that could bind into the pocket surrounding Arg-232 of Spi1 in LPS-activated THP-1 cells. We 
discovered that soluble L-Arginine added to the media significantly reduced IL1B gene expression 
and the interaction of C/EBPβ with Spi1 on the IL1B promoter in TLR4-activated monocytes. 
These results, along with our laboratory’s previous mutation studies (Listman et al., 2005) suggest 
that the Spi1:C/EBPβ interaction on the IL1B promoter plays an important role in IL1B gene 
transcription and can be potentially targeted using small molecule inhibitors. This is also the first 
example that we are aware of a specific druggable promoter, possibly related to the unique 
involvement of Spi1, a specific transcription activator, acting at the IL1B promoter as a general 
transcription factor (i.e., a factor similar to those of TBP and the RNA Polymerase II pre-initiation 
complex that are associated with the general process of transcription). IL-1β protein plays a central 
role in many anti-inflammatory diseases and current anti-IL-1β therapies target the “storm” of 
IL-1β protein molecules downstream of IL1B gene transcription. However, this study provides an 
unique approach to target IL-1β at the transcription level and act as a model to design novel 
anti-inflammatory small molecules that can potentially target IL1B gene induction. This approach 
can be expanded by testing other small molecules from the computational screen with high 
potential to both enter the cell and bind to the Spi1:C/EBPβ interaction pocket. Molecules that 
have the potential to decrease IL1B gene transcription by disrupting the Spi1:C/EBPβ interaction 
at the IL1B gene promoter, without affecting the direct interaction of either Spi1 or C/EBPβ with 
DNA can be further evaluated. We were fortunate in our use of L-Arginine because it can be taken 
up by macrophages like THP-1 cells at reasonable concentrations. However, other potential 
inhibitors that might be effective direct inhibitors may not be readily transported into cells. Since 
the primary target is inside the cell, a direct means of evaluation of compounds for inhibiting the 
Spi1:C/EBPβ interaction is critical, with methods of intracellular transport being an important, but 
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secondary goal. One of the potential techniques for ex vivo testing of compounds would be to use 
glutathione-s-transferase fusions, as we have reported (Pulugulla et al., 2018b). However, even 
more effective and with a broader set of capabilities, a technique like surface plasmon resonance 
might be most effective in characterizing a small molecule’s binding kinetics, concentration and 
affinity (Huber and Mueller, 2006). This sensitive and quantitative approach extensively used in 
drug discovery can be utilized to rapidly screen binding on and off rates for numerous compounds 
under various conditions, generating structural characteristics for binding that can be readily 
evaluated for cell uptake. Selected compounds from this screen can then be derivatization, if 
required, in preparation for pre-clinical animal trials involving organism cytotoxicity, 
pharmacokinetics and dynamics prior to testing for efficacy in in vivo diseased animal models. 
            The fourth chapter contains a series of unpublished preliminary results that provide new 
molecular insights into IL1B gene regulation. Using mRNA expression and ChIP, we have 
demonstrated a differential functional role for NF-κB and C/EBPβ in IL1B and TNF gene 
expression for LPS and PMA-activated THP-1 cells. Our results suggest that NF-κB is required 
for both early and late expression of the IL1B gene in LPS-activated monocytes. Recent studies 
have revealed that the TLR-4 receptor gets internalized and activates NF-κB in a secondary kinetic 
late phase via TRIF adaptor function (Cheng et al., 2015; Tan et al., 2015; Zanoni et al., 2011). 
This raises the question as to whether the TRIF pathway plays a role in the sustained late phase 
expression of the IL1B gene that might be resolved by using available TRIF inhibitors. We have 
preliminary evidence that extracellular succinate may support LPS re-stimulation of the IL1B gene 
in THP-1 monocytes as a form of Trained Innate Immune Memory (Netea et al., 2016; Quintin et 
al., 2014). Finally, we have demonstrated that TLR4-dependent phosphorylation of Spi1 plays an 
important role in IL1B gene transcription. As hypothesized in Chapter 4, this study can be further 
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expanded to determine whether Spi1 phosphorylation is necessary for TBP recruitment to the IL1B 
gene promoter.  
            The work highlighted in this dissertation provides new molecular insights into IL1B gene 
expression in monocytes and lymphoid CD4 T cells. Results from this work could be used to 
design future studies that would assist in discovering potential regulatory control points for this 
immunologically important gene, which could ultimately lead to the development of novel 















Appendix A1. CD4 T cells express proIL-1β following TCR stimulation independent of Spi1. 
(1) Full-length blots of cropped images from Fig. 1C. The short and long exposures of proIL-1β 
and Spi1 blots illustrate the relative abundance of these proteins in ex vivo TCR-activated CD4 T 
cells in comparison with resting CD4 T cells, HEK293 cells, and THP-1 cells (unstimulated or 
LPS-treated for 1.5 h) for two individual patient donors. Membranes were stripped and re-probed 
for β-actin. Samples were normalized by cell equivalents, 1.5x105 for all lanes. (2) Full-length 
blots of cropped images from Fig. 2D show expression of proIL-1β for in vivo-differentiated 
CCR5+ and naïve CCR5- CD4 T lymphocytes from two individual patient donors. HEK293, 
unstimulated and 1.5 h LPS-treated THP-1 cells were used as controls. Membranes were stripped 
and re-probed for β-actin. Samples were normalized by cell equivalents: 1.5x104 cell equivalents 







Abderrazak, A., Syrovets, T., Couchie, D., El Hadri, K., Friguet, B., Simmet, T., and Rouis, M. 
(2015). NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative 
stress and inflammatory diseases. Redox Biol 4, 296-307. 
Acuto, O., and Michel, F. (2003). CD28-mediated co-stimulation: a quantitative support for TCR 
signalling. Nat Rev Immunol 3, 939-951. 
Adamik, J., Wang, K.Z., Unlu, S., Su, A.J., Tannahill, G.M., Galson, D.L., O'Neill, L.A., and 
Auron, P.E. (2013). Distinct mechanisms for induction and tolerance regulate the immediate 
early genes encoding interleukin 1beta and tumor necrosis factor alpha. PLoS One 8, e70622. 
Adelman, K., Kennedy, M.A., Nechaev, S., Gilchrist, D.A., Muse, G.W., Chinenov, Y., and 
Rogatsky, I. (2009). Immediate mediators of the inflammatory response are poised for gene 
activation through RNA polymerase II stalling. Proc Natl Acad Sci U S A 106, 18207-18212. 
Akira, S., Uematsu, S., and Takeuchi, O. (2006). Pathogen recognition and innate immunity. Cell 
124, 783-801. 
Arbore, G., West, E.E., Spolski, R., Robertson, A.A., Klos, A., Rheinheimer, C., Dutow, P., 
Woodruff, T.M., Yu, Z.X., O'Neill, L.A., et al. (2016). T helper 1 immunity requires 
complement-driven NLRP3 inflammasome activity in CD4(+) T cells. Science 352, aad1210. 
Armant, M.A., and Fenton, M.J. (2002). Toll-like receptors: a family of pattern-recognition 
receptors in mammals. Genome Biol 3, REVIEWS3011. 
Asgari, E., Le Friec, G., Yamamoto, H., Perucha, E., Sacks, S.S., Kohl, J., Cook, H.T., and 
Kemper, C. (2013). C3a modulates IL-1beta secretion in human monocytes by regulating ATP 
efflux and subsequent NLRP3 inflammasome activation. Blood 122, 3473-3481. 
Baccam, M., Woo, S.Y., Vinson, C., and Bishop, G.A. (2003). CD40-mediated transcriptional 
regulation of the IL-6 gene in B lymphocytes: involvement of NF-kappa B, AP-1, and C/EBP. J 
Immunol 170, 3099-3108. 
Bahrami, S., and Drablos, F. (2016). Gene regulation in the immediate-early response process. 
Adv Biol Regul 62, 37-49. 
Barozzi, I., Simonatto, M., Bonifacio, S., Yang, L., Rohs, R., Ghisletti, S., and Natoli, G. (2014). 
Coregulation of transcription factor binding and nucleosome occupancy through DNA features 
of mammalian enhancers. Mol Cell 54, 844-857. 
Berard, M., and Tough, D.F. (2002). Qualitative differences between naive and memory T cells. 
Immunology 106, 127-138. 
Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N., 
and Bourne, P.E. (2000). The Protein Data Bank. Nucleic Acids Res 28, 235-242. 




Blasius, A.L., and Beutler, B. (2010). Intracellular toll-like receptors. Immunity 32, 305-315. 
Bleul, C.C., Wu, L., Hoxie, J.A., Springer, T.A., and Mackay, C.R. (1997). The HIV coreceptors 
CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc 
Natl Acad Sci U S A 94, 1925-1930. 
Bonilla, F.A., and Oettgen, H.C. (2010). Adaptive immunity. J Allergy Clin Immunol 125, S33-
40. 
Braddock, M., and Quinn, A. (2004). Targeting IL-1 in inflammatory disease: new opportunities 
for therapeutic intervention. Nat Rev Drug Discov 3, 330-339. 
Brooks, S.A., Connolly, J.E., and Rigby, W.F. (2004). The role of mRNA turnover in the 
regulation of tristetraprolin expression: evidence for an extracellular signal-regulated kinase-
specific, AU-rich element-dependent, autoregulatory pathway. J Immunol 172, 7263-7271. 
Caligiuri, M.A. (2008). Human natural killer cells. Blood 112, 461-469. 
Calo, E., and Wysocka, J. (2013). Modification of enhancer chromatin: what, how, and why? 
Mol Cell 49, 825-837. 
Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U., and Nishizuka, Y. (1982). Direct 
activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting 
phorbol esters. J Biol Chem 257, 7847-7851. 
Celada, A., Borras, F.E., Soler, C., Lloberas, J., Klemsz, M., van Beveren, C., McKercher, S., 
and Maki, R.A. (1996). The transcription factor PU.1 is involved in macrophage proliferation. J 
Exp Med 184, 61-69. 
Chang, H.-A., Zhang, S., Thieu, V.T., Slee, R.B., Bruns, H.A., Laribee, R.N., Klemsz, M.J., and 
Kaplan, M.H. (2005). PU.1 expression delineates heterogeneity in primary Th2 cells. Immunity 
22, 693-703. 
Chang, H.-C., Sehra, S., Goswami, R., Yao, W., Yu, Q., Stritesky, G.L., Jabeen, R., McKinley, 
C., Ahyi, A.-N., Han, L., et al. (2010). The transcription factor PU.1 is required for the 
development of IL-9-producing T Cells and allergic inflammation. Nature Immunol 11, 527-534. 
Chanput, W., Mes, J., Vreeburg, R.A., Savelkoul, H.F., and Wichers, H.J. (2010). Transcription 
profiles of LPS-stimulated THP-1 monocytes and macrophages: a tool to study inflammation 
modulating effects of food-derived compounds. Food & function 1, 254-261. 
Chaplin, D.D. (2010). Overview of the immune response. J Allergy Clin Immunol 125, S3-23. 
Cheng, Z., Taylor, B., Ourthiague, D.R., and Hoffmann, A. (2015). Distinct single-cell signaling 
characteristics are conferred by the MyD88 and TRIF pathways during TLR4 activation. Sci 
Signal 8, ra69. 
Coudronniere, N., Villalba, M., Englund, N., and Altman, A. (2000). NF-kappa B activation 
induced by T cell receptor/CD28 costimulation is mediated by protein kinase C-theta. Proc Natl 
Acad Sci U S A 97, 3394-3399. 
 
 105 
Darden, T., York, D., and Pedersen, L. (1993). Particle mesh Ewald: An N·log(N) method for 
Ewald sums in large systems. Journal of Chemical Physics 98, 10089-10092. 
de Vries, S.J., van Dijk, M., and Bonvin, A.M. (2010). The HADDOCK web server for data-
driven biomolecular docking. Nat Protoc 5, 883-897. 
Dinarello, C.A. (2009). Immunological and inflammatory functions of the interleukin-1 family. 
Annu Rev Immunol 27, 519-550. 
Dinarello, C.A. (2011). Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. 
Blood 117, 3720-3732. 
Dinarello, C.A. (2018). Overview of the IL-1 family in innate inflammation and acquired 
immunity. Immunol Rev 281, 8-27. 
Doitsh, G., Cavrois, M., Lassen, K.G., Zepeda, O., Yang, Z., Santiago, M.L., Hebbeler, A.M., 
and Greene, W.C. (2010). Abortive HIV Infection Mediates CD4 T Cell Depletion and 
Inflammation in Human Lymphoid Tissue. Cell 143, 789-801. 
Doitsh, G., Galloway, N.L., Geng, X., Yang, Z., Monroe, K.M., Zepeda, O., Hunt, P.W., Hatano, 
H., Sowinski, S., Munoz-Arias, I., et al. (2014). Cell death by pyroptosis drives CD4 T-cell 
depletion in HIV-1 infection. Nature 505, 509-514. 
Doitsh, G., and Greene, W.C. (2016). Dissecting How CD4 T Cells Are Lost During HIV 
Infection. Cell host & microbe 19, 280-291. 
Dominguez, C., Boelens, R., and Bonvin, A.M. (2003). HADDOCK: a protein-protein docking 
approach based on biochemical or biophysical information. J Am Chem Soc 125, 1731-1737. 
Donner, A.J., Ebmeier, C.C., Taatjes, D.J., and Espinosa, J.M. (2010). CDK8 is a positive 
regulator of transcriptional elongation within the serum response network. Nat Struct Mol Biol 
17, 194-201. 
Dubyak, G.R. (2012). P2X7 receptor regulation of non-classical secretion from immune effector 
cells. Cell Microbiol 14, 1697-1706. 
Eckstein, D.A., Penn, M.L., Korin, Y.D., Scripture-Adams, D.D., Zack, J.A., Kreisberg, J.F., 
Roederer, M., Sherman, M.P., Chin, P.S., and Goldsmith, M.A. (2001). HIV-1 actively replicates 
in naive CD4(+) T cells residing within human lymphoid tissues. Immunity 15, 671-682. 
Edelsbrunner, H. (1992). Weighted Alpha Shapes (University of Illinois at Urbana-Champaign, 
Champaign, IL). 
Edelsbrunner, H., Facello, M., Fu, R., and Liang, J. (1995). Measuring Proteins and Voids in 
Proteins. In Proceedings of the 28th Hawaii International Conference on Systems Science 
(Hawaii, USA), pp. 256-264. 
Eder, C. (2009). Mechanisms of interleukin-1beta release. Immunobiology 214, 543-553. 
 
 106 
Evavold, C.L., Ruan, J., Tan, Y., Xia, S., Wu, H., and Kagan, J.C. (2018). The Pore-Forming 
Protein Gasdermin D Regulates Interleukin-1 Secretion from Living Macrophages. Immunity 48, 
35-44 e36. 
Everett, B.M., Donath, M.Y., Pradhan, A.D., Thuren, T., Pais, P., Nicolau, J.C., Glynn, R.J., 
Libby, P., and Ridker, P.M. (2018). Anti-Inflammatory Therapy With Canakinumab for the 
Prevention and Management of Diabetes. J Am Coll Cardiol 71, 2392-2401. 
Fenton, M.J., Vermeulen, M.W., Clark, B.D., Webb, A.C., and Auron, P.E. (1988). Human pro-
IL-1 beta gene expression in monocytic cells is regulated by two distinct pathways. J Immunol 
140, 2267-2273. 
Foell, D., Wittkowski, H., and Roth, J. (2007). Mechanisms of disease: a 'DAMP' view of 
inflammatory arthritis. Nat Clin Pract Rheumatol 3, 382-390. 
Fritz, J.H. (2013). Arginine cools the inflamed gut. Infect Immun 81, 3500-3502. 
Frostegard, J. (2013). Immunity, atherosclerosis and cardiovascular disease. BMC Med 11, 117. 
Galloway, N.L., Doitsh, G., Monroe, K.M., Yang, Z., Munoz-Arias, I., Levy, D.N., and Greene, 
W.C. (2015). Cell-to-Cell Transmission of HIV-1 Is Required to Trigger Pyroptotic Death of 
Lymphoid-Tissue-Derived CD4 T Cells. Cell Rep 12, 1555-1563. 
Galson, D.L., Hensold, J.O., Bishop, T.R., Schalling, M., D'Andrea, A.D., Jones, C., Auron, 
P.E., and Housman, D.E. (1993). Mouse beta-globin DNA-binding protein B1 is identical to a 
proto-oncogene, the transcription factor Spi-1/PU.1, and is restricted in expression to 
hematopoietic cells and the testis. Mol Cell Biol 13, 2929-2941. 
Geijtenbeek, T.B., and Gringhuis, S.I. (2009). Signalling through C-type lectin receptors: 
shaping immune responses. Nat Rev Immunol 9, 465-479. 
Geissmann, F., Manz, M.G., Jung, S., Sieweke, M.H., Merad, M., and Ley, K. (2010). 
Development of monocytes, macrophages, and dendritic cells. Science 327, 656-661. 
Gerber, P.R., and Muller, K. (1995). MAB, a generally applicable molecular force field for 
structure modelling in medicinal chemistry. J Comput Aided Mol Des 9, 251-268. 
Ghisletti, S., Barozzi, I., Mietton, F., Polletti, S., De Santa, F., Venturini, E., Gregory, L., Lonie, 
L., Chew, A., Wei, C.L., et al. (2010). Identification and characterization of enhancers 
controlling the inflammatory gene expression program in macrophages. Immunity 32, 317-328. 
Glushakova, S., Baibakov, B., Margolis, L.B., and Zimmerberg, J. (1995). Infection of human 
tonsil histocultures: a model for HIV pathogenesis. Nat Med 1, 1320-1322. 
Gray, J.G., Chandra, G., Clay, W.C., Stinnett, S.W., Haneline, S.A., Lorenz, J.J., Patel, I.R., 
Wisely, G.B., Furdon, P.J., Taylor, J.D., et al. (1993). A CRE/ATF-like site in the upstream 
regulatory sequence of the human interleukin 1 beta gene is necessary for induction in U937 and 
THP-1 monocytic cell lines. Mol Cell Biol 13, 6678-6689. 
 
 107 
Gupte, R., Muse, G.W., Chinenov, Y., Adelman, K., and Rogatsky, I. (2013). Glucocorticoid 
receptor represses proinflammatory genes at distinct steps of the transcription cycle. Proc Natl 
Acad Sci U S A 110, 14616-14621. 
Hagemeier, C., Bannister, A.J., Cook, A., and Kouzarides, T. (1993). The activation domain of 
transcription factor PU.1 binds the retinoblastoma (RB) protein and the transcription factor 
TFIID in vitro: RB shows sequence similarity to TFIID and TFIIB. Proc Natl Acad Sci U S A 
90, 1580-1584. 
Hall, M.J., Williams, S.N., DeFrances, C.J., and Golosinskiy, A. (2011). Inpatient care for 
septicemia or sepsis: a challenge for patients and hospitals. NCHS Data Brief, 1-8. 
Hansen, K.H., Bracken, A.P., Pasini, D., Dietrich, N., Gehani, S.S., Monrad, A., Rappsilber, J., 
Lerdrup, M., and Helin, K. (2008). A model for transmission of the H3K27me3 epigenetic mark. 
Nat Cell Biol 10, 1291-1300. 
Heilig, R., Dick, M.S., Sborgi, L., Meunier, E., Hiller, S., and Broz, P. (2018). The Gasdermin-D 
pore acts as a conduit for IL-1beta secretion in mice. Eur J Immunol 48, 584-592. 
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X., Murre, C., 
Singh, H., and Glass, C.K. (2010). Simple combinations of lineage-determining transcription 
factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 38, 
576-589. 
Heinzel, S., Marchingo, J.M., Horton, M.B., and Hodgkin, P.D. (2018). The regulation of 
lymphocyte activation and proliferation. Curr Opin Immunol 51, 32-38. 
Henikoff, S., and Shilatifard, A. (2011). Histone modification: cause or cog? Trends in genetics : 
TIG 27, 389-396. 
Hmama, Z., Knutson, K.L., Herrera-Velit, P., Nandan, D., and Reiner, N.E. (1999). Monocyte 
adherence induced by lipopolysaccharide involves CD14, LFA-1, and cytohesin-1. Regulation 
by Rho and phosphatidylinositol 3-kinase. J Biol Chem 274, 1050-1057. 
Hoffman, H.M. (2009). Therapy of autoinflammatory syndromes. J Allergy Clin Immunol 124, 
1129-1138; quiz 1139-1140. 
Hollenhorst, P.C., McIntosh, L.P., and Graves, B.J. (2011). Genomic and biochemical insights 
into the specificity of ETS transcription factors. Annu Rev Biochem 80, 437-471. 
Hoving, J.C., Wilson, G.J., and Brown, G.D. (2014). Signalling C-type lectin receptors, 
microbial recognition and immunity. Cell Microbiol 16, 185-194. 
Huang, J., and MacKerell, A.D., Jr. (2013). CHARMM36 all-atom additive protein force field: 
validation based on comparison to NMR data. J Comput Chem 34, 2135-2145. 
Huber, W., and Mueller, F. (2006). Biomolecular interaction analysis in drug discovery using 
surface plasmon resonance technology. Curr Pharm Des 12, 3999-4021. 
 
 108 
Humphery, W., Dalke, A., and Schulten, K. (1996). VMD: Visual Molecular Dynamics. Journal 
of Molecular Graphics 14, 33-38. 
Italiani, P., and Boraschi, D. (2014). From Monocytes to M1/M2 Macrophages: Phenotypical vs. 
Functional Differentiation. Front Immunol 5, 514. 
Iwafuchi-Doi, M., Donahue, G., Kakumanu, A., Watts, J.A., Mahony, S., Pugh, B.F., Lee, D., 
Kaestner, K.H., and Zaret, K.S. (2016). The Pioneer Transcription Factor FoxA Maintains an 
Accessible Nucleosome Configuration at Enhancers for Tissue-Specific Gene Activation. Mol 
Cell 62, 79-91. 
Janeway, C.A., Jr., and Medzhitov, R. (2002). Innate immune recognition. Annu Rev Immunol 
20, 197-216. 
Janin, J., Rodier, F., Chakrabarti, P., and Bahadur, R.P. (2007). Macromolecular recognition in 
the Protein Data Bank. Acta Crystallogr D Biol Crystallogr 63, 1-8. 
Jekle, A., Keppler, O.T., De Clercq, E., Schols, D., Weinstein, M., and Goldsmith, M.A. (2003). 
In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity 
through CXCR4-mediated killing of uninfected CD4 T cells. J Virol 77, 5846-5854. 
Jonkers, I., and Lis, J.T. (2015). Getting up to speed with transcription elongation by RNA 
polymerase II. Nature reviews Molecular cell biology 16, 167-177. 
Jorgensen, W.L., Chandrasekhar, J., and Madura, J.D. (1983). Comparison of simple potential 
functions for simulating liquid water. Journal of Chemical Physics 79, 926-935. 
Kanneganti, T.D., Lamkanfi, M., and Nunez, G. (2007). Intracellular NOD-like receptors in host 
defense and disease. Immunity 27, 549-559. 
Kaspar, R.L., and Gehrke, L. (1994). Peripheral blood mononuclear cells stimulated with C5a or 
lipopolysaccharide to synthesize equivalent levels of IL-1 mRNA show unequal IL-1beta  
protein accumulation but similar polyribosome profiles. J Immunol 153, 277-286. 
Kato, H., Takeuchi, O., Mikamo-Satoh, E., Hirai, R., Kawai, T., Matsushita, K., Hiiragi, A., 
Dermody, T.S., Fujita, T., and Akira, S. (2008). Length-dependent recognition of double-
stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-
associated gene 5. J Exp Med 205, 1601-1610. 
Kawai, T., and Akira, S. (2010). The role of pattern-recognition receptors in innate immunity: 
update on Toll-like receptors. Nat Immunol 11, 373-384. 
Kawasaki, T., and Kawai, T. (2014). Toll-like receptor signaling pathways. Front Immunol 5, 
461. 
Kayagaki, N., Stowe, I.B., Lee, B.L., O'Rourke, K., Anderson, K., Warming, S., Cuellar, T., 
Haley, B., Roose-Girma, M., Phung, Q.T., et al. (2015). Caspase-11 cleaves gasdermin D for 
non-canonical inflammasome signalling. Nature 526, 666-671. 
 
 109 
Klein, M., Bruhl, T.J., Staudt, V., Reuter, S., Grebe, N., Gerlitzki, B., Hoffmann, M., Bohn, T., 
Ulges, A., Stergiou, N., et al. (2015). Tick Salivary Sialostatin L Represses the Initiation of 
Immune Responses by Targeting IRF4-Dependent Transcription in Murine Mast Cells. J 
Immunol 195, 621-631. 
Kodandapani, R., Pio, F., Ni, C.Z., Piccialli, G., Klemsz, M., McKercher, S., Maki, R.A., and 
Ely, K.R. (1996). A new pattern for helix-turn-helix recognition revealed by the PU.1 ETS-
domain-DNA complex. Nature 380, 456-460. 
Kominato, Y., Galson, D., Waterman, W.R., Webb, A.C., and Auron, P.E. (1995). Monocyte 
expression of the human prointerleukin 1 beta gene (IL1B) is dependent on promoter sequences 
which bind the hematopoietic transcription factor Spi-1/PU.1. Mol Cell Biol 15, 58-68. 
Kumagai, Y., Takeuchi, O., and Akira, S. (2008). TLR9 as a key receptor for the recognition of 
DNA. Adv Drug Deliv Rev 60, 795-804. 
Labute, P. (2010). LowModeMD--implicit low-mode velocity filtering applied to conformational 
search of macrocycles and protein loops. J Chem Inf Model 50, 792-800. 
Lam, S.Y., Yeung, R.C., Yu, T.H., Sze, K.H., and Wong, K.B. (2011). A rigidifying salt-bridge 
favors the activity of thermophilic enzyme at high temperatures at the expense of low-
temperature activity. PLoS Biol 9, e1001027. 
Land, W.G. (2015). The Role of Damage-Associated Molecular Patterns (DAMPs) in Human 
Diseases: Part II: DAMPs as diagnostics, prognostics and therapeutics in clinical medicine. 
Sultan Qaboos Univ Med J 15, e157-170. 
Lanzavecchia, A., and Sallusto, F. (2000). Dynamics of T lymphocyte responses: intermediates, 
effectors, and memory cells. Science 290, 92-97. 
Latz, E., Xiao, T.S., and Stutz, A. (2013). Activation and regulation of the inflammasomes. Nat 
Rev Immunol 13, 397-411. 
Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A.C., Liu, Y., Maciejewski, A., Arndt, D., 
Wilson, M., Neveu, V., et al. (2014). DrugBank 4.0: shedding new light on drug metabolism. 
Nucleic Acids Res 42, D1091-1097. 
Lawrence, T., and Natoli, G. (2011). Transcriptional regulation of macrophage polarization: 
enabling diversity with identity. Nat Rev Immunol 11, 750-761. 
Libby, P., Ordovas, J.M., Auger, K.R., Robbins, A.H., Birinyi, L.K., and Dinarello, C.A. (1986). 
Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human 
vascular endothelial cells. Am J Pathol 124, 179-185. 
Linton, B., and Hamilton, A.D. (1999). Host-guest chemistry: combinatorial receptors. Curr 
Opin Chem Biol 3, 307-312. 
Listman, J.A., Wara-aswapati, N., Race, J.E., Blystone, L.W., Walker-Kopp, N., Yang, Z., and 
Auron, P.E. (2005). Conserved ETS domain arginines mediate DNA binding, nuclear 
localization, and a novel mode of bZIP interaction. J Biol Chem 280, 41421-41428. 
 
 110 
Littlewood-Evans, A., Sarret, S., Apfel, V., Loesle, P., Dawson, J., Zhang, J., Muller, A., Tigani, 
B., Kneuer, R., Patel, S., et al. (2016). GPR91 senses extracellular succinate released from 
inflammatory macrophages and exacerbates rheumatoid arthritis. J Exp Med 213, 1655-1662. 
Liu, X., Kraus, W.L., and Bai, X. (2015). Ready, pause, go: regulation of RNA polymerase II 
pausing and release by cellular signaling pathways. Trends Biochem Sci 40, 516-525. 
Lodie, T.A., Savedra, R., Jr., Golenbock, D.T., Van Beveren, C.P., Maki, R.A., and Fenton, M.J. 
(1997). Stimulation of macrophages by lipopolysaccharide alters the phosphorylation state, 
conformation, and function of PU.1 via activation of casein kinase II. J Immunol 158, 1848-
1856. 
Loetscher, P., Uguccioni, M., Bordoli, L., Baggiolini, M., Moser, B., Chizzolini, C., and Dayer, 
J.M. (1998). CCR5 is characteristic of Th1 lymphocytes. Nature 391, 344-345. 
Loo, Y.M., and Gale, M., Jr. (2011). Immune signaling by RIG-I-like receptors. Immunity 34, 
680-692. 
Luckheeram, R.V., Zhou, R., Verma, A.D., and Xia, B. (2012). CD4(+)T cells: differentiation 
and functions. Clin Dev Immunol 2012, 925135. 
Mackay, C.R. (1993). Immunological memory. Adv Immunol 53, 217-265. 
Malhotra, V. (2013). Unconventional protein secretion: an evolving mechanism. EMBO J 32, 
1660-1664. 
Marecki, S., McCarthy, K.M., and Nikolajczyk, B.S. (2004). PU.1 as a chromatin accessibility 
factor for immunoglobulin genes. Mol Immunol 40, 723-731. 
Martin, B.N., Wang, C., Zhang, C.J., Kang, Z., Gulen, M.F., Zepp, J.A., Zhao, J., Bian, G., Do, 
J.S., Min, B., et al. (2016). T cell-intrinsic ASC critically promotes T(H)17-mediated 
experimental autoimmune encephalomyelitis. Nat Immunol 17, 583-592. 
Matzinger, P. (1994). Tolerance, danger, and the extended family. Annu Rev Immunol 12, 991-
1045. 
Medzhitov, R., and Janeway, C.A., Jr. (1997). Innate immunity: the virtues of a nonclonal 
system of recognition. Cell 91, 295-298. 
Meraro, D., Hashmueli, S., Koren, B., Azriel, A., Oumard, A., Kirchhoff, S., Hauser, H., 
Nagulapalli, S., Atchison, M.L., and Levi, B.Z. (1999). Protein-protein and DNA-protein 
interactions affect the activity of lymphoid-specific IFN regulatory factors. J Immunol 163, 
6468-6478. 
Mills, E.L., Kelly, B., Logan, A., Costa, A.S.H., Varma, M., Bryant, C.E., Tourlomousis, P., 
Dabritz, J.H.M., Gottlieb, E., Latorre, I., et al. (2016). Succinate Dehydrogenase Supports 




Mogensen, T.H. (2009). Pathogen recognition and inflammatory signaling in innate immune 
defenses. Clin Microbiol Rev 22, 240-273, Table of Contents. 
Morris, S.M., Jr. (2016). Arginine Metabolism Revisited. J Nutr 146, 2579S-2586S. 
Munde, M., Wang, S., Kumar, A., Stephens, C.E., Farahat, A.A., Boykin, D.W., Wilson, W.D., 
and Poon, G.M. (2014). Structure-dependent inhibition of the ETS-family transcription factor 
PU.1 by novel heterocyclic diamidines. Nucleic Acids Res 42, 1379-1390. 
Murray, P.J., and Wynn, T.A. (2011). Protective and pathogenic functions of macrophage 
subsets. Nat Rev Immunol 11, 723-737. 
Nagulapalli, S., Pongubala, J.M., and Atchison, M.L. (1995). Multiple proteins physically 
interact with PU.1. Transcriptional synergy with NF-IL6 beta (C/EBP delta, CRP3). J Immunol 
155, 4330-4338. 
Natoli, G. (2012). NF-kappaB and chromatin: ten years on the path from basic mechanisms to 
candidate drugs. Immunol Rev 246, 183-192. 
Netea, M.G., Joosten, L.A., Latz, E., Mills, K.H., Natoli, G., Stunnenberg, H.G., O'Neill, L.A., 
and Xavier, R.J. (2016). Trained immunity: A program of innate immune memory in health and 
disease. Science 352, aaf1098. 
Nogales, E., Louder, R.K., and He, Y. (2017). Structural Insights into the Eukaryotic 
Transcription Initiation Machinery. Annu Rev Biophys 46, 59-83. 
Oskeritzian, C.A. (2012). Mast Cells and Wound Healing. Adv Wound Care (New Rochelle) 1, 
23-28. 
Ozinsky, A., Underhill, D.M., Fontenot, J.D., Hajjar, A.M., Smith, K.D., Wilson, C.B., 
Schroeder, L., and Aderem, A. (2000). The repertoire for pattern recognition of pathogens by the 
innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci 
U S A 97, 13766-13771. 
Perkel, J.M., and Atchison, M.L. (1998). A two-step mechanism for recruitment of Pip by PU.1. 
J Immunol 160, 241-252. 
Petosa, C., Morand, P., Baudin, F., Moulin, M., Artero, J.B., and Muller, C.W. (2006). Structural 
basis of lytic cycle activation by the Epstein-Barr virus ZEBRA protein. Mol Cell 21, 565-572. 
Petrilli, V., Dostert, C., Muruve, D.A., and Tschopp, J. (2007). The inflammasome: a danger 
sensing complex triggering innate immunity. Curr Opin Immunol 19, 615-622. 
Phillips, J.C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, 
R.D., Kale, L., and Schulten, K. (2005). Scalable molecular dynamics with NAMD. J Comput 
Chem 26, 1781-1802. 
Pierce, B.G., Wiehe, K., Hwang, H., Kim, B.H., Vreven, T., and Weng, Z. (2014). ZDOCK 
server: interactive docking prediction of protein-protein complexes and symmetric multimers. 
Bioinformatics 30, 1771-1773. 
 
 112 
Pugh, B.F., and Venters, B.J. (2016). Genomic Organization of Human Transcription Initiation 
Complexes. PLoS One 11, e0149339. 
Pulugulla, S.H., Packard, T.A., Galloway, N.L.K., Grimmett, Z.W., Doitsh, G., Adamik, J., 
Galson, D.L., Greene, W.C., and Auron, P.E. (2018a). Distinct mechanisms regulate IL1B gene 
transcription in lymphoid CD4 T cells and monocytes. Cytokine 111, 373-381. 
Pulugulla, S.H., Workman, R., Rutter, N.W., Yang, Z., Adamik, J., Lupish, B., Macar, D.A., El 
Abdouni, S., Esposito, E.X., Galson, D.L., et al. (2018b). A combined computational and 
experimental approach reveals the structure of a C/EBPbeta-Spi1 interaction required for IL1B 
gene transcription. J Biol Chem 293, 19942-19956. 
Quintin, J., Cheng, S.C., van der Meer, J.W., and Netea, M.G. (2014). Innate immune memory: 
towards a better understanding of host defense mechanisms. Curr Opin Immunol 29, 1-7. 
Ridker, P.M., MacFadyen, J.G., Thuren, T., Everett, B.M., Libby, P., Glynn, R.J., and Group, 
C.T. (2017). Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in 
patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-
controlled trial. Lancet 390, 1833-1842. 
Roh, J.S., and Sohn, D.H. (2018). Damage-Associated Molecular Patterns in Inflammatory 
Diseases. Immune Netw 18, e27. 
Roh, T.Y., Cuddapah, S., Cui, K., and Zhao, K. (2006). The genomic landscape of histone 
modifications in human T cells. Proc Natl Acad Sci U S A 103, 15782-15787. 
Roman, J., Ritzenthaler, J.D., Fenton, M.J., Roser, S., and Schuyler, W. (2000). Transcriptional 
regulation of the human interleukin 1beta gene by fibronectin: role of protein kinase C and 
activator protein 1 (AP-1). Cytokine 12, 1581-1596. 
Rothenberg, E.V., Champhekar, A., Damle, S., Del Real, M.M., Kueh, H.Y., Li, L., and Yui, 
M.A. (2013). Transcriptional establishment of cell-type identity: dynamics and causal 
mechanisms of T-cell lineage commitment. Cold Spring Harb Symp Quant Biol 78, 31-41. 
Roy, A.M., Schweighardt, B., Eckstein, L.A., Goldsmith, M.A., and McCune, J.M. (2005). 
Enhanced replication of R5 HIV-1 over X4 HIV-1 in CD4(+)CCR5(+)CXCR4(+) T cells. J 
Acquir Immune Defic Syndr 40, 267-275. 
Rubic-Schneider, T., Carballido-Perrig, N., Regairaz, C., Raad, L., Jost, S., Rauld, C., Christen, 
B., Wieczorek, G., Kreutzer, R., Dawson, J., et al. (2017). GPR91 deficiency exacerbates allergic 
contact dermatitis while reducing arthritic disease in mice. Allergy 72, 444-452. 
Ryser, S., Fujita, T., Tortola, S., Piuz, I., and Schlegel, W. (2007). The rate of c-fos transcription 
in vivo is continuously regulated at the level of elongation by dynamic stimulus-coupled 
recruitment of positive transcription elongation factor b. J Biol Chem 282, 5075-5084. 
Sallusto, F., Lenig, D., Forster, R., Lipp, M., and Lanzavecchia, A. (1999). Two subsets of 




SAPSE, A.M., and RUSSELL, C.S. (1984). A b Initio Calculations of Guanidinium-Carboxylate 
Interaction. International Journal of Quantum Chemistry 26, 91-99. 
Schweighardt, B., Roy, A.M., Meiklejohn, D.A., Grace, E.J., 2nd, Moretto, W.J., Heymann, J.J., 
and Nixon, D.F. (2004). R5 human immunodeficiency virus type 1 (HIV-1) replicates more 
efficiently in primary CD4+ T-cell cultures than X4 HIV-1. J Virol 78, 9164-9173. 
Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., 
Pan, Y., Simon, M.C., Thompson, C.B., and Gottlieb, E. (2005). Succinate links TCA cycle 
dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7, 77-85. 
Sellak, H., Franzini, E., Hakim, J., and Pasquier, C. (1994). Reactive oxygen species rapidly 
increase endothelial ICAM-1 ability to bind neutrophils without detectable upregulation. Blood 
83, 2669-2677. 
Shen, X., and Orkin, S.H. (2009). Glimpses of the epigenetic landscape. Cell stem cell 4, 1-2. 
Shimokawa, T., Nunomura, S., Enomoto, Y., and Ra, C. (2010). Amino acid residues in the 
beta3 strand and subsequent loop of the conserved ETS domain that mediate basic leucine zipper 
(bZIP) recruitment and potentially distinguish functional attributes of Ets proteins. Biochem J 
430, 129-139. 
Shimokawa, T., Nunomura, S., Fujisawa, D., and Ra, C. (2013). Identification of the 
C/EBPalpha C-terminal tail residues involved in the protein interaction with GABP and their 
potency in myeloid differentiation of K562 cells. Biochim Biophys Acta 1829, 1207-1217. 
Shimokawa, T., and Ra, C. (2005). C/EBPalpha functionally and physically interacts with GABP 
to activate the human myeloid IgA Fc receptor (Fc alphaR, CD89) gene promoter. Blood 106, 
2534-2542. 
Shin, J.J., Lee, E.K., Park, T.J., and Kim, W. (2015). Damage-associated molecular patterns and 
their pathological relevance in diabetes mellitus. Ageing Res Rev 24, 66-76. 
Shirakawa, F., Saito, K., Bonagura, C.A., Galson, D.L., Fenton, M.J., Webb, A.C., and Auron, 
P.E. (1993). The human prointerleukin 1 beta gene requires DNA sequences both proximal and 
distal to the transcription start site for tissue-specific induction. Mol Cell Biol 13, 1332-1344. 
Smith-Garvin, J.E., Koretzky, G.A., and Jordan, M.S. (2009). T cell activation. Annu Rev 
Immunol 27, 591-619. 
Stone, K.D., Prussin, C., and Metcalfe, D.D. (2010). IgE, mast cells, basophils, and eosinophils. 
J Allergy Clin Immunol 125, S73-80. 
Tahirov, T.H., Sato, K., Ichikawa-Iwata, E., Sasaki, M., Inoue-Bungo, T., Shiina, M., Kimura, 
K., Takata, S., Fujikawa, A., Morii, H., et al. (2002). Mechanism of c-Myb-C/EBP beta 
cooperation from separated sites on a promoter. Cell 108, 57-70. 
Takamatsu, S. (2018). Naturally occurring cell adhesion inhibitors. J Nat Med 72, 817-835. 
 
 114 
Takeuchi, O., and Akira, S. (2010). Pattern recognition receptors and inflammation. Cell 140, 
805-820. 
Tan, Y., Zanoni, I., Cullen, T.W., Goodman, A.L., and Kagan, J.C. (2015). Mechanisms of Toll-
like Receptor 4 Endocytosis Reveal a Common Immune-Evasion Strategy Used by Pathogenic 
and Commensal Bacteria. Immunity 43, 909-922. 
Tannahill, G.M., Curtis, A.M., Adamik, J., Palsson-McDermott, E.M., McGettrick, A.F., Goel, 
G., Frezza, C., Bernard, N.J., Kelly, B., Foley, N.H., et al. (2013). Succinate is an inflammatory 
signal that induces IL-1beta through HIF-1alpha. Nature 496, 238-242. 
Thaker, Y.R., Schneider, H., and Rudd, C.E. (2015). TCR and CD28 activate the transcription 
factor NF-kappaB in T-cells via distinct adaptor signaling complexes. Immunol Lett 163, 113-
119. 
The UniProt, C. (2017). UniProt: the universal protein knowledgebase. Nucleic Acids Res 45, 
D158-D169. 
Traore, K., Trush, M.A., George, M., Jr., Spannhake, E.W., Anderson, W., and Asseffa, A. 
(2005). Signal transduction of phorbol 12-myristate 13-acetate (PMA)-induced growth inhibition 
of human monocytic leukemia THP-1 cells is reactive oxygen dependent. Leuk Res 29, 863-879. 
Tsukada, J., Misago, M., Serino, Y., Ogawa, R., Murakami, S., Nakanishi, M., Tonai, S., 
Kominato, Y., Morimoto, I., Auron, P.E., et al. (1997). Human T-cell leukemia virus type I Tax 
transactivates the promoter of human prointerleukin-1beta gene through association with two 
transcription factors, nuclear factor-interleukin-6 and Spi-1. Blood 90, 3142-3153. 
Tsukada, J., Saito, K., Waterman, W.R., Webb, A.C., and Auron, P.E. (1994). Transcription 
factors NF-IL6 and CREB recognize a common essential site in the human prointerleukin 1 beta 
gene. Mol Cell Biol 14, 7285-7297. 
Tsukada, J., Yoshida, Y., Kominato, Y., and Auron, P.E. (2011). The CCAAT/enhancer (C/EBP) 
family of basic-leucine zipper (bZIP) transcription factors is a multifaceted highly-regulated 
system for gene regulation. Cytokine 54, 6-19. 
Turkistany, S.A., and DeKoter, R.P. (2011). The transcription factor PU.1 is a critical regulator 
of cellular communication in the immune system. Arch Immunol Ther Exp (Warsz) 59, 431-440. 
Turvey, S.E., and Broide, D.H. (2010). Innate immunity. J Allergy Clin Immunol 125, S24-32. 
Unlu, S., Kumar, A., Waterman, W.R., Tsukada, J., Wang, K.Z., Galson, D.L., and Auron, P.E. 
(2007). Phosphorylation of IRF8 in a pre-associated complex with Spi-1/PU.1 and non-
phosphorylated Stat1 is critical for LPS induction of the IL1B gene. Mol Immunol 44, 3364-
3379. 
van Diepen, J.A., Robben, J.H., Hooiveld, G.J., Carmone, C., Alsady, M., Boutens, L., 
Bekkenkamp-Grovenstein, M., Hijmans, A., Engelke, U.F.H., Wevers, R.A., et al. (2017). 
SUCNR1-mediated chemotaxis of macrophages aggravates obesity-induced inflammation and 
diabetes. Diabetologia 60, 1304-1313. 
 
 115 
van Zundert, G.C.P., Rodrigues, J., Trellet, M., Schmitz, C., Kastritis, P.L., Karaca, E., 
Melquiond, A.S.J., van Dijk, M., de Vries, S.J., and Bonvin, A. (2016). The HADDOCK2.2 Web 
Server: User-Friendly Integrative Modeling of Biomolecular Complexes. J Mol Biol 428, 720-
725. 
Vaquerizas, J.M., and Torres-Padilla, M.E. (2016). Developmental biology: Panoramic views of 
the early epigenome. Nature 537, 494-496. 
Venereau, E., Ceriotti, C., and Bianchi, M.E. (2015). DAMPs from Cell Death to New Life. 
Front Immunol 6, 422. 
Voigt, P., Tee, W.W., and Reinberg, D. (2013). A double take on bivalent promoters. Genes & 
development 27, 1318-1338. 
Wagner, E.J., and Carpenter, P.B. (2012). Understanding the language of Lys36 methylation at 
histone H3. Nature reviews Molecular cell biology 13, 115-126. 
Wang, D., Matsumoto, R., You, Y., Che, T., Lin, X.Y., Gaffen, S.L., and Lin, X. (2004). 
CD3/CD28 costimulation-induced NF-kappaB activation is mediated by recruitment of protein 
kinase C-theta, Bcl10, and IkappaB kinase beta to the immunological synapse through 
CARMA1. Mol Cell Biol 24, 164-171. 
Wang, K.Z., Galson, D.L., and Auron, P.E. (2010). TRAF6 is autoinhibited by an intramolecular 
interaction which is counteracted by trans-ubiquitination. Journal of cellular biochemistry 110, 
763-771. 
Wang, K.Z., Wara-Aswapati, N., Boch, J.A., Yoshida, Y., Hu, C.D., Galson, D.L., and Auron, 
P.E. (2006). TRAF6 activation of PI 3-kinase-dependent cytoskeletal changes is cooperative with 
Ras and is mediated by an interaction with cytoplasmic Src. J Cell Sci 119, 1579-1591. 
Wang, Z., Zang, C., Rosenfeld, J.A., Schones, D.E., Barski, A., Cuddapah, S., Cui, K., Roh, 
T.Y., Peng, W., Zhang, M.Q., et al. (2008). Combinatorial patterns of histone acetylations and 
methylations in the human genome. Nature genetics 40, 897-903. 
Wara-aswapati, N., Yang, Z., Waterman, W.R., Koyama, Y., Tetradis, S., Choy, B.K., Webb, 
A.C., and Auron, P.E. (1999). Cytomegalovirus IE2 protein stimulates interleukin 1beta gene 
transcription via tethering to Spi-1/PU.1. Mol Cell Biol 19, 6803-6814. 
Webb, A.C., Collins, K.L., Auron, P.E., Eddy, R.L., Nakai, H., Byers, M.G., Haley, L.L., Henry, 
W.M., and Shows, T.B. (1986). Interleukin-1 gene (IL1) assigned to long arm of human 
chromosome 2. Lymphokine Res 5, 77-85. 
Williams, L.M., and Ridley, A.J. (2000). Lipopolysaccharide induces actin reorganization and 
tyrosine phosphorylation of Pyk2 and paxillin in monocytes and macrophages. J Immunol 164, 
2028-2036. 
Winterbourn, C.C., Kettle, A.J., and Hampton, M.B. (2016). Reactive Oxygen Species and 
Neutrophil Function. Annu Rev Biochem 85, 765-792. 
 
 116 
Wojciechowski, M., and Lesyng, B. (2004). Generalized Born Model: Analysis, Refinement and 
Applications to Proteins. J Phys Chem B 108, 18368-18376. 
Wood, K.A., and Angus, D.C. (2004). Pharmacoeconomic implications of new therapies in 
sepsis. Pharmacoeconomics 22, 895-906. 
Yang, Z., Wara-Aswapati, N., Chen, C., Tsukada, J., and Auron, P.E. (2000). NF-IL6 
(C/EBPbeta ) vigorously activates il1b gene expression via a Spi-1 (PU.1) protein-protein tether. 
J Biol Chem 275, 21272-21277. 
Zanoni, I., Ostuni, R., Marek, L.R., Barresi, S., Barbalat, R., Barton, G.M., Granucci, F., and 
Kagan, J.C. (2011). CD14 controls the LPS-induced endocytosis of Toll-like receptor 4. Cell 
147, 868-880. 
Zhang, Y., Broser, M., and Rom, W.N. (1994). Activation of the interleukin 6 gene by 
Mycobacterium tuberculosis or lipopolysaccharide is mediated by nuclear factors NF-IL6 and 
NF-kappa B. Proc Natl Acad Sci U S A 91, 2225-2229. 
Zhang, Y., Saccani, S., Shin, H., and Nikolajczyk, B.S. (2008). Dynamic protein associations 
define two phases of IL-1beta transcriptional activation. J Immunol 181, 503-512. 
Zhu, J., and Paul, W.E. (2008). CD4 T cells: fates, functions, and faults. Blood 112, 1557-1569. 
Zhu, J., Yamane, H., and Paul, W.E. (2010). Differentiation of effector CD4 T cell populations 
(*). Annu Rev Immunol 28, 445-489. 
 
 117 
